Single O
- O
dose O
bioequivalence O
of O
105 O
- O
mg O
fenofibric B-DRUG
acid I-DRUG
tablets O
versus O
145 O
- O
mg O
fenofibrate B-DRUG
tablets O
under O
fasting O
and O
fed O
conditions O
: O
a O
report O
of O
two O
phase O
I O
, O
open O
- O
label O
, O
single O
- O
dose O
, O
randomized O
, O
crossover O
clinical O
trials O
. O
Fenofibrate B-DRUG
is O
used O
to O
treat O
primary O
hypercholesterolemia O
, O
mixed O
lipidemia O
, O
and O
hypertriglyceridemia O
in O
adults O
who O
do O
not O
respond O
to O
nonpharmacologic O
measures O
. O
Fenofibrate B-DRUG
is O
a O
prodrug O
that O
is O
rapidly O
and O
completely O
hydrolyzed O
to O
fenofibric B-DRUG_N
acid I-DRUG_N
, O
the O
active O
moiety O
. O
A O
new O
orally O
administered O
agent O
, O
fenofibric B-DRUG
acid I-DRUG
, O
was O
developed O
as O
an O
alternative O
to O
fenofibrate B-DRUG
. O
Two O
separate O
studies O
were O
conducted O
to O
evaluate O
the O
bioequivalence O
of O
fenofibric B-DRUG
acid I-DRUG
relative O
to O
fenofibrate B-DRUG
under O
fasted O
and O
fed O
( O
standard O
breakfast O
) O
conditions O
, O
characterize O
the O
pharmacokinetic O
profile O
, O
and O
assess O
the O
safety O
and O
tolerability O
of O
fenofibric B-DRUG
acid I-DRUG
. O
In O
study O
1 O
( O
fasted O
) O
, O
during O
each O
study O
period O
, O
volunteers O
received O
a O
single O
105 O
- O
mg O
dose O
of O
fenofibric B-DRUG
acid I-DRUG
or O
single O
145 O
- O
mg O
dose O
of O
fenofibrate B-DRUG
( O
depending O
on O
their O
randomization O
scheme O
) O
after O
an O
overnight O
fast O
( O
a O
minimum O
fast O
of O
10 O
hours O
) O
. O
A O
7 O
- O
day O
washout O
period O
followed O
the O
first O
treatment O
period O
, O
after O
which O
the O
volunteers O
received O
the O
alternate O
treatment O
. O
Study O
2 O
followed O
a O
similar O
dosing O
scheme O
and O
differed O
only O
in O
that O
volunteers O
received O
their O
single O
dose O
after O
being O
fed O
a O
standard O
meal O
( O
575 O
calories O
, O
of O
which O
36 O
% O
were O
contributed O
by O
fat O
) O
. O
Serial O
blood O
samples O
in O
both O
studies O
were O
collected O
up O
to O
72 O
hours O
after O
drug O
administration O
. O
The O
pharmacokinetic O
parameters O
of O
interest O
for O
assessing O
bioequivalence O
were O
AUC O
( O
0 O
- O
t O
) O
, O
AUC O
( O
0 O
- O
) O
, O
C O
( O
max O
) O
, O
and O
T O
( O
max O
) O
. O
The O
criterion O
for O
a O
lack O
of O
difference O
between O
products O
was O
a O
90 O
% O
CI O
between O
0 O
. O
80 O
and O
1 O
. O
25 O
for O
the O
fenofibric B-DRUG
acid I-DRUG
: O
fenofibrate B-DRUG
ratios O
for O
AUC O
( O
0 O
- O
t O
) O
, O
AUC O
( O
0 O
- O
) O
, O
and O
C O
( O
max O
. O
) O
Tolerability O
was O
assessed O
by O
adverse O
events O
( O
AEs O
) O
, O
laboratory O
parameters O
, O
vital O
signs O
, O
and O
physical O
examinations O
. O
Volunteers O
in O
study O
1 O
( O
fasted O
; O
n O
= O
54 O
) O
were O
aged O
18 O
to O

43 O
years O
; O
19 O
( O
35 O
% O
) O
were O
men O
and O
35 O
( O
65 O
% O
) O
were O
women O
; O
mean O
weight O
was O
155 O
. O
2 O
pounds O
( O
range O
, O
103 O
. O
0 O
- O
267 O
. O
0 O
pounds O
) O
; O
and O
48 O
( O
89 O
% O
) O
were O
white O
, O
1 O
( O
2 O
% O
) O
was O
black O
, O
and O
5 O
( O
9 O
% O
) O
were O
white O
/ O
American O
Indian O
/ O
Alaskan O
native O
/ O
Asian O
. O
Volunteers O
in O
study O
2 O
( O
fed O
; O
n O
= O
54 O
) O
were O
aged O
18 O
to O
43 O
years O
; O
27 O
( O
50 O
% O
) O
were O
men O
and O
27 O
( O
50 O
% O
) O
were O
women O
; O
mean O
weight O
was O
161 O
. O
9 O
pounds O
( O
range O
, O
112 O
. O
0 O
- O
225 O
. O
0 O
pounds O
) O
; O
and O
51 O
( O
94 O
% O
) O
were O
white O
( O
including O
2 O
Hispanic O
) O
and O
3 O
( O
6 O
% O
) O
were O
black O
. O
The O
90 O
% O
CIs O
about O
the O
ratio O
of O
the O
fenofibric B-DRUG
acid I-DRUG
geometric O
mean O
to O
the O
fenofibrate B-DRUG
geometric O
mean O
were O
within O
the O
80 O
% O
and O
125 O
% O
limits O
for O
the O
pharmacokinetic O
parameters O
C O
( O
max O
) O
, O
AUC O
( O
0 O
- O
t O
) O
, O
and O
AUC O
( O
0 O
- O
) O
of O
the O
ln O
- O
transformed O
data O
in O
both O
study O
1 O
( O
fasted O
) O
and O
study O
2 O
. O
In O
study O
1 O
( O
fasted O
) O
, O
14 O
volunteers O
( O
26 O
% O
) O
experienced O
a O
total O
of O
29 O
AEs O
; O
the O
most O
common O
nonlaboratory O
AEs O
were O
dizziness O
( O
6 O
% O
) O
and O
headache O
( O
4 O
% O
) O
. O
In O
study O
2 O
, O
12 O
volunteers O
( O
22 O
% O
) O
experienced O
a O
total O
of O
19 O
AEs O
; O
the O
most O
common O
nonlaboratory O
AEs O
were O
headache O
( O
17 O
% O
) O
and O
dry O
throat O
( O
4 O
% O
) O
. O
AEs O
were O
generally O
mild O
or O
moderate O
in O
intensity O
. O
In O
these O
2 O
single O
- O
dose O
studies O
, O
these O
healthy O
volunteers O
administered O
a O
single O
oral O
dose O
of O
105 O
- O
mg O
fenofibric B-DRUG
acid I-DRUG
met O
the O
US O
Food O
and O
Drug O
Administration O
regulatory O
criteria O
for O
assuming O
bioequivalence O
to O
a O
single O
oral O
dose O
of O
145 O
- O
mg O
fenofibrate B-DRUG
tablets O
with O
respect O
to O
the O
rate O
and O
extent O
of O
fenofibric B-DRUG
acid I-DRUG
absorption O
in O
both O
fed O
and O
fasted O
states O
. O
Fenofibric B-DRUG
acid I-DRUG
at O
the O
dose O
studied O
was O
well O
tolerated O
in O
this O
population O
. O

Metabotropic O
glutamate O
receptor O
5 O
antagonist O
protects O
dopaminergic O
and O
noradrenergic O
neurons O
from O
degeneration O
in O
MPTP B-DRUG_N
- O
treated O
monkeys O
. O
Degeneration O
of O
the O
dopaminergic O
nigrostriatal O
system O
and O
of O
noradrenergic O
neurons O
in O
the O
locus O
coeruleus O
are O
important O
pathological O
features O
of O
Parkinson O
' O
s O
disease O
. O
There O
is O
an O
urgent O
need O
to O
develop O
therapies O
that O
slow O
down O
the O
progression O
of O
neurodegeneration O
in O
Parkinson O
' O
s O
disease O
. O
In O
the O
present O
study O
, O
we O
tested O
whether O
the O
highly O
specific O
metabotropic O
glutamate O
receptor O
5 O
antagonist O
, O
3 B-DRUG_N
- I-DRUG_N
[ I-DRUG_N
( I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
thiazol I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
yl I-DRUG_N
) I-DRUG_N
ethynyl I-DRUG_N
] I-DRUG_N
pyridine I-DRUG_N
, O
reduces O
dopaminergic O
and O
noradrenergic O
neuronal O
loss O
in O
monkeys O
rendered O
parkinsonian O
by O
chronic O
treatment O
with O
low O
doses O
of O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
. O
Weekly O
intramuscular O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
injections O
( O
0 O
. O
2 O
- O
0 O
. O
5 O
mg O
/ O
kg O
body O
weight O
) O
, O
in O
combination O
with O
daily O
administration O
of O
3 B-DRUG_N
- I-DRUG_N
[ I-DRUG_N
( I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
thiazol I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
yl I-DRUG_N
) I-DRUG_N
ethynyl I-DRUG_N
] I-DRUG_N
pyridine I-DRUG_N
or O
vehicle O
, O
were O
performed O
until O
the O
development O
of O
parkinsonian O
motor O
symptoms O
in O
either O
of O
the O
two O
experimental O
groups O
( O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
/ O
3 B-DRUG_N
- I-DRUG_N
[ I-DRUG_N
( I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
thiazol I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
yl I-DRUG_N
) I-DRUG_N
ethynyl I-DRUG_N
] I-DRUG_N
pyridine I-DRUG_N
versus O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
/ O
vehicle O
) O
. O
After O
21 O
weeks O
of O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
treatment O
, O
all O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
/ O
vehicle O
- O
treated O
animals O
displayed O
parkinsonian O
symptoms O
, O
whereas O
none O
of O
the O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N

tetrahydropyridine I-DRUG_N
/ O
3 B-DRUG_N
- I-DRUG_N
[ I-DRUG_N
( I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
thiazol I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
yl I-DRUG_N
) I-DRUG_N
ethynyl I-DRUG_N
] I-DRUG_N
pyridine I-DRUG_N
- O
treated O
monkeys O
were O
significantly O
affected O
. O
These O
behavioural O
observations O
were O
consistent O
with O
in O
vivo O
positron O
emission O
tomography O
dopamine O
transporter O
imaging O
data O
, O
and O
with O
post O
- O
mortem O
stereological O
counts O
of O
midbrain O
dopaminergic O
neurons O
, O
as O
well O
as O
striatal O
intensity O
measurements O
of O
dopamine O
transporter O
and O
tyrosine O
hydroxylase O
immunoreactivity O
, O
which O
were O
all O
significantly O
higher O
in O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
/ O
3 B-DRUG_N
- I-DRUG_N
[ I-DRUG_N
( I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
thiazol I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
yl I-DRUG_N
) I-DRUG_N
ethynyl I-DRUG_N
] I-DRUG_N
pyridine I-DRUG_N
- O
treated O
animals O
than O
in O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
/ O
vehicle O
- O
treated O
monkeys O
. O
The O
3 B-DRUG_N
- I-DRUG_N
[ I-DRUG_N
( I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
thiazol I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
yl I-DRUG_N
) I-DRUG_N
ethynyl I-DRUG_N
] I-DRUG_N
pyridine I-DRUG_N
treatment O
also O
had O
a O
significant O
effect O
on O
the O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
- O
induced O
loss O
of O
norepinephrine O
neurons O
in O
the O
locus O
coeruleus O
and O
adjoining O
A5 O
and O
A7 O
noradrenaline O
cell O
groups O
. O
In O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
/ O
vehicle O
- O
treated O
animals O
, O
almost O
40 O
% O
loss O
of O
tyrosine O
hydroxylase O
- O
positive O
norepinephrine O
neurons O
was O
found O
in O
locus O
coeruleus O
/ O
A5 O
/ O
A7 O
noradrenaline O
cell O
groups O
, O
whereas O
the O
extent O
of O
neuronal O
loss O
was O
lower O
than O
15 O
% O
of O
control O
values O
in O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
/ O
3 B-DRUG_N
- I-DRUG_N
[ I-DRUG_N
( I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
thiazol I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
yl I-DRUG_N
) I-DRUG_N
ethynyl I-DRUG_N
] I-DRUG_N
pyridine I-DRUG_N
- O
treated O
monkeys O
. O
Our O
data O
demonstrate O
that O
chronic O
treatment O
with O
the O
metabotropic O
glutamate O
receptor O
5 O
antagonist O
, O
3 B-DRUG_N
- I-DRUG_N
[ I-DRUG_N
( I-DRUG_N
2 I-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N

1 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
- I-DRUG_N
thiazol I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
yl I-DRUG_N
) I-DRUG_N
ethynyl I-DRUG_N
] I-DRUG_N
pyridine I-DRUG_N
, O
significantly O
reduces O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
toxicity O
towards O
dopaminergic O
and O
noradrenergic O
cell O
groups O
in O
non O
- O
human O
primates O
. O
This O
suggests O
that O
the O
use O
of O
metabotropic O
glutamate O
receptor O
5 O
antagonists O
may O
be O
a O
useful O
strategy O
to O
reduce O
degeneration O
of O
catecholaminergic O
neurons O
in O
Parkinson O
' O
s O
disease O
. O

Effect O
of O
ketoconazole B-DRUG
- O
mediated O
CYP3A4 O
inhibition O
on O
clinical O
pharmacokinetics O
of O
panobinostat B-DRUG
( O
LBH589 B-DRUG
) O
, O
an O
orally O
active O
histone B-GROUP
deacetylase I-GROUP
inhibitor I-GROUP
. O
Panobinostat B-DRUG
is O
partly O
metabolized O
by O
CYP3A4 O
in O
vitro O
. O
This O
study O
evaluated O
the O
effect O
of O
a O
potent O
CYP3A O
inhibitor O
, O
ketoconazole B-DRUG
, O
on O
the O
pharmacokinetics O
and O
safety O
of O
panobinostat B-DRUG
. O
Patients O
received O
a O
single O
panobinostat B-DRUG
oral O
dose O
on O
day O
1 O
, O
followed O
by O
4 O
days O
wash O
- O
out O
period O
. O
On O
days O
5 O
- O
9 O
, O
ketoconazole B-DRUG
was O
administered O
. O
On O
day O
8 O
, O
a O
single O
panobinostat B-DRUG
dose O
was O
co O
- O
administered O
with O
ketoconazole B-DRUG
. O
Panobinostat B-DRUG
was O
administered O
as O
single O
agent O
three O
times O
a O
week O
on O
day O
15 O
and O
onward O
. O
In O
the O
presence O
of O
ketoconazole B-DRUG
, O
there O
was O
1 O
. O
6 O
- O
and O
1 O
. O
8 O
- O
fold O
increase O
in O
C O
( O
max O
) O
and O
AUC O
of O
panobinostat B-DRUG
, O
respectively O
. O
No O
substantial O
change O
in O
T O
( O
max O
) O
or O
half O
- O
life O
was O
observed O
. O
No O
difference O
in O
panobinostat B-DRUG
- O
pharmacokinetics O
between O
patients O
carrying O
CYP3A5 O
* O
1 O
/ O
* O
3 O
and O
CYP3A5 O
* O
3 O
/ O
* O
3 O
alleles O
was O
observed O
. O
Most O
frequently O
reported O
adverse O
events O
were O
gastrointestinal O
related O
. O
Patients O
had O
asymptomatic O
hypophosphatemia O
( O
64 O
% O
) O
, O
and O
urine O
analysis O
suggested O
renal O
phosphate O
wasting O
. O
Co O
- O
administration O
of O
panobinostat B-DRUG
with O
CYP3A O
inhibitors O
is O
feasible O
as O
the O
observed O
increase O
in O
panobinostat B-DRUG
PK O
parameters O
was O
not O
considered O
clinically O
relevant O
. O
Considering O
the O
variability O
in O
exposure O
following O
enzyme O
inhibition O
and O
the O
fact O
that O
chronic O
dosing O
of O
panobinostat B-DRUG
was O
not O
studied O
with O
CYP3A O
inhibitors O
, O
close O
monitoring O
of O
panobinostat B-DRUG
- O
related O
adverse O
events O
is O
necessary O
. O

Polypharmacy O
in O
older O
adults O
. O
This O
article O
explores O
the O
issue O
of O
polypharmacy O
in O
older O
adults O
. O
The O
physiological O
changes O
in O
organ O
function O
in O
older O
people O
and O
the O
effect O
of O
this O
on O
pharmacokinetics O
and O
pharmacodynamics O
are O
discussed O
. O
The O
risks O
of O
adverse O
drug O
reactions O
and O
adverse O
drug O
interactions O
linked O
to O
polypharmacy O
are O
explored O
. O
Strategies O
to O
achieve O
optimal O
prescribing O
in O
older O
people O
are O
considered O
. O

Tuberculosis O
and O
HIV O
co O
- O
infection O
: O
screening O
and O
treatment O
strategies O
. O
Globally O
, O
tuberculosis O
( O
TB O
) O
and O
HIV O
interact O
in O
deadly O
synergy O
. O
The O
high O
burden O
of O
TB O
among O
HIV O
- O
infected O
individuals O
underlies O
the O
importance O
of O
TB O
diagnosis O
, O
treatment O
and O
prevention O
for O
clinicians O
involved O
in O
HIV O
care O
. O
Despite O
expanding O
access O
to O
antiretroviral B-GROUP
therapy O
( O
ART O
) O
to O
treat O
HIV O
infection O
in O
resource O
- O
limited O
settings O
, O
many O
individuals O
in O
need O
of O
therapy O
initiate O
ART O
too O
late O
and O
have O
already O
developed O
clinically O
significant O
TB O
by O
the O
time O
they O
present O
for O
care O
. O
Many O
co O
- O
infected O
individuals O
are O
in O
need O
of O
concurrent O
ART O
and O
anti O
- O
TB O
therapy O
, O
which O
dramatically O
improves O
survival O
, O
but O
also O
raises O
several O
management O
challenges O
, O
including O
drug O
interactions O
, O
shared O
drug O
toxicities O
and O
TB O
immune O
reconstitution O
inflammatory O
syndrome O
( O
IRIS O
) O
. O
Due O
to O
the O
survival O
benefits O
of O
promptly O
initiating O
ART O
among O
all O
HIV O
- O
infected O
individuals O
, O
including O
those O
with O
TB O
, O
it O
is O
recommended O
that O
co O
- O
infected O
individuals O
receive O
treatment O
for O
both O
diseases O
, O
regardless O
of O
CD4 O
+ O
cell O
count O
. O
We O
review O
current O
screening O
and O
treatment O
strategies O
for O
TB O
and O
HIV O
co O
- O
infection O
. O
Recent O
findings O
and O
ongoing O
studies O
will O
assist O
clinicians O
in O
managing O
the O
prevention O
and O
treatment O
of O
TB O
and O
HIV O
co O
- O
infection O
, O
which O
remains O
a O
major O
global O
health O
challenge O
. O

Interaction O
study O
of O
moxifloxacin B-DRUG
and O
lomefloxacin B-DRUG
with O
co O
- O
administered O
drugs O
. O
Moxifloxacin B-DRUG
and O
lomefloxacin B-DRUG
are O
fluoroquinolone B-GROUP
antibiotics I-GROUP
used O
in O
treating O
urinary O
and O
respiratory O
tract O
infections O
. O
Fluoroquinolones B-GROUP
are O
known O
to O
have O
interactions O
with O
drugs O
that O
are O
active O
in O
gastro O
intestinal O
tract O
. O
Being O
moxifloxacin B-DRUG
and O
lomefloxacin O
fluoroquinolones B-GROUP
the O
interaction O
study O
of O
was O
carried O
out O
with O
sucralfate B-DRUG
, O
gelusil B-BRAND
, O
erythromycin B-DRUG
and O
multi B-GROUP
minerals I-GROUP
. O
The O
interaction O
was O
studied O
at O
neutral O
, O
acidic O
and O
basic O
conditions O
both O
at O
room O
temperature O
and O
37 O
C O
. O
The O
effect O
of O
dissolution O
medium O
simulating O
various O
body O
environments O
with O
response O
to O
pH O
has O
been O
examined O
in O
order O
to O
elucidate O
the O
interactions O
. O
The O
response O
of O
moxifloxacin B-DRUG
and O
lomefloxacin B-DRUG
after O
interaction O
with O
co O
- O
administered O
drugs O
at O
different O
conditions O
and O
temperature O
were O
noted O
using O
a O
Shimadzu O
HPLC O
system O
with O
PDA O
detector O
. O
It O
was O
seen O
that O
interaction O
of O
these O
fluoroquinolones B-GROUP
was O
more O
at O
37 O
C O
than O
at O
room O
temperature O
. O
Moxifloxacin B-DRUG
and O
Lomefloxacin B-DRUG
reacts O
faster O
with O
sucralfate B-DRUG
and O
gelusil B-BRAND
in O
acidic O
media O
whereas O
with O
erythromycin B-DRUG
in O
basic O
media O
and O
multi B-GROUP
- I-GROUP
minerals I-GROUP
in O
neutral O
media O
. O
The O
study O
ensures O
the O
interaction O
of O
fluoroquinolones B-GROUP
with O
selected O
class O
of O
drugs O
. O
In O
order O
to O
achieve O
the O
effective O
therapeutic O
effect O
appropriate O
time O
intervals O
between O
administrations O
of O
drugs O
is O
essential O
. O

Older O
adults O
with O
multi O
- O
morbidity O
: O
medication O
management O
processes O
and O
design O
implications O
for O
personal O
health O
applications O
. O
Older O
adults O
often O
have O
multiple O
chronic O
problems O
requiring O
them O
to O
manage O
complex O
medication O
regimens O
overseen O
by O
various O
clinicians O
. O
Personal O
health O
applications O
( O
PHAs O
) O
show O
promise O
assisting O
in O
medication O
self O
- O
management O
, O
but O
adoption O
of O
new O
computer O
technologies O
by O
this O
population O
is O
challenging O
. O
Optimizing O
the O
utility O
of O
PHAs O
requires O
a O
thorough O
understanding O
of O
older O
adults O
' O
needs O
, O
preferences O
, O
and O
practices O
. O

Exposure O
to O
oral O
S B-DRUG
- I-DRUG
ketamine I-DRUG
is O
unaffected O
by O
itraconazole B-DRUG
but O
greatly O
increased O
by O
ticlopidine B-DRUG
. O
This O
study O
examined O
drug O
- O
drug O
interactions O
of O
oral O
S B-DRUG
- I-DRUG
ketamine I-DRUG
with O
the O
cytochrome O
P450 O
( O
CYP O
) O
2B6 O
inhibitor O
ticlopidine B-DRUG
and O
the O
CYP3A O
inhibitor O
itraconazole B-DRUG
. O
In O
this O
randomized O
, O
blinded O
, O
crossover O
study O
, O
11 O
healthy O
volunteers O
ingested O
0 O
. O
2 O
mg O
/ O
kg O
S B-DRUG
- I-DRUG
ketamine I-DRUG
after O
pretreatments O
with O
oral O
ticlopidine B-DRUG
( O
250 O
mg O
twice O
daily O
) O
, O
itraconazole B-DRUG
( O
200 O
mg O
once O
daily O
) O
, O
or O
placebo O
in O
6 O
- O
day O
treatment O
periods O
at O
intervals O
of O
4 O
weeks O
. O
Ticlopidine B-DRUG
treatment O
increased O
the O
mean O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
extrapolated O
to O
infinity O
( O
AUC O
( O
0 O
- O
) O
) O
of O
oral O
ketamine B-DRUG
by O
2 O
. O
4 O
- O
fold O
, O
whereas O
itraconazole B-DRUG
treatment O
did O
not O
increase O
the O
exposure O
to O
S B-DRUG
- I-DRUG
ketamine I-DRUG
. O
The O
ratio O
of O
norketamine B-DRUG_N
AUC O
( O
0 O
- O
) O
to O
ketamine B-DRUG
AUC O
( O
0 O
- O
) O
was O
significantly O
decreased O
in O
the O
ticlopidine B-DRUG
( O
P O
& O
lt O
; O
0 O
. O
001 O
) O
and O
itraconazole B-DRUG
phases O
( O
P O
= O
0 O
. O
006 O
) O
as O
compared O
to O
placebo O
. O
In O
the O
ticlopidine B-DRUG
and O
itraconazole B-DRUG
phases O
, O
the O
areas O
under O
the O
effect O
- O
time O
curves O
( O
self O
- O
reported O
drowsiness O
and O
performance O
) O
were O
significantly O
higher O
than O
those O
in O
the O
placebo O
phase O
( O
P O
< O
0 O
. O
05 O
) O
. O
The O
findings O
suggest O
that O
the O
dosage O
of O
S B-DRUG
- I-DRUG
ketamine I-DRUG
should O
be O
reduced O
in O
patients O
receiving O
ticlopidine B-DRUG
. O

Determinants O
of O
sensitivity O
to O
DZNep B-DRUG_N
induced O
apoptosis O
in O
multiple O
myeloma O
cells O
. O
The O
3 B-DRUG_N
- I-DRUG_N
Deazaneplanocin I-DRUG_N
A I-DRUG_N
( O
DZNep B-DRUG_N
) O
, O
one O
of O
S O
- O
adenosylhomocysteine O
( O
AdoHcy O
) O
hydrolase O
inhibitors O
, O
has O
shown O
antitumor O
activities O
in O
a O
broad O
range O
of O
solid O
tumors O
and O
acute O
myeloid O
leukemia O
. O
Here O
, O
we O
examined O
its O
effects O
on O
multiple O
myeloma O
( O
MM O
) O
cells O
and O
found O
that O
, O
at O
500 O
nM O
, O
it O
potently O
inhibited O
growth O
and O
induced O
apoptosis O
in O
2 O
of O
8 O
MM O
cell O
lines O
. O
RNA O
from O
un O
- O
treated O
and O
DZNep B-DRUG_N
treated O
cells O
was O
profiled O
by O
Affymetrix O
HG O
- O
U133 O
Plus O
2 O
. O
0 O
microarray O
and O
genes O
with O
a O
significant O
change O
in O
gene O
expression O
were O
determined O
by O
significance O
analysis O
of O
microarray O
( O
SAM O
) O
testing O
. O
ALOX5 O
was O
the O
most O
down O
- O
regulated O
gene O
( O
5 O
. O
8 O
- O
fold O
) O
in O
sensitive O
cells O
and O
was O
expressed O
at O
low O
level O
in O
resistant O
cells O
. O
The O
results O
were O
corroborated O
by O
quantitative O
RT O
- O
PCR O
. O
Western O
- O
blot O
analysis O
indicated O
ALOX5 O
was O
highly O
expressed O
only O
in O
sensitive O
cell O
line O
H929 O
and O
greatly O
decreased O
upon O
DZNep B-DRUG_N
treatment O
. O
Ectopic O
expression O
of O
ALOX5 O
reduced O
sensitivity O
to O
DZNep B-DRUG_N
in O
H929 O
cells O
. O
Furthermore O
, O
down O
- O
regulation O
of O
ALOX5 O
by O
RNA O
interference O
could O
also O
induce O
apoptosis O
in O
H929 O
. O
Gene O
expression O
analysis O
on O
MM O
patient O
dataset O
indicated O
ALOX5 O
expression O
was O
significantly O
higher O
in O
MM O
patients O
compared O
to O
normal O
plasma O
cells O
. O
We O
also O
found O
that O
Bcl O
- O
2 O
was O
overexpressed O
in O
DZNep B-DRUG_N
insensitive O
cells O
, O
and O
cotreatment O
with O
DZNep B-DRUG_N
and O
ABT B-DRUG_N
- I-DRUG_N
737 I-DRUG_N
, O
a O
Bcl O
- O
2 O
family O
inhibitor O
, O
synergistically O
inhibited O
growth O
and O
induced O
apoptosis O
of O
DZNep B-DRUG_N
insensitive O
MM O
cells O
. O
Taken O
together O
, O
this O
study O
shows O
one O
of O
mechanisms O
of O
the O
DZNep B-DRUG_N
efficacy O
on O
MM O
correlates O
with O
its O
ability O
to O
down O
- O
regulate O
the O
ALOX5 O
levels O
. O
In O
addition O
, O
DZNep B-DRUG_N
insensitivity O
might O
be O
associated O
with O
overexpression O
of O
Bcl O
- O
2 O
, O
and O
the O
combination O
of O
ABT B-DRUG_N
- I-DRUG_N
737 I-DRUG_N
and O
DZNep B-DRUG_N
could O
synergistically O
induced O
apoptosis O
. O
These O
results O
suggest O
that O
DZNep B-DRUG_N
may O
be O
exploited O
therapeutically O

for O
a O
subset O
of O
MM O
. O

Flow O
cytometry O
- O
based O
pharmacodynamic O
monitoring O
after O
organ O
transplantation O
. O
Conventional O
therapeutic O
drug O
monitoring O
based O
on O
measuring O
immunosupressive B-GROUP
drug I-GROUP
concentrations O
in O
blood O
is O
important O
in O
the O
clinical O
management O
of O
immunosuppressive B-GROUP
therapy O
in O
transplantation O
medicine O
. O
Since O
rejection O
or O
infection O
occurs O
at O
irregular O
drug O
concentrations O
immunosuppressive B-GROUP
drug I-GROUP
therapy O
is O
often O
empiric O
and O
prophylactic O
in O
nature O
. O
In O
addition O
, O
blood O
immunosuppressant B-GROUP
levels O
are O
only O
indirect O
predictors O
of O
the O
pharmacologic O
effects O
on O
immune O
cells O
, O
because O
the O
genetic O
heterogeneity O
the O
immune O
systems O
of O
transplant O
recipients O
are O
not O
equally O
sensitive O
to O
drug O
effects O
. O
Therefore O
, O
therapeutic O
drug O
monitoring O
requires O
the O
application O
of O
reliable O
and O
effective O
methods O
to O
study O
the O
pharmacodynamic O
variability O
by O
direct O
measurements O
of O
drug O
effects O
on O
immune O
cell O
functions O
. O
Flow O
cytometry O
offers O
a O
multiplicity O
of O
quantitative O
analysis O
possibilities O
, O
from O
detection O
of O
phosphorylated O
molecules O
up O
to O
complex O
multicolor O
analysis O
of O
whole O
blood O
samples O
. O
A O
large O
spectrum O
of O
flow O
cytometry O
- O
based O
applications O
for O
pharmacodynamic O
monitoring O
is O
available O
and O
allows O
detection O
and O
analysis O
of O
diverse O
function O
of O
T O
cells O
and O
dendritic O
cell O
subsets O
. O
By O
combining O
several O
assays O
, O
it O
is O
possible O
to O
generate O
a O
broad O
picture O
of O
the O
immune O
status O
of O
every O
single O
transplanted O
recipient O
. O
Furthermore O
, O
it O
is O
even O
possible O
to O
differentiate O
between O
synergistic O
and O
antagonistic O
pharmacodynamic O
effects O
of O
immunosuppressive B-GROUP
drug I-GROUP
combination O
therapy O
in O
vitro O
and O
to O
predict O
the O
pharmacodynamic O
drug O
effects O
in O
transplanted O
recipients O
. O
Such O
a O
pharmacodynamic O
drug O
monitoring O
may O
offer O
the O
opportunity O
to O
complete O
conventional O
therapeutic O
drug O
monitoring O
and O
, O
therefore O
, O
to O
tailor O
immunosuppressive B-GROUP
therapy O
more O
individually O
. O

[ O
Tuberculosis O
and O
HIV O
- O
features O
of O
the O
co O
- O
infection O
] O
. O
The O
human O
immunodeficiency O
virus O
( O
HIV O
) O
epidemic O
has O
allowed O
the O
incidence O
of O
tuberculosis O
to O
rise O
globally O
and O
particularly O
in O
sub O
- O
Saharan O
Africa O
. O
Diagnosis O
and O
treatment O
of O
tuberculosis O
is O
more O
complex O
in O
patients O
with O
HIV O
/ O
AIDS O
. O
Sputum O
smear O
microscopy O
is O
performing O
poorly O
in O
HIV O
- O
infected O
individuals O
, O
who O
are O
often O
started O
on O
antituberculosis O
treatment O
on O
clinical O
grounds O
. O
The O
treatment O
of O
coinfected O
patients O
requires O
antituberculosis B-GROUP
and I-GROUP
antiretroviral I-GROUP
drugs I-GROUP
to O
be O
administered O
concomittantly O
; O
challenges O
include O
pill O
burden O
and O
patient O
compliance O
, O
drug O
interactions O
, O
overlapping O
toxic O
effects O
, O
and O
immune O
reconstitution O
inflammatory O
syndrome O
. O
Current O
guidelines O
recommend O
starting O
antiretroviral B-GROUP
treatment O
within O
a O
few O
weeks O
of O
antituberculosis B-GROUP
therapy O
for O
patients O
with O
CD4 O
cell O
counts O
350 O
cells O
/ O
ul O
. O

[ O
Medical O
treatment O
of O
tuberculosis O
- O
update O
2011 O
] O
. O
Tuberculosis O
is O
the O
second O
most O
common O
cause O
of O
death O
from O
an O
infectious O
disease O
after O
HIV O
/ O
AIDS O
and O
the O
leading O
cause O
of O
death O
from O
an O
infectious O
disease O
in O
HIV O
- O
co O
- O
infected O
patients O
. O
Currently O
, O
drug O
susceptible O
TB O
is O
treated O
with O
a O
four O
drug O
regimen O
given O
over O
a O
period O
of O
two O
months O
followed O
by O
two O
drugs O
for O
four O
months O
. O
Drug O
resistant O
tuberculosis O
requires O
more O
complex O
and O
longer O
treatment O
with O
alternative O
substances O
. O
New O
antituberculosis B-GROUP
drugs I-GROUP
are O
currently O
being O
developed O
and O
investigated O
and O
are O
urgently O
needed O
to O
treat O
drug O
susceptible O
and O
drug O
resistant O
TB O
. O

Effects O
of O
neferine B-DRUG_N
on O
the O
pharmacokinetics O
of O
amiodarone B-DRUG
in O
rats O
. O
Amiodarone B-DRUG
, O
an O
iodinated O
benzofuran O
derivative O
with O
predominantly O
class O
III O
anti O
- O
arrhythmic O
effects O
, O
is O
used O
to O
treat O
supraventricular O
and O
ventricular O
arrhythmias O
. O
The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
potential O
of O
neferine B-DRUG_N
, O
an O
effective O
anti O
- O
pulmonary O
fibrosis O
drug O
isolated O
from O
the O
embryo O
of O
Nelumbo O
nucifera O
Gaertner O
' O
s O
seeds O
, O
to O
alter O
the O
pharmacokinetic O
profile O
of O
amiodarone B-DRUG
. O
Experimental O
Sprague O
- O
Dawley O
rats O
were O
randomly O
divided O
into O
two O
groups O
. O
In O
groups O
1 O
and O
2 O
, O
amiodarone B-DRUG
was O
given O
to O
rats O
by O
intragastric O
and O
intravenous O
administration O
, O
respectively O
, O
while O
neferine B-DRUG_N
was O
co O
- O
administratered O
by O
intragastric O
administration O
. O
Blood O
samples O
were O
collected O
from O
the O
orbital O
venous O
plexus O
at O
indicated O
time O
points O
and O
were O
analyzed O
for O
amiodarone B-DRUG
concentration O
using O
RP O
- O
HPLC O
. O
The O
geometric O
mean O
ratio O
for O
C O
( O
max O
) O
and O
AUC O
( O
0 O
- O
96 O
) O
was O
calculated O
. O
There O
were O
no O
significant O
differences O
between O
the O
pharmacokinetics O
parameters O
of O
amiodarone B-DRUG
administered O
intravenously O
or O
intragastrically O
and O
the O
control O
( O
without O
neferine B-DRUG_N
) O
group O
( O
with O
ratios O
of O
0 O
. O
7 O
- O
1 O
. O
4 O
in O
all O
experimental O
groups O
) O
, O
suggesting O
that O
neferine B-DRUG_N
had O
no O
effect O
on O
amiodarone B-DRUG
plasma O
pharmacokinetics O
. O
The O
dosage O
regimen O
of O
amiodarone B-DRUG
does O
not O
need O
to O
be O
taken O
into O
consideration O
when O
combined O
with O
neferine B-DRUG_N
. O

Implanon B-BRAND
failure O
in O
an O
HIV O
- O
positive O
woman O
on O
antiretroviral B-GROUP
therapy O
resulting O
in O
two O
ectopic O
pregnancies O
. O
Since O
its O
introduction O
in O
1999 O
, O
Implanon B-BRAND
remains O
one O
of O
the O
preferred O
contraceptive O
choices O
for O
many O
women O
as O
it O
offers O
a O
highly O
effective O
means O
of O
long O
- O
term O
contraception O
for O
three O
years O
that O
does O
not O
rely O
on O
adherence O
. O
Like O
all O
hormonal B-GROUP
contraceptives I-GROUP
, O
certain O
hepatic O
enzyme O
- O
inducing O
drugs O
may O
reduce O
its O
efficacy O
. O
We O
present O
an O
interesting O
case O
of O
an O
HIV O
- O
positive O
woman O
on O
antiretroviral B-GROUP
therapy O
having O
tubal O
pregnancies O
on O
two O
separate O
occasions O
with O
Implanon B-BRAND
in O
place O
. O

Structural O
basis O
for O
alcohol B-DRUG
modulation O
of O
a O
pentameric O
ligand O
- O
gated O
ion O
channel O
. O
Despite O
its O
long O
history O
of O
use O
and O
abuse O
in O
human O
culture O
, O
the O
molecular O
basis O
for O
alcohol B-DRUG
action O
in O
the O
brain O
is O
poorly O
understood O
. O
The O
recent O
determination O
of O
the O
atomic O
- O
scale O
structure O
of O
GLIC O
, O
a O
prokaryotic O
member O
of O
the O
pentameric O
ligand O
- O
gated O
ion O
channel O
( O
pLGIC O
) O
family O
, O
provides O
a O
unique O
opportunity O
to O
characterize O
the O
structural O
basis O
for O
modulation O
of O
these O
channels O
, O
many O
of O
which O
are O
alcohol B-DRUG
targets O
in O
brain O
. O
We O
observed O
that O
GLIC O
recapitulates O
bimodal O
modulation O
by O
n O
- O
alcohols O
, O
similar O
to O
some O
eukaryotic O
pLGICs O
: O
methanol B-DRUG_N
and O
ethanol B-DRUG
weakly O
potentiated O
proton O
- O
activated O
currents O
in O
GLIC O
, O
whereas O
n O
- O
alcohols O
larger O
than O
ethanol O
inhibited O
them O
. O
Mapping O
of O
residues O
important O
to O
alcohol B-DRUG
modulation O
of O
ionotropic O
receptors O
for O
glycine O
, O
- O
aminobutyric O
acid O
, O
and O
acetylcholine O
onto O
GLIC O
revealed O
their O
proximity O
to O
transmembrane O
cavities O
that O
may O
accommodate O
one O
or O
more O
alcohol B-DRUG
molecules O
. O
Site O
- O
directed O
mutations O
in O
the O
pore O
- O
lining O
M2 O
helix O
allowed O
the O
identification O
of O
four O
residues O
that O
influence O
alcohol B-DRUG
potentiation O
, O
with O
the O
direction O
of O
their O
effects O
reflecting O
- O
helical O
structure O
. O
At O
one O
of O
the O
potentiation O
- O
enhancing O
residues O
, O
decreased O
side O
chain O
volume O
converted O
GLIC O
into O
a O
highly O
ethanol B-DRUG
- O
sensitive O
channel O
, O
comparable O
to O
its O
eukaryotic O
relatives O
. O
Covalent O
labeling O
of O
M2 O
positions O
with O
an O
alcohol B-DRUG
analog O
, O
a O
methanethiosulfonate O
reagent O
, O
further O
implicated O
residues O
at O
the O
extracellular O
end O
of O
the O
helix O
in O
alcohol O
binding O
. O
Molecular O
dynamics O
simulations O
elucidated O
the O
structural O
consequences O
of O
a O
potentiation O
- O
enhancing O
mutation O
and O
suggested O
a O
structural O
mechanism O
for O
alcohol B-DRUG
potentiation O
via O
interaction O
with O
a O
transmembrane O
cavity O
previously O
termed O
the O
" O
linking O
tunnel O
. O
" O
These O
results O
provide O
a O
unique O
structural O
model O
for O
independent O
potentiating O
and O
inhibitory O
interactions O
of O
n O
- O
alcohols O
with O
a O
pLGIC O
family O
member O
. O

Neuropharmacological O
approach O
against O
MPTP B-DRUG_N
( O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
) O
- O
induced O
mouse O
model O
of O
Parkinson O
' O
s O
disease O
. O
Parkinson O
' O
s O
disease O
( O
PD O
) O
is O
a O
common O
neurodegenerative O
disease O
that O
appears O
essentially O
as O
a O
sporadic O
condition O
. O
PD O
is O
well O
known O
to O
be O
a O
chronic O
and O
progressive O
neurodegenerative O
disease O
produced O
by O
a O
selective O
degeneration O
of O
dopaminergic O
neurons O
in O
the O
substantia O
nigra O
pars O
compacta O
. O
The O
main O
clinical O
features O
of O
PD O
include O
tremor O
, O
bradykinesia O
, O
rigidity O
and O
postural O
instability O
. O
Most O
insights O
into O
pathogenesis O
of O
PD O
come O
from O
investigations O
performed O
in O
experimental O
models O
of O
PD O
, O
especially O
those O
produced O
by O
neurotoxins O
. O
The O
biochemical O
and O
cellular O
alterations O
that O
occur O
after O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
6 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
( O
MPTP B-DRUG_N
) O
treatment O
are O
remarkably O
similar O
to O
that O
observed O
in O
idiopathic O
PD O
. O
Furthermore O
, O
it O
is O
well O
known O
that O
acute O
treatment O
with O
MPTP B-DRUG_N
can O
cause O
a O
severe O
loss O
of O
tyrosine O
hydroxylase O
and O
dopamine O
transporter O
protein O
levels O
and O
dopamine O
contents O
in O
the O
striatum O
of O
mice O
, O
as O
compared O
to O
continuous O
MPTP B-DRUG_N
treatment O
. O
Thus O
these O
findings O
may O
support O
the O
validity O
of O
acute O
MPTP B-DRUG_N
treatment O
model O
for O
unraveling O
in O
the O
neurodegenerative O
processes O
in O
PD O
. O
In O
this O
review O
, O
we O
discuss O
the O
neuroprotective O
effects O
of O
various O
compounds O
against O
neuronal O
cell O
loss O
in O
an O
MPTP B-DRUG_N
model O
of O
PD O
. O
This O
review O
may O
lead O
to O
a O
much O
better O
understanding O
of O
PD O
as O
well O
as O
provide O
novel O
clues O
to O
new O
targets O
for O
therapeutic O
interventions O
in O
PD O
patients O
. O

Antidepressant B-GROUP
- O
warfarin B-DRUG
interaction O
and O
associated O
gastrointestinal O
bleeding O
risk O
in O
a O
case O
- O
control O
study O
. O
Bleeding O
is O
the O
most O
common O
and O
worrisome O
adverse O
effect O
of O
warfarin B-DRUG
therapy O
. O
One O
of O
the O
factors O
that O
might O
increase O
bleeding O
risk O
is O
initiation O
of O
interacting O
drugs O
that O
potentiate O
warfarin B-DRUG
. O
We O
sought O
to O
evaluate O
whether O
initiation O
of O
an O
antidepressant B-GROUP
increases O
the O
risk O
of O
hospitalization O
for O
gastrointestinal O
bleeding O
in O
warfarin B-DRUG
users O
. O
Medicaid O
claims O
data O
( O
1999 O
- O
2005 O
) O
were O
used O
to O
perform O
an O
observational O
case O
- O
control O
study O
nested O
within O
person O
- O
time O
exposed O
to O
warfarin B-DRUG
in O
those O
18 O
years O
. O
In O
total O
, O
430 O
, O
455 O
warfarin B-DRUG
users O
contributed O
407 O
, O
370 O
person O
- O
years O
of O
warfarin B-DRUG
use O
. O
The O
incidence O
rate O
of O
hospitalization O
for O
GI O
bleeding O
among O
warfarin B-DRUG
users O
was O
4 O
. O
48 O
per O
100 O
person O
- O
years O
( O
95 O
% O
CI O
, O
4 O
. O
42 O
- O
4 O
. O
55 O
) O
. O
Each O
gastrointestinal O
bleeding O
cases O
was O
matched O
to O
50 O
controls O
based O
on O
index O
date O
and O
state O
. O
Warfarin B-DRUG
users O
had O
an O
increased O
odds O
ratio O
of O
gastrointestinal O
bleeding O
upon O
initiation O
of O
citalopram B-DRUG
( O
OR O
= O
1 O
. O
73 O
[ O
95 O
% O
CI O
, O
1 O
. O
25 O
- O
2 O
. O
38 O
] O
) O
, O
fluoxetine B-DRUG
( O
OR O
= O
1 O
. O
63 O
[ O
95 O
% O
CI O
, O
1 O
. O
11 O
- O
2 O
. O
38 O
] O
) O
, O
paroxetine B-DRUG
( O
OR O
= O
1 O
. O
64 O
[ O
95 O
% O
CI O
, O
1 O
. O
27 O
- O
2 O
. O
12 O
] O
) O
, O
amitriptyline B-DRUG
( O
OR O
= O
1 O
. O
47 O
[ O
95 O
% O
CI O
, O
1 O
. O
02 O
- O
2 O
. O
11 O
] O
) O
. O
Also O
mirtazapine B-DRUG
, O
which O
is O
not O
believed O
to O
interact O
with O
warfarin B-DRUG
, O
increased O
the O
risk O
of O
GI O
bleeding O
( O
OR O
= O
1 O
. O
75 O
[ O
95 O
% O
CI O
, O
1 O
. O
30 O
- O
2 O
. O
35 O
] O
) O
. O
Warfarin B-DRUG
users O
who O
initiated O
citalopram B-DRUG
, O
fluoxetine B-DRUG
, O
paroxetine B-DRUG
, O
amitriptyline B-DRUG
, O
or O
mirtazapine B-DRUG
had O
an O
increased O
risk O
of O
hospitalization O
for O
gastrointestinal O
bleeding O
. O
However O
, O
the O
elevated O
risk O
with O
mirtazapine B-DRUG
suggests O
that O
a O
drug O
- O
drug O
interaction O
may O
not O
have O
been O
responsible O
for O
all O
of O
the O
observed O
increased O
risk O
. O

Mechanisms O
of O
drug O
toxicity O
or O
intolerance O
. O
Classically O
, O
adverse O
drug O
reactions O
had O
been O
considered O
as O
type O
A O
reactions O
which O
are O
related O
to O
the O
main O
pharmacological O
action O
of O
the O
drug O
and O
therefore O
are O
predictable O
. O
Such O
reactions O
are O
predictable O
, O
reversible O
, O
and O
usually O
can O
be O
managed O
by O
lowering O
the O
dose O
of O
the O
offending O
drug O
. O
However O
, O
other O
adverse O
effects O
of O
drugs O
can O
occur O
which O
are O
unrelated O
to O
the O
main O
pharmacological O
action O
of O
the O
drug O
- O
type O
B O
reactions O
. O
Such O
adverse O
effects O
are O
termed O
idiosyncratic O
and O
are O
often O
initiated O
by O
metabolites O
of O
the O
parent O
drug O
or O
by O
other O
indirect O
mechanisms O
. O
The O
detailed O
understanding O
of O
adverse O
drug O
events O
has O
become O
a O
major O
focus O
of O
the O
regulatory O
agencies O
throughout O
the O
world O
. O
The O
pharmacotherapy O
of O
gastrointestinal O
and O
liver O
disorders O
is O
becoming O
increasingly O
complex O
. O
In O
recent O
years O
, O
with O
the O
advent O
of O
novel O
therapeutic O
agents O
to O
treat O
a O
host O
of O
disorders O
, O
including O
viral O
hepatitis O
, O
gastrointestinal O
motility O
disorders O
, O
inflammatory O
bowel O
disease O
and O
others O
, O
the O
potential O
for O
serious O
clinically O
relevant O
drug O
reactions O
has O
increased O
. O
In O
the O
pharmacotherapy O
of O
gastrointestinal O
and O
liver O
diseases O
, O
a O
significant O
number O
of O
adverse O
events O
that O
occur O
can O
be O
explained O
by O
drug O
interactions O
. O
Some O
pharmacokinetic O
drug O
interactions O
are O
based O
on O
the O
competitive O
inhibition O
of O
the O
rate O
of O
drug O
metabolism O
of O
one O
of O
the O
drugs O
, O
leading O
to O
an O
increased O
concentration O
of O
the O
drug O
which O
was O
not O
intended O
. O
In O
other O
examples O
, O
the O
interaction O
can O
be O
mechanistic O
in O
which O
one O
or O
more O
drugs O
when O
co O
- O
administered O
potentiate O
each O
other O
' O
s O
actions O
without O
any O
change O
in O
drug O
levels O
, O
termed O
pharmacodynamic O
interactions O
. O

Unrecognized O
fatalities O
related O
to O
colchicine B-DRUG
in O
hospitalized O
patients O
. O
Colchicine B-DRUG
is O
commonly O
used O
for O
the O
treatment O
of O
gout O
and O
occasionally O
for O
other O
inflammatory O
diseases O
. O
It O
has O
a O
narrow O
therapeutic O
index O
and O
the O
potential O
for O
severe O
or O
fatal O
toxicity O
. O
We O
sought O
to O
determine O
( O
1 O
) O
the O
frequency O
of O
colchicine B-DRUG
toxicity O
among O
hospitalized O
patients O
taking O
colchicine B-DRUG
who O
died O
during O
an O
admission O
, O
( O
2 O
) O
the O
likelihood O
that O
colchicine B-DRUG
contributed O
to O
death O
, O
( O
3 O
) O
whether O
patients O
were O
taking O
interacting O
medications O
that O
could O
have O
contributed O
to O
toxicity O
, O
and O
( O
4 O
) O
whether O
colchicine B-DRUG
dosing O
among O
these O
patients O
adhered O
to O
established O
guidelines O
. O
We O
conducted O
an O
IRB O
- O
approved O
, O
retrospective O
chart O
review O
at O
an O
urban O
, O
tertiary O
care O
, O
1228 O
- O
bed O
, O
university O
hospital O
. O
Subjects O
included O
hospitalized O
patients O
who O
received O
colchicine B-DRUG
and O
died O
in O
hospital O
between O
1 O
January O
2000 O
and O
28 O
February O
2007 O
. O
We O
reviewed O
charts O
for O
signs O
and O
symptoms O
of O
colchicine B-DRUG
toxicity O
. O
An O
expert O
panel O
reviewed O
each O
case O
and O
classified O
the O
likelihood O
of O
colchicine B-DRUG
toxicity O
, O
the O
likelihood O
of O
a O
causal O
role O
of O
colchicine B-DRUG
in O
the O
death O
using O
the O
WHO O
classification O
system O
, O
and O
the O
appropriateness O
of O
colchicine B-DRUG
dosing O
. O
Thirty O
- O
seven O
hospitalized O
patients O
who O
died O
during O
the O
86 O
- O
month O
study O
period O
received O
colchicine B-DRUG
. O
Toxicity O
was O
unlikely O
in O
20 O
/ O
37 O
, O
possible O
in O
8 O
/ O
37 O
, O
likely O
in O
5 O
/ O
37 O
, O
and O
certain O
in O
4 O
/ O
37 O
. O
A O
contributing O
role O
for O
colchicine B-DRUG
in O
causing O
death O
was O
unlikely O
in O
24 O
/ O
37 O
, O
possible O
in O
7 O
/ O
37 O
, O
likely O
in O
3 O
/ O
37 O
, O
and O
certain O
in O
3 O
/ O
37 O
. O
Colchicine B-DRUG
doses O
( O
based O
on O
creatinine O
clearance O
) O
exceeded O
the O
accepted O
range O
for O
12 O
patients O
, O
including O
10 O
of O
17 O
cases O
of O
toxicity O
and O
8 O
of O
13 O
cases O
of O
death O
classified O
as O
possible O
or O
higher O
. O
Seventeen O
patients O
received O
interacting O
medications O
, O
including O
8 O
of O
17 O
cases O
of O
toxicity O
and O
8 O
of O
13 O
cases O
of O
death O
classified O
as O
possible O
or O
higher O
. O
Colchicine B-DRUG
toxicity O
was O
frequent O
in O
this O
cohort O
and O
may O
have O
contributed O
to O
about O
one O
- O
third O
of O
the O
deaths O
. O
Inappropriate O
dosing O
of O
colchicine B-DRUG
occurred O
frequently O
and O
was O
related O
to O
toxicity O
and O
death O
. O

Effects O
of O
CYP O
inhibitors O
on O
precocene B-DRUG_N
I I-DRUG_N
metabolism O
and O
toxicity O
in O
rat O
liver O
slices O
. O
We O
present O
a O
comprehensive O
in O
vitro O
approach O
to O
assessing O
metabolism O
- O
mediated O
hepatotoxicity O
using O
male O
Sprague O
- O
Dawley O
rat O
liver O
slices O
incubated O
with O
the O
well O
characterized O
hepatotoxicant O
, O
precocene B-DRUG_N
I I-DRUG_N
, O
and O
inhibitors O
of O
cytochrome O
P450 O
( O
CYP O
) O
enzymes O
. O
This O
approach O
combines O
liquid O
chromatography O
mass O
spectrometry O
( O
LC O
MS O
) O
detection O
methods O
with O
multiple O
toxicity O
endpoints O
to O
enable O
identification O
of O
critical O
metabolic O
pathways O
for O
hepatotoxicity O
. O
The O
incubations O
were O
performed O
in O
the O
absence O
and O
presence O
of O
the O
non O
- O
specific O
CYP O
inhibitor O
, O
1 B-DRUG_N
- I-DRUG_N
aminobenzotriazole I-DRUG_N
( O
ABT B-DRUG_N
) O
and O
isoform O
- O
specific O
inhibitors O
. O
The O
metabolite O
profile O
of O
precocene B-DRUG_N
I I-DRUG_N
in O
rat O
liver O
slices O
shares O
some O
features O
of O
the O
in O
vivo O
profile O
, O
but O
also O
had O
a O
major O
difference O
in O
that O
epoxide O
dihydrodiol O
hydrolysis O
products O
were O
not O
observed O
to O
a O
measurable O
extent O
. O
As O
examples O
of O
our O
liver O
slice O
metabolite O
identification O
procedure O
, O
a O
minor O
glutathione O
adduct O
and O
previously O
unreported O
7 O
- O
O O
- O
desmethyl O
and O
glucuronidated O
metabolites O
of O
precocene B-DRUG_N
I I-DRUG_N
are O
reported O
. O
Precocene B-DRUG_N
I I-DRUG_N
induced O
hepatocellular O
necrosis O
in O
a O
dose O
- O
and O
time O
- O
dependent O
manner O
. O
ABT B-DRUG_N
decreased O
the O
toxicity O
of O
precocene B-DRUG_N
I I-DRUG_N
, O
increased O
exposure O
to O
parent O
compound O
, O
and O
decreased O
metabolite O
levels O
in O
a O
dose O
- O
dependent O
manner O
. O
Of O
the O
isoform O
- O
specific O
CYP O
inhibitors O
tested O
for O
an O
effect O
on O
the O
precocene B-DRUG_N
I I-DRUG_N
metabolite O
profile O
, O
only O
tranylcypromine B-DRUG
was O
noticeably O
effective O
, O
indicating O
a O
role O
of O
CYPs O
2A6 O
, O
2C9 O
, O
2Cl9 O
, O
and O
2E1 O
. O
With O
respect O
to O
toxicity O
, O
the O
order O
of O
CYP O
inhibitor O
effectiveness O
was O
ABT B-DRUG_N
> O
diethyldithiocarbamate B-DRUG_N
~ O
tranylcypromine B-DRUG
> O
ketoconazole B-DRUG
. O
Furafylline B-DRUG_N
and O
sulfaphenazole B-DRUG_N
had O
no O
effect O
, O
while O
quinidine B-DRUG
appeared O
to O
augment O
precocene B-DRUG_N
I I-DRUG_N
toxicity O
. O
These O
results O
suggest O
that O
rat O
liver O
slices O
do O
not O
reproduce O
the O
reported O
in O
vivo O
biotransformation O
of O
precocene B-DRUG_N
I I-DRUG_N
and O
therefore O
may O
not O
be O
an O
appropriate O
model O
for O
precocene B-DRUG_N
I I-DRUG_N
metabolism O
. O
However O
, O
these O
results O
provide O
an O
example O

of O
how O
small O
molecule O
manipulation O
of O
CYP O
activity O
in O
an O
in O
vitro O
model O
can O
be O
used O
to O
confirm O
metabolism O
- O
mediated O
toxicity O
. O

Stroke O
prevention O
in O
atrial O
fibrillation O
: O
current O
status O
and O
near O
- O
future O
directions O
. O
Prevention O
of O
atrial O
fibrillation O
- O
related O
stroke O
is O
an O
important O
part O
of O
atrial O
fibrillation O
management O
. O
However O
, O
stroke O
risk O
is O
not O
homogeneous O
and O
varies O
with O
associated O
morbidities O
and O
risk O
factors O
. O
Risk O
stratification O
schemes O
have O
been O
developed O
that O
categorize O
patients O
' O
stroke O
risk O
into O
classes O
based O
on O
a O
combination O
of O
risk O
factors O
. O
According O
to O
the O
calculated O
level O
of O
risk O
, O
guidelines O
recommend O
patients O
with O
atrial O
fibrillation O
receive O
antithrombotic B-GROUP
therapy O
either O
as O
a O
vitamin B-GROUP
K I-GROUP
antagonist I-GROUP
or O
aspirin B-BRAND
. O
Despite O
recommendations O
, O
however O
, O
many O
patients O
with O
atrial O
fibrillation O
do O
not O
receive O
adequate O
thromboprophylaxis O
. O
We O
will O
discuss O
some O
of O
the O
underlying O
reasons O
, O
in O
part O
related O
to O
the O
drawbacks O
associated O
with O
vitamin B-GROUP
K I-GROUP
antagonists I-GROUP
. O
These O
highlight O
the O
need O
for O
new O
anticoagulants B-GROUP
in O
atrial O
fibrillation O
. O
The O
novel O
oral O
anticoagulants B-GROUP
in O
development O
may O
overcome O
some O
of O
the O
limitations O
of O
vitamin B-GROUP
K I-GROUP
antagonists I-GROUP
and O
address O
their O
underuse O
and O
safety O
concerns O
. O

Combining O
chondroitinase O
ABC O
and O
growth O
factors O
promotes O
the O
integration O
of O
murine O
retinal O
progenitor O
cells O
transplanted O
into O
Rho O
( O
- O
/ O
- O
) O
mice O
. O
The O
aim O
of O
this O
study O
is O
to O
investigate O
the O
synergistic O
effect O
of O
chondroitinase O
ABC O
and O
growth O
factors O
in O
the O
integration O
of O
murine O
retinal O
progenitor O
cells O
( O
mRPCs O
) O
transplanted O
into O
Rho O
( O
- O
/ O
- O
) O
mice O
. O
mRPCs O
from O
P1 O
green O
fluorescent O
protein O
- O
transgenic O
mice O
were O
isolated O
and O
expanded O
for O
transplantation O
. O
All O
mRPCs O
of O
20 O
passages O
or O
less O
were O
transplanted O
into O
the O
subretinal O
space O
of O
B6 O
mice O
together O
with O
chondroitinase O
ABC O
, O
and O
into O
Rho O
( O
- O
/ O
- O
) O
mice O
combined O
with O
chondroitinase O
ABC O
, O
N B-DRUG_N
- I-DRUG_N
[ I-DRUG_N
N I-DRUG_N
- I-DRUG_N
( I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
5 I-DRUG_N
- I-DRUG_N
Difluorophenacetyl I-DRUG_N
) I-DRUG_N
- I-DRUG_N
L I-DRUG_N
- I-DRUG_N
alanyl I-DRUG_N
] I-DRUG_N
- I-DRUG_N
S I-DRUG_N
- I-DRUG_N
phenylglycine I-DRUG_N
t I-DRUG_N
- I-DRUG_N
butyl I-DRUG_N
ester I-DRUG_N
( O
DAPT B-DRUG_N
) O
, O
and O
insulin B-DRUG_N
growth I-DRUG_N
factor I-DRUG_N
( B-DRUG_N
IGF I-DRUG_N
) I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
. O
Cell O
counts O
were O
used O
to O
examine O
the O
migration O
and O
survival O
rate O
of O
mRPCs O
in O
B6 O
mice O
. O
Immunohistochemistry O
was O
used O
to O
evaluate O
the O
differentiation O
and O
integration O
of O
mRPCs O
in O
B6 O
and O
Rho O
( O
- O
/ O
- O
) O
mice O
. O
Our O
results O
show O
that O
substantial O
numbers O
of O
mRPCs O
migrated O
and O
survived O
in O
the O
retina O
when O
transplanted O
with O
chondroitinase O
ABC O
into O
B6 O
and O
Rho O
( O
- O
/ O
- O
) O
mice O
. O
Chondroitinase O
ABC O
disrupted O
the O
glial O
scar O
around O
the O
mRPCs O
in O
the O
subretinal O
space O
. O
Only O
a O
few O
mRPCs O
expressed O
recoverin O
in O
B6 O
mice O
. O
More O
mRPCs O
expressed O
rhodopsin O
, O
recoverin O
, O
and O
synaptophysin O
after O
transplantation O
into O
Rho O
( O
- O
/ O
- O
) O
mice O
when O
combined O
with O
chondroitinase O
ABC O
and O
growth O
factors O
. O
The O
synergistic O
effect O
of O
chondroitinase O
ABC O
and O
growth O
factors O
facilitates O
the O
anatomic O
integration O
of O
mRPCs O
transplanted O
into O
Rho O
( O
- O
/ O
- O
) O
mice O
. O

Glycosidic O
enzymes O
enhance O
retinal O
transduction O
following O
intravitreal O
delivery O
of O
AAV2 B-DRUG_N
. O
To O
determine O
whether O
the O
co O
- O
injection O
of O
extracellular O
matrix O
degrading O
enzymes O
improves O
retinal O
transduction O
following O
intravitreal O
delivery O
of O
adeno B-DRUG_N
- I-DRUG_N
associated I-DRUG_N
virus I-DRUG_N
- I-DRUG_N
2 I-DRUG_N
( O
AAV2 B-DRUG_N
) O
. O
AAV2 B-DRUG_N
containing O
cDNA O
encoding O
enhanced O
green O
fluorescent O
protein O
( O
GFP O
) O
, O
under O
the O
control O
of O
a O
chicken O
- O
actin O
promoter O
, O
was O
delivered O
by O
intravitreal O
injection O
to O
adult O
mice O
in O
conjunction O
with O
enzymes O
including O
collagenase B-DRUG_N
, O
hyaluronan B-DRUG_N
lyase I-DRUG_N
, O
heparinase B-DRUG_N
III I-DRUG_N
, O
or O
chondroitin B-DRUG_N
ABC I-DRUG_N
lyase I-DRUG_N
. O
Two O
weeks O
later O
, O
retinal O
flatmounts O
were O
examined O
for O
GFP O
expression O
using O
confocal O
microscopy O
. O
Without O
the O
addition O
of O
enzymes O
, O
transduction O
was O
limited O
to O
occasional O
cells O
in O
the O
retinal O
ganglion O
cell O
layer O
. O
The O
addition O
of O
heparinase B-DRUG_N
III I-DRUG_N
or O
chondroitin B-DRUG_N
ABC I-DRUG_N
lyase I-DRUG_N
greatly O
enhanced O
transduction O
of O
the O
retinal O
ganglion O
cell O
layer O
and O
increased O
the O
depth O
of O
transduction O
into O
the O
outer O
retina O
. O
Hyaluronan B-DRUG_N
lyase I-DRUG_N
had O
a O
limited O
effect O
and O
collagenase B-DRUG_N
was O
ineffective O
. O
Electroretinograms O
survived O
with O
higher O
concentrations O
of O
heparinase B-DRUG_N
III I-DRUG_N
and O
chondroitin B-DRUG_N
ABC I-DRUG_N
lyase I-DRUG_N
than O
were O
required O
for O
optimal O
retinal O
transduction O
. O
AAV2 B-DRUG_N
- O
mediated O
retinal O
transduction O
is O
improved O
by O
co O
- O
injection O
of O
heparinase B-DRUG_N
III I-DRUG_N
or O
chondroitin B-DRUG_N
ABC I-DRUG_N
lyase I-DRUG_N
. O
Improved O
transduction O
efficiency O
may O
allow O
intravitreal O
injection O
to O
become O
the O
preferred O
route O
for O
delivering O
gene O
therapy O
to O
both O
the O
inner O
and O
outer O
retina O
. O

Placebo O
effect O
in O
patients O
with O
irritable O
bowel O
syndrome O
. O
The O
placebo O
effect O
has O
evolved O
from O
being O
considered O
a O
nuisance O
factor O
in O
clinical O
research O
to O
a O
hot O
topic O
of O
scientific O
investigation O
. O
New O
research O
findings O
show O
that O
a O
placebo O
has O
real O
psychobiological O
and O
biological O
effects O
that O
are O
attributable O
to O
the O
overall O
therapeutic O
context O
. O
Irritable O
bowel O
syndrome O
( O
IBS O
) O
is O
a O
functional O
disorder O
of O
the O
gastrointestinal O
tract O
that O
shows O
a O
significant O
placebo O
response O
of O
around O
40 O
50 O
% O
among O
different O
clinical O
trials O
. O
A O
positive O
patient O
- O
practitioner O
relationship O
can O
enhance O
the O
placebo O
effect O
in O
IBS O
patients O
. O
Emerging O
literature O
using O
functional O
brain O
imaging O
has O
started O
to O
document O
the O
neuronal O
changes O
associated O
with O
the O
placebo O
phenomenon O
in O
IBS O
patients O
, O
showing O
aberrant O
neural O
network O
during O
visceral O
placebo O
analgesia O
when O
compared O
to O
controls O
. O
Further O
promotion O
and O
integration O
of O
laboratory O
and O
clinical O
research O
are O
encouraged O
to O
advance O
the O
understanding O
of O
placebo O
mechanisms O
in O
IBS O
patients O
. O

[ O
Seniors O
and O
cardiovascular O
medications O
] O
. O
Authors O
analyze O
the O
situation O
in O
the O
therapy O
of O
cardiovascular O
diseases O
- O
- O
unsatisfactory O
situation O
especially O
from O
the O
dyslipidaemia O
point O
of O
view O
. O
Different O
groups O
of O
medications O
are O
discussed O
and O
their O
risks O
for O
elderly O
patients O
. O
Angiotensin B-GROUP
converting I-GROUP
enzyme I-GROUP
blockers I-GROUP
and O
their O
influence O
on O
the O
endothelial O
dysfunction O
, O
but O
the O
risk O
of O
hyperpotassemia O
are O
showed O
. O
The O
risk O
of O
gastrointestinal O
bleeding O
during O
the O
treatment O
with O
antiagregants B-GROUP
and O
anticoagulants B-GROUP
, O
the O
risk O
of O
bradycardia O
in O
beta O
- O
blockade O
, O
possible O
interactions O
with O
other O
medications O
lowering O
the O
heart O
rate O
are O
discussed O
. O
Attention O
is O
paid O
to O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
, O
diuretics B-GROUP
and O
digoxin B-DRUG
. O
The O
table O
containing O
possible O
clinical O
symptoms O
of O
unwanted O
side O
effect O
of O
most O
frequently O
used O
cardiovascular O
medications O
in O
elderly O
is O
added O
as O
the O
conclusion O
of O
the O
article O
. O

Post O
- O
exposure O
prophylaxis O
for O
H1N1 O
with O
oseltamivir B-DRUG
in O
renal O
allograft O
recipient O
- O
- O
safe O
and O
effective O
without O
any O
immunosuppresive B-GROUP
drug I-GROUP
interaction O
. O
Kidney O
transplant O
recipients O
are O
at O
a O
high O
risk O
for O
H1N1 O
infection O
associated O
complications O
during O
the O
current O
pandemic O
. O
Prevention O
of O
infection O
by O
immunization O
, O
together O
with O
early O
recognition O
and O
prompt O
antiviral O
treatment O
are O
critical O
. O
Post O
- O
exposure O
prophylaxis O
of O
H1N1 O
with O
oseltamivir B-DRUG
was O
safe O
, O
effective O
and O
well O
tolerated O
to O
prevent O
H1N1 O
influenza O
A O
virus O
infection O
in O
newly O
transplanted O
renal O
allograft O
recipient O
receiving O
triple O
immunosuppression O
without O
any O
interaction O
with O
tacrolimus B-DRUG
level O
. O
Oseltamivir B-DRUG
was O
effective O
for O
post O
- O
exposure O
prophylaxis O
of O
H1N1 O
in O
close O
contact O
. O

Prevention O
of O
emergence O
agitation O
in O
seven O
children O
receiving O
low O
- O
dose O
ketamine B-DRUG
and O
propofol B-DRUG
total O
intravenous O
anesthesia O
. O
Emergence O
agitation O
( O
EA O
) O
can O
be O
a O
distressing O
side O
effect O
of O
pediatric O
anesthesia O
. O
We O
retrospectively O
reviewed O
the O
records O
of O
7 O
pediatric O
oncology O
patients O
who O
received O
low O
- O
dose O
ketamine B-DRUG
in O
conjunction O
with O
propofol B-DRUG
for O
total O
intravenous O
anesthesia O
( O
TIVA O
) O
repeatedly O
for O
radiation O
therapy O
. O
EA O
signs O
were O
observed O
in O
all O
7 O
patients O
in O
association O
with O
propofol B-DRUG
TIVA O
but O
did O
not O
recur O
in O
any O
of O
123 O
subsequent O
anesthetics O
sessions O
during O
which O
low O
- O
dose O
ketamine B-DRUG
was O
added O
to O
propofol B-DRUG
. O
Based O
on O
this O
experience O
, O
we O
suggest O
that O
low O
- O
dose O
ketamine B-DRUG
added O
to O
propofol B-DRUG
may O
be O
associated O
with O
prevention O
of O
EA O
in O
children O
with O
a O
history O
of O
EA O
with O
propofol B-DRUG
TIVA O
. O

Tamoxifen B-DRUG
and O
CYP O
2D6 O
inhibitors O
: O
caution O
. O
Tamoxifen B-DRUG
, O
an O
estrogen B-GROUP
antagonist I-GROUP
, O
is O
the O
standard O
hormone O
treatment O
for O
breast O
cancer O
. O
It O
is O
extensively O
transformed O
into O
its O
active O
metabolites O
by O
the O
cytochrome O
P450 O
enzyme O
system O
, O
especially O
into O
endoxifen B-DRUG_N
by O
isoenzyme O
CYP O
2D6 O
. O
Co O
- O
administration O
of O
tamoxifen B-DRUG
with O
isoenzyme O
CYP O
2D6 O
inhibitors O
reduces O
this O
metabolism O
. O
Selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitor I-GROUP
( I-GROUP
SSRI I-GROUP
) I-GROUP
antidepressants I-GROUP
inhibit O
isoenzyme O
CYP O
2D6 O
. O
Paroxetine B-DRUG
and O
fluoxetine B-DRUG
reduce O
the O
plasma O
concentration O
of O
endoxifen B-DRUG_N
by O
about O
50 O
% O
. O
Two O
epidemiological O
studies O
involving O
about O
3700 O
women O
have O
shown O
a O
link O
between O
the O
use O
of O
SSRI B-GROUP
antidepressants I-GROUP
and O
an O
increased O
frequency O
of O
breast O
cancer O
recurrence O
. O
Other O
studies O
, O
with O
a O
lower O
level O
of O
evidence O
, O
were O
less O
convincing O
. O
Studies O
of O
other O
isoenzyme O
CYP O
2D6 O
inhibitors O
showed O
no O
increase O
in O
the O
risk O
of O
breast O
cancer O
recurrence O
, O
but O
they O
lacked O
statistical O
power O
. O
It O
is O
better O
to O
avoid O
prescribing O
isoenzyme O
CYP O
2D6 O
inhibitors O
to O
women O
treated O
with O
tamoxifen B-DRUG
for O
breast O
cancer O
, O
especially O
SSRI B-GROUP
antidepressants I-GROUP
such O
as O
paroxetine B-DRUG
and O
fluoxetine B-DRUG
. O
Depression O
does O
not O
always O
require O
antidepressant B-GROUP
drug I-GROUP
therapy O
, O
and O
antidepressants B-GROUP
have O
no O
proven O
preventive O
impact O
on O
hot O
flushes O
linked O
to O
the O
menopause O
. O
If O
in O
certain O
cases O
, O
an O
antidepressant B-GROUP
is O
considered O
necessary O
, O
it O
may O
be O
advisable O
to O
replace O
tamoxifen B-DRUG
with O
anastrozole B-DRUG
. O

Clarity O
and O
applicability O
of O
drug O
- O
drug O
interaction O
management O
guidelines O
: O
a O
systematic O
appraisal O
by O
general O
practitioners O
and O
community O
pharmacists O
in O
the O
Netherlands O
. O
Despite O
the O
availability O
and O
daily O
use O
of O
computerized O
drug O
- O
drug O
interaction O
surveillance O
systems O
, O
exposure O
to O
potentially O
relevant O
drug O
- O
drug O
interactions O
( O
DDIs O
) O
continues O
. O
DDI O
management O
guidelines O
are O
often O
inadequate O
and O
clear O
management O
options O
are O
lacking O
, O
which O
attributes O
to O
overriding O
of O
DDI O
signals O
. O
Although O
general O
criteria O
for O
the O
development O
and O
reporting O
of O
high O
- O
quality O
clinical O
practice O
guidelines O
have O
been O
identified O
, O
it O
appears O
these O
have O
not O
yet O
been O
applied O
to O
DDI O
management O
guidelines O
. O
The O
aim O
of O
the O
study O
was O
to O
assess O
the O
clarity O
and O
applicability O
of O
guidelines O
for O
the O
management O
of O
potentially O
harmful O
DDIs O
. O
We O
selected O
13 O
DDIs O
that O
are O
potentially O
harmful O
for O
patients O
and O
frequently O
occur O
in O
community O
pharmacy O
practice O
in O
the O
Netherlands O
. O
The O
clarity O
and O
applicability O
of O
the O
management O
guidelines O
of O
these O
DDIs O
were O
appraised O
using O
the O
appropriate O
two O
domains O
- O
' O
Clarity O
and O
presentation O
' O
and O
' O
Applicability O
' O
, O
of O
the O
validated O
Appraisal O
of O
Guidelines O
for O
Research O
and O
Evaluation O
( O
AGREE O
) O
Instrument O
. O
The O
appraisal O
was O
performed O
by O
12 O
community O
pharmacists O
and O
12 O
general O
practitioners O
. O
The O
standardized O
domain O
scores O
and O
mean O
item O
scores O
for O
' O
Clarity O
and O
presentation O
' O
and O
' O
Applicability O
' O
were O
compared O
. O
All O
DDI O
management O
guidelines O
were O
generally O
found O
to O
score O
well O
on O
' O
Clarity O
and O
presentation O
' O
, O
but O
poorly O
with O
respect O
to O
' O
Applicability O
' O
( O
standardized O
domain O
scores O
68 O
. O
0 O
vs O
26 O
. O
1 O
% O
) O
. O
Within O
the O
domain O
' O
Clarity O
and O
presentation O
' O
, O
the O
item O
' O
tools O
for O
application O
' O
received O
the O
lowest O
scores O
. O
Within O
the O
domain O
' O
Applicability O
' O
, O
cost O
implications O
, O
organizational O
barriers O
and O
key O
review O
criteria O
were O
all O
poorly O
documented O
. O
All O
guidelines O
presented O
non O
- O
directive O
advice O
using O
words O
such O
as O
' O
consider O
' O
and O
' O
regularly O
' O
. O
Developers O
of O
DDI O
management O
guidelines O
should O
take O
the O
appropriate O
domains O
of O
the O
AGREE O
Instrument O
into O
consideration O
in O
their O
development O
processes O
. O
The O
applicability O
of O
DDI O
management O
guidelines O
should O
be O
pretested O
before O
publishing O
. O
To O
improve O
guideline O
quality O
, O
more O
attention O
should O
particularly O
be O
paid O
to O
the O
available O
tools O
for O
applications O
and O
cost O
implications O
. O

Motor O
deficits O
and O
recovery O
in O
rats O
with O
unilateral O
spinal O
cord O
hemisection O
mimic O
the O
Brown O
- O
Sequard O
syndrome O
. O
Cervical O
incomplete O
spinal O
cord O
injuries O
often O
lead O
to O
severe O
and O
persistent O
impairments O
of O
sensorimotor O
functions O
and O
are O
clinically O
the O
most O
frequent O
type O
of O
spinal O
cord O
injury O
. O
Understanding O
the O
motor O
impairments O
and O
the O
possible O
functional O
recovery O
of O
upper O
and O
lower O
extremities O
is O
of O
great O
importance O
. O
Animal O
models O
investigating O
motor O
dysfunction O
following O
cervical O
spinal O
cord O
injury O
are O
rare O
. O
We O
analysed O
the O
differential O
spontaneous O
recovery O
of O
fore O
- O
and O
hindlimb O
locomotion O
by O
detailed O
kinematic O
analysis O
in O
adult O
rats O
with O
unilateral O
C4 O
/ O
C5 O
hemisection O
, O
a O
lesion O
that O
leads O
to O
the O
Brown O
- O
S O
quard O
syndrome O
in O
humans O
. O
The O
results O
showed O
disproportionately O
better O
performance O
of O
hindlimb O
compared O
with O
forelimb O
locomotion O
; O
hindlimb O
locomotion O
showed O
substantial O
recovery O
, O
whereas O
the O
ipsilesional O
forelimb O
remained O
in O
a O
very O
poor O
functional O
state O
. O
Such O
a O
differential O
motor O
recovery O
pattern O
is O
also O
known O
to O
occur O
in O
monkeys O
and O
in O
humans O
after O
similar O
spinal O
cord O
lesions O
. O
On O
the O
lesioned O
side O
, O
cortico O
- O
, O
rubro O
- O
, O
vestibulo O
- O
and O
reticulospinal O
tracts O
and O
the O
important O
modulatory O
serotonergic O
, O
dopaminergic O
and O
noradrenergic O
fibre O
systems O
were O
interrupted O
by O
the O
lesion O
. O
In O
an O
attempt O
to O
facilitate O
locomotion O
, O
different O
monoaminergic O
agonists O
were O
injected O
intrathecally O
. O
Injections O
of O
specific O
serotonergic O
and O
noradrenergic O
agonists O
in O
the O
chronic O
phase O
after O
the O
spinal O
cord O
lesion O
revealed O
remarkable O
, O
although O
mostly O
functionally O
negative O
, O
modulations O
of O
particular O
parameters O
of O
hindlimb O
locomotion O
. O
In O
contrast O
, O
forelimb O
locomotion O
was O
mostly O
unresponsive O
to O
these O
agonists O
. O
These O
results O
, O
therefore O
, O
show O
fundamental O
differences O
between O
fore O
- O
and O
hindlimb O
spinal O
motor O
circuitries O
and O
their O
functional O
dependence O
on O
remaining O
descending O
inputs O
and O
exogenous O
spinal O
excitation O
. O
Understanding O
these O
differences O
may O
help O
to O
develop O
future O
therapeutic O
strategies O
to O
improve O
upper O
and O
lower O
limb O
function O
in O
patients O
with O
incomplete O
cervical O
spinal O
cord O
injuries O
. O

Amphetamine B-DRUG
locomotor O
sensitization O
and O
conditioned O
place O
preference O
in O
adolescent O
male O
and O
female O
rats O
neonatally O
treated O
with O
quinpirole B-DRUG_N
. O
Neonatal O
quinpirole B-DRUG_N
treatment O
has O
been O
shown O
to O
produce O
an O
increase O
in O
dopamine O
D2 O
- O
like O
receptor O
sensitivity O
that O
persists O
throughout O
the O
subject O
' O
s O
lifetime O
. O
The O
objective O
was O
to O
analyze O
the O
effects O
of O
neonatal O
quinpirole B-DRUG_N
treatment O
on O
effects O
of O
amphetamine B-DRUG
in O
adolescent O
rats O
using O
locomotor O
sensitization O
and O
conditioned O
place O
preference O
procedures O
. O
Sprague O
- O
Dawley O
rats O
were O
treated O
with O
quinpirole B-DRUG_N
( O
1 O
mg O
/ O
kg O
) O
or O
saline O
from O
postnatal O
days O
( O
P O
) O
1 O
to O
P11 O
and O
raised O
to O
adolescence O
. O
For O
locomotor O
sensitization O
, O
subjects O
were O
given O
amphetamine B-DRUG
( O
1 O
mg O
/ O
kg O
) O
or O
saline O
every O
second O
day O
from O
P35 O
to O
P47 O
and O
were O
placed O
into O
a O
locomotor O
arena O
. O
In O
female O
rats O
, O
neonatal O
quinpirole B-DRUG_N
treatment O
enhanced O
amphetamine B-DRUG
locomotor O
sensitization O
compared O
with O
quinpirole B-DRUG_N
- O
free O
controls O
sensitized O
to O
amphetamine B-DRUG
. O
Male O
rats O
demonstrated O
sensitization O
to O
amphetamine B-DRUG
, O
although O
this O
was O
muted O
compared O
with O
female O
rats O
, O
and O
were O
unaffected O
by O
neonatal O
quinpirole B-DRUG_N
. O
For O
conditioned O
place O
preference O
, O
subjects O
were O
conditioned O
for O
8 O
consecutive O
days O
( O
P32 O
- O
39 O
) O
with O
amphetamine B-DRUG
( O
1 O
mg O
/ O
kg O
) O
or O
saline O
and O
a O
drug O
- O
free O
preference O
test O
was O
conducted O
at O
P40 O
. O
Rats O
treated O
with O
neonatal O
quinpirole B-DRUG_N
enhanced O
time O
spent O
in O
the O
amphetamine B-DRUG
- O
paired O
context O
compared O
with O
quinpirole B-DRUG_N
- O
free O
controls O
conditioned O
with O
amphetamine B-DRUG
, O
but O
only O
female O
controls O
conditioned O
with O
amphetamine B-DRUG
spent O
more O
time O
in O
the O
drug O
- O
paired O
context O
compared O
with O
saline O
- O
treated O
controls O
. O
Increased O
D O
- O
like O
receptor O
sensitivity O
appears O
to O
have O
enhanced O
the O
behavioral O
effects O
of O
amphetamine B-DRUG
, O
but O
these O
effects O
were O
more O
prevalent O
in O
adolescent O
female O
rats O
compared O
with O
male O
rats O
. O

In O
vivo O
CYP3A O
activity O
is O
significantly O
lower O
in O
cyclosporine B-DRUG
- O
treated O
as O
compared O
with O
tacrolimus B-DRUG
- O
treated O
renal O
allograft O
recipients O
. O
In O
vitro O
studies O
have O
identified O
cyclosporine B-DRUG
and O
tacrolimus B-DRUG
as O
CYP3A O
inhibitors O
. O
In O
the O
current O
study O
in O
renal O
allograft O
recipients O
, O
we O
used O
intravenously O
and O
orally O
administered O
midazolam B-DRUG
as O
a O
drug O
probe O
to O
assess O
whether O
the O
study O
drugs O
at O
doses O
that O
are O
generally O
used O
in O
clinical O
practice O
have O
differential O
effects O
on O
in O
vivo O
hepatic O
and O
first O
- O
pass O
CYP3A O
activities O
. O
Systemic O
and O
apparent O
oral O
midazolam B-DRUG
clearance O
were O
24 O
% O
( O
269 O
73 O
vs O
. O
354 O
102 O
ml O
/ O
min O
, O
P O
= O
0 O
. O
022 O
) O
and O
31 O
% O
( O
479 O
190 O
vs O
. O
688 O
265 O
ml O
/ O
min O
, O
P O
= O
0 O
. O
013 O
) O
, O
respectively O
, O
lower O
in O
cyclosporine B-DRUG
- O
treated O
patients O
( O
n O
= O
20 O
) O
than O
in O
matched O
tacrolimus B-DRUG
- O
treated O
patients O
( O
n O
= O
20 O
) O
. O
The O
latter O
displayed O
midazolam B-DRUG
clearances O
similar O
to O
those O
in O
two O
larger O
cohorts O
of O
nonmatched O
tacrolimus B-DRUG
- O
treated O
patients O
( O
n O
= O
58 O
and O
n O
= O
80 O
) O
and O
to O
those O
receiving O
a O
calcineurin B-GROUP
inhibitor I-GROUP
- O
free O
regimen O
( O
n O
= O
6 O
) O
. O
This O
implies O
that O
in O
vivo O
hepatic O
and O
first O
- O
pass O
CYP3A O
activities O
are O
significantly O
lower O
in O
patients O
receiving O
cyclosporine B-DRUG
than O
in O
those O
receiving O
tacrolimus B-DRUG
, O
indicating O
that O
, O
at O
the O
doses O
generally O
used O
in O
clinical O
practice O
, O
cyclosporine B-DRUG
is O
the O
stronger O
of O
the O
two O
with O
respect O
to O
CYP3A O
inhibition O
. O
This O
observation O
has O
important O
implications O
in O
the O
context O
of O
drug O
- O
drug O
interactions O
in O
transplant O
recipients O
. O

Improvement O
of O
colchicine B-DRUG
oral O
bioavailability O
by O
incorporating O
eugenol B-DRUG
in O
the O
nanoemulsion O
as O
an O
oil O
excipient O
and O
enhancer O
. O
The O
effect O
of O
eugenol B-DRUG
on O
colchicine B-DRUG
transport O
across O
an O
isolated O
rat O
intestinal O
membrane O
was O
studied O
using O
an O
in O
vitro O
diffusion O
chamber O
system O
. O
We O
found O
that O
eugenol B-DRUG
increased O
the O
absorptive O
transport O
of O
the O
drug O
efficiently O
. O
The O
effect O
of O
eugenol B-DRUG
on O
intestinal O
absorption O
of O
colchicine B-DRUG
in O
an O
oral O
administrative O
nanoemulsion O
formulation O
was O
also O
demonstrated O
in O
vivo O
. O
The O
colchicine B-DRUG
nanoemulsion O
was O
prepared O
with O
isopropyl B-DRUG_N
myristate I-DRUG_N
, O
eugenol B-DRUG
, O
Tween80 B-DRUG_N
, O
ethanol B-DRUG
and O
water O
, O
and O
eugenol B-DRUG
was O
used O
as O
an O
oil O
phase O
in O
the O
formulation O
; O
an O
average O
particle O
size O
of O
this O
nanoemulsion O
was O
41 O
. O
2 O
7 O
. O
2 O
nm O
. O
The O
permeation O
of O
colchicine B-DRUG
in O
the O
nanoemulsion O
across O
the O
intestinal O
membrane O
was O
significantly O
different O
from O
that O
of O
the O
control O
group O
( O
0 O
. O
2 O
mM O
colchicine B-DRUG
) O
. O
Finally O
, O
co O
- O
administration O
of O
eugenol B-DRUG
in O
colchicine B-DRUG
nanoemulsion O
to O
enhance O
the O
colchicine B-DRUG
bioavailability O
was O
investigated O
by O
an O
oral O
administration O
method O
. O
After O
oral O
administration O
of O
colchicine B-DRUG
( O
8 O
mg O
/ O
kg O
) O
in O
the O
form O
of O
either O
the O
nanoemulsion O
or O
in O
free O
colchicine B-DRUG
solution O
, O
the O
relative O
bioavailability O
of O
nanoemulsion O
and O
eugenol B-DRUG
- O
nanoemulsion O
were O
enhanced O
by O
about O
1 O
. O
6 O
- O
and O
2 O
. O
1 O
- O
fold O
, O
respectively O
, O
compared O
with O
free O
colchicine B-DRUG
solution O
. O
The O
procedure O
indicated O
that O
the O
intestinal O
absorption O
of O
colchicine B-DRUG
was O
enhanced O
significantly O
by O
eugenol B-DRUG
in O
the O
tested O
nanoemulsion O
. O
All O
the O
results O
suggested O
that O
eugenol B-DRUG
is O
an O
efficient O
component O
in O
an O
oral O
administrative O
formulation O
for O
improving O
the O
intestinal O
absorption O
of O
colchicine B-DRUG
. O

[ O
Protective O
effects O
of O
ginseng B-DRUG
- O
ginko B-DRUG
extracts O
combination O
on O
rat O
primary O
cultured O
neurons O
induced O
by O
Abeta B-DRUG_N
( I-DRUG_N
1 I-DRUG_N
- I-DRUG_N
40 I-DRUG_N
) I-DRUG_N
] O
. O
To O
observe O
the O
injury O
in O
rat O
primary O
cultured O
neurons O
induced O
by O
Abeta B-DRUG_N
( I-DRUG_N
1 I-DRUG_N
- I-DRUG_N
40 I-DRUG_N
) I-DRUG_N
and O
the O
protective O
effects O
of O
combination O
of O
ginseng B-DRUG
and O
ginko B-DRUG
extracts O
. O
Primary O
neurons O
were O
induced O
by O
Abeta B-DRUG_N
( I-DRUG_N
1 I-DRUG_N
- I-DRUG_N
40 I-DRUG_N
) I-DRUG_N
to O
establish O
the O
cell O
model O
of O
toxic O
injury O
. O
Using O
flow O
cytometry O
with O
Annexin O
V O
- O
FITC O
/ O
PI O
double O
staining O
, O
MTP O
assay O
, O
transmission O
electron O
microscopy O
and O
Western O
blot O
, O
the O
appropriate O
concentration O
and O
duration O
of O
AP O
for O
cell O
model O
establishment O
were O
determined O
. O
The O
effects O
of O
extracts O
of O
ginseng B-DRUG
and O
ginko B-DRUG
( O
EGGB B-DRUG
) O
on O
cellular O
proliferative O
activity O
, O
apoptotic O
rate O
, O
ultrastructure O
and O
caspase O
- O
3 O
expression O
were O
detected O
. O
The O
apoptotic O
rate O
was O
increased O
significantly O
after O
neurons O
were O
induced O
by O
1 O
micromol O
x O
L O
( O
- O
1 O
) O
Abeta B-DRUG_N
( I-DRUG_N
- I-DRUG_N
40 I-DRUG_N
) I-DRUG_N
for O
24 O
h O
( O
P O
< O
0 O
. O
01 O
) O
. O
EGGB B-DRUG
( O
5 O
, O
50 O
mg O
L O
( O
- O
1 O
) O
) O
significantly O
enhanced O
the O
proliferative O
activity O
( O
P O
< O
0 O
. O
05 O
) O
. O
Meanwhile O
, O
EGGB B-DRUG
( O
50 O
mg O
L O
( O
- O
1 O
) O
) O
inhibited O
neuronal O
apoptosis O
and O
caspase O
- O
3 O
overexpression O
and O
improved O
cellular O
ultrastructure O
remarkably O
( O
P O
< O
0 O
. O
05 O
, O
P O
< O
0 O
. O
01 O
) O
. O
Abeta B-DRUG
( I-DRUG
1 I-DRUG
- I-DRUG
40 I-DRUG
) I-DRUG
could O
significantly O
induce O
primary O
cultured O
neurons O
to O
apoptosis O
in O
vitro O
. O
EGGB B-DRUG
showed O
beneficial O
neuroprotective O
effects O
against O
neuronal O
apoptosis O
, O
which O
might O
be O
due O
to O
improving O
the O
structures O
of O
neuron O
and O
its O
subcellular O
organelles O
, O
enhancing O
cellular O
proliferative O
activity O
and O
inhibiting O
caspase O
- O
3 O
overexpression O
in O
neurons O
. O

[ O
Effects O
of O
glycyrrhiza B-DRUG_N
extract I-DRUG_N
on O
pharmacokinetics O
property O
of O
daphnetin B-DRUG_N
in O
rats O
] O
. O
To O
research O
the O
influence O
of O
glycyrrhiza B-DRUG_N
extract I-DRUG_N
on O
the O
pharmacokinetics O
characteristic O
parameters O
of O
daphnetin B-DRUG_N
, O
which O
was O
aimed O
to O
explore O
the O
rationality O
of O
concert O
application O
of O
drugs O
. O
The O
rats O
received O
intragastric O
administration O
of O
daphnetin B-DRUG_N
and O
glycyrrhiza B-DRUG_N
extract I-DRUG_N
containing O
the O
same O
daphnetin B-DRUG_N
respectively O
. O
The O
blood O
concentration O
of O
daphnetin B-DRUG_N
was O
assayed O
by O
LC O
- O
MS O
. O
The O
data O
was O
processed O
by O
program O
DAS2 O
. O
1 O
. O
1 O
. O
Glycyrrhiza O
extract O
can O
reduce O
the O
t O
( O
1 O
/ O
2 O
) O
, O
tmax O
and O
Ke O
of O
daphnetin B-DRUG_N
, O
while O
increased O
the O
Ka O
and O
AUC O
( O
0 O
- O
infinity O
) O
. O
Glycyrrhiza O
extract O
promoted O
the O
oral O
absorption O
of O
daphnetin B-DRUG_N
, O
slowed O
down O
the O
elimination O
and O
increased O
the O
biological O
availability O
. O

Antimicrobial O
effects O
of O
o B-DRUG_N
- I-DRUG_N
cymen I-DRUG_N
- I-DRUG_N
5 I-DRUG_N
- I-DRUG_N
ol I-DRUG_N
and O
zinc B-DRUG
, O
alone O
& O
in O
combination O
in O
simple O
solutions O
and O
toothpaste O
formulations O
. O
This O
study O
aimed O
to O
evaluate O
antimicrobial O
effects O
of O
an O
o B-DRUG_N
- I-DRUG_N
cymen I-DRUG_N
- I-DRUG_N
5 I-DRUG_N
- I-DRUG_N
ol I-DRUG_N
/ O
zinc B-DRUG
system O
. O
o B-DRUG_N
- I-DRUG_N
Cymen I-DRUG_N
- I-DRUG_N
5 I-DRUG_N
- I-DRUG_N
ol I-DRUG_N
and O
zinc B-DRUG
gluconate I-DRUG
minimum O
inhibitory O
concentration O
( O
MIC O
) O
and O
minimum O
bactericidal O
concentration O
( O
MBC O
) O
were O
determined O
against O
Streptococcus O
mutans O
, O
Actinomyces O
viscosus O
, O
Porphyromonas O
gingivalis O
, O
Fusobacterium O
nucleatum O
and O
Candida O
albicans O
. O
Synergy O
was O
investigated O
by O
checkerboard O
MIC O
/ O
MBC O
; O
inhibition O
of O
P O
. O
gingivalis O
protease O
activity O
and O
S O
. O
mutans O
glycolysis O
were O
investigated O
. O
Slurried O
toothpastes O
containing O
the O
system O
were O
assessed O
in O
kill O
time O
assays O
against O
S O
. O
mutans O
and O
E O
. O
coli O
. O
o B-DRUG_N
- I-DRUG_N
Cymen I-DRUG_N
- I-DRUG_N
5 I-DRUG_N
- I-DRUG_N
ol I-DRUG_N
MIC O
was O
between O
1 O
. O
7 O
mM O
to O
3 O
. O
4 O
mM O
; O
MBC O
was O
3 O
. O
4 O
mM O
to O
6 O
. O
7 O
mM O
. O
Zinc B-DRUG
gluconate I-DRUG
MIC O
was O
2 O
. O
8 O
mM O
to O
11 O
mM O
; O
MBC O
was O
between O
11 O
mM O
and O
> O
44 O
mM O
. O
The O
two O
agents O
in O
solution O
showed O
synergy O
( O
FICI O
0 O
. O
50 O
) O
against O
P O
. O
gingivalis O
and O
F O
. O
nucleatum O
, O
with O
MIC O
of O
0 O
. O
42 O
mM O
/ O
0 O
. O
69 O
mM O
for O
o B-DRUG_N
- I-DRUG_N
cymen I-DRUG_N
- I-DRUG_N
5 I-DRUG_N
- I-DRUG_N
ol I-DRUG_N
/ O
zinc B-DRUG
gluconate I-DRUG
, O
respectively O
. O
Zinc B-DRUG
inhibited O
glycolysis O
and O
protease O
to O
a O
greater O
degree O
than O
o B-DRUG_N
- I-DRUG_N
cymen I-DRUG_N
- I-DRUG_N
5 I-DRUG_N
- I-DRUG_N
ol I-DRUG_N
; O
glycolysis O
inhibition O
by O
the O
two O
agents O
was O
additive O
. O
o B-DRUG_N
- I-DRUG_N
Cymen I-DRUG_N
- I-DRUG_N
5 I-DRUG_N
- I-DRUG_N
ol I-DRUG_N
/ O
zinc B-DRUG
chloride I-DRUG
in O
toothpaste O
showed O
greater O
effects O
than O
placebo O
( O
120s O
log10 O
kill O
= O
7 O
. O
35 O
0 O
. O
40 O
and O
4 O
. O
02 O
0 O
. O
40 O
, O
respectively O
) O
. O
The O
zinc B-DRUG
/ O
o B-DRUG_N
- I-DRUG_N
cymen I-DRUG_N
- I-DRUG_N
5 I-DRUG_N
- I-DRUG_N
ol I-DRUG_N
system O
has O
direct O
antimicrobial O
effects O
and O
inhibits O
oral O
disease O
- O
related O
processes O
. O
Synergistic O
effects O
were O
seen O
against O
anaerobes O
. O
A O
system O
combining O
o B-DRUG_N
- I-DRUG_N
cymen I-DRUG_N
- I-DRUG_N
5 I-DRUG_N
- I-DRUG_N
ol I-DRUG_N
and O
zinc B-DRUG
shows O
properties O
desirable O
for O
incorporation O
in O
toothpastes O
. O

Improved O
parathyroid O
hormone O
control O
by O
cinacalcet B-DRUG
is O
associated O
with O
reduction O
in O
darbepoetin B-DRUG
requirement O
in O
patients O
with O
end O
- O
stage O
renal O
disease O
. O
Uncontrolled O
hy O
- O
per O
- O
parathyroidism O
causes O
bone O
marrow O
fibrosis O
, O
leading O
to O
erythropoietin B-DRUG
( O
EPO B-DRUG
) O
resistance O
. O
Medical O
treatment O
with O
cinacalcet B-DRUG
is O
effective O
in O
reducing O
plasma O
parathyroid O
hormone O
( O
PTH O
) O
levels O
, O
but O
its O
effect O
on O
darbepoetin B-DRUG
dosing O
is O
unknown O
. O
METHODS O
AND O
AIMS O
: O
We O
conducted O
a O
retrospective O
cohort O
study O
of O
40 O
end O
- O
stage O
renal O
disease O
( O
ESRD O
) O
patients O
( O
age O
: O
55 O
14 O
; O
mean O
SD O
; O
21 O
: O
male O
) O
who O
had O
at O
least O
12 O
months O
of O
cinacalcet B-DRUG
therapy O
. O
The O
distribution O
of O
renal O
replacement O
therapies O
were O
: O
14 O
peritoneal O
dialysis O
, O
18 O
conventional O
hemodialysis O
and O
8 O
nocturnal O
hemodialysis O
. O
Standard O
dialysis O
related O
biochemical O
indices O
and O
medications O
used O
were O
recorded O
. O
The O
primary O
objective O
of O
the O
study O
was O
to O
ascertain O
the O
difference O
in O
darbepoetin B-DRUG
responsiveness O
before O
and O
after O
12 O
months O
of O
cinacalcet B-DRUG
therapy O
. O
Our O
secondary O
objective O
was O
to O
determine O
if O
there O
was O
a O
relationship O
between O
the O
changes O
in O
PTH O
and O
darbepoetin B-DRUG
requirement O
. O
Overall O
, O
PTH O
levels O
decreased O
from O
197 O
. O
5 O
( O
151 O
. O
8 O
; O
249 O
. O
2 O
) O
to O
66 O
. O
1 O
( O
41 O
. O
2 O
; O
136 O
. O
5 O
) O
( O
median O
( O
25th O
; O
75th O
percentile O
) O
) O
pmol O
/ O
l O
; O
p O
& O
lt O
; O
0 O
. O
001 O
. O
Cinacalcet B-DRUG
dose O
increased O
from O
30 O
. O
0 O
6 O
to O
63 O
25 O
mg O
/ O
day O
, O
p O
< O
0 O
. O
05 O
. O
Hemoglobin O
remained O
unchanged O
( O
116 O
13 O
to O
116 O
13 O
g O
/ O
l O
) O
, O
while O
darbepoetin B-DRUG
requirement O
decreased O
from O
40 O
( O
20 O
; O
60 O
) O
to O
24 O
( O
19 O
; O
59 O
) O
g O
/ O
week O
, O
p O
= O
0 O
. O
02 O
. O
The O
remainder O
of O
the O
dialysis O
- O
related O
biochemistry O
( O
electrolytes O
, O
calcium O
, O
phosphate O
, O
iron O
status O
) O
and O
vitamin O
D O
use O
remained O
unchanged O
. O
A O
reduction O
in O
PTH O
level O
of O
greater O
than O
30 O
% O
was O
experienced O
by O
82 O
. O
5 O
% O
( O
33 O
/ O
40 O
) O
of O
our O
cohort O
. O
Among O
the O
responders O
, O
the O
fall O
in O
PTH O
and O
reduction O
darbepoetin B-DRUG
requirement O
were O
related O
( O
R O
= O
- O
0 O
. O
48 O
, O
p O
= O
0 O
. O
004 O
) O
. O
Reduction O
of O

PTH O
by O
cinacalcet B-DRUG
is O
associated O
with O
a O
decrease O
in O
darbepoetin B-DRUG
requirement O
. O
The O
interface O
between O
bone O
and O
bone O
marrow O
in O
uremia O
represents O
a O
critical O
step O
in O
red O
blood O
cell O
production O
which O
merits O
further O
investigation O
. O

Interaction O
of O
celecoxib B-DRUG
with O
different O
anti B-GROUP
- I-GROUP
cancer I-GROUP
drugs I-GROUP
is O
antagonistic O
in O
breast O
but O
not O
in O
other O
cancer O
cells O
. O
Celecoxib B-DRUG
, O
an O
inhibitor O
of O
cyclooxygenase O
- O
2 O
, O
is O
being O
investigated O
for O
enhancement O
of O
chemotherapy O
efficacy O
in O
cancer O
clinical O
trials O
. O
This O
study O
investigates O
the O
ability O
of O
cyclooxygenase B-GROUP
- I-GROUP
2 I-GROUP
inhibitors I-GROUP
to O
sensitize O
cells O
from O
different O
origins O
to O
several O
chemotherapeutic B-GROUP
agents I-GROUP
. O
The O
effect O
of O
the O
drug O
' O
s O
mechanism O
of O
action O
and O
sequence O
of O
administration O
are O
also O
investigated O
. O
The O
sensitivity O
, O
cell O
cycle O
, O
apoptosis O
and O
DNA O
damage O
of O
five O
different O
cancer O
cell O
lines O
( O
HeLa O
, O
HCT116 O
, O
HepG2 O
, O
MCF7 O
and O
U251 O
) O
to O
5 B-DRUG
- I-DRUG
FU I-DRUG
, O
cisplatin B-DRUG
, O
doxorubicin B-DRUG
and O
etoposide B-DRUG
celecoxib B-DRUG
following O
different O
incubation O
schedules O
were O
analyzed O
. O
We O
found O
antagonism O
between O
celecoxib B-DRUG
and O
the O
four O
drugs O
in O
the O
breast O
cancer O
cells O
MCF7 O
following O
all O
incubation O
schedules O
and O
between O
celecoxib B-DRUG
and O
doxorubicin B-DRUG
in O
all O
cell O
lines O
except O
for O
two O
combinations O
in O
HCT116 O
cells O
. O
Celecoxib B-DRUG
with O
the O
other O
three O
drugs O
in O
the O
remaining O
four O
cell O
lines O
resulted O
in O
variable O
interactions O
. O
Mechanistic O
investigations O
revealed O
that O
celecoxib B-DRUG
exerts O
different O
molecular O
effects O
in O
different O
cells O
. O
In O
some O
lines O
, O
it O
abrogates O
the O
drug O
- O
induced O
G2 O
/ O
M O
arrest O
enhancing O
pre O
- O
mature O
entry O
into O
mitosis O
with O
damaged O
DNA O
thus O
increasing O
apoptosis O
and O
resulting O
in O
synergism O
. O
In O
other O
cells O
, O
it O
enhances O
drug O
- O
induced O
G2 O
/ O
M O
arrest O
allowing O
time O
to O
repair O
drug O
- O
induced O
DNA O
damage O
before O
entry O
into O
mitosis O
and O
decreasing O
cell O
death O
resulting O
in O
antagonism O
. O
In O
some O
synergistic O
combinations O
, O
celecoxib O
- O
induced O
abrogation O
of O
G2 O
/ O
M O
arrest O
was O
not O
associated O
with O
apoptosis O
but O
permanent O
arrest O
in O
G1 O
phase O
. O
These O
results O
, O
if O
confirmed O
in O
- O
vivo O
, O
indicate O
that O
celecoxib B-DRUG
is O
not O
a O
suitable O
chemosensitizer O
for O
breast O
cancer O
or O
with O
doxorubicin B-DRUG
for O
other O
cancers O
. O
Moreover O
, O
combination O
of O
celecoxib B-DRUG
with O
other O
drugs O
should O
be O
tailored O
to O
the O
tumor O
type O
, O
drug O
and O
administration O
schedule O
. O

Opportunities O
and O
challenges O
in O
the O
development O
of O
experimental O
drug O
combinations O
for O
cancer O
. O
It O
is O
becoming O
increasingly O
evident O
that O
cancers O
are O
dependent O
on O
a O
number O
of O
altered O
molecular O
pathways O
and O
can O
develop O
diverse O
mechanisms O
of O
resistance O
to O
therapy O
with O
single O
agents O
. O
Therefore O
, O
combination O
regimens O
may O
provide O
the O
best O
hope O
for O
effective O
therapies O
with O
durable O
effects O
. O
Despite O
preclinical O
data O
to O
support O
this O
notion O
, O
there O
are O
many O
challenges O
to O
the O
development O
of O
targeted O
combinations O
including O
scientific O
, O
economic O
, O
legal O
, O
and O
regulatory O
barriers O
. O
A O
discussion O
of O
these O
challenges O
and O
identification O
of O
models O
and O
best O
practices O
are O
presented O
with O
intent O
of O
aiding O
the O
research O
community O
in O
addressing O
real O
and O
perceived O
barriers O
to O
the O
development O
of O
combination O
therapies O
for O
cancer O
. O

Network O
neighbors O
of O
drug O
targets O
contribute O
to O
drug O
side O
- O
effect O
similarity O
. O
In O
pharmacology O
, O
it O
is O
essential O
to O
identify O
the O
molecular O
mechanisms O
of O
drug O
action O
in O
order O
to O
understand O
adverse O
side O
effects O
. O
These O
adverse O
side O
effects O
have O
been O
used O
to O
infer O
whether O
two O
drugs O
share O
a O
target O
protein O
. O
However O
, O
side O
- O
effect O
similarity O
of O
drugs O
could O
also O
be O
caused O
by O
their O
target O
proteins O
being O
close O
in O
a O
molecular O
network O
, O
which O
as O
such O
could O
cause O
similar O
downstream O
effects O
. O
In O
this O
study O
, O
we O
investigated O
the O
proportion O
of O
side O
- O
effect O
similarities O
that O
is O
due O
to O
targets O
that O
are O
close O
in O
the O
network O
compared O
to O
shared O
drug O
targets O
. O
We O
found O
that O
only O
a O
minor O
fraction O
of O
side O
- O
effect O
similarities O
( O
5 O
. O
8 O
% O
) O
are O
caused O
by O
drugs O
targeting O
proteins O
close O
in O
the O
network O
, O
compared O
to O
side O
- O
effect O
similarities O
caused O
by O
overlapping O
drug O
targets O
( O
64 O
% O
) O
. O
Moreover O
, O
these O
targets O
that O
cause O
similar O
side O
effects O
are O
more O
often O
in O
a O
linear O
part O
of O
the O
network O
, O
having O
two O
or O
less O
interactions O
, O
than O
drug O
targets O
in O
general O
. O
Based O
on O
the O
examples O
, O
we O
gained O
novel O
insight O
into O
the O
molecular O
mechanisms O
of O
side O
effects O
associated O
with O
several O
drug O
targets O
. O
Looking O
forward O
, O
such O
analyses O
will O
be O
extremely O
useful O
in O
the O
process O
of O
drug O
development O
to O
better O
understand O
adverse O
side O
effects O
. O

[ O
Does O
implementation O
of O
benchmarking O
in O
quality O
circles O
improve O
the O
quality O
of O
care O
of O
patients O
with O
asthma O
and O
reduce O
drug O
interaction O
] O
. O
The O
purpose O
of O
this O
cluster O
- O
randomised O
controlled O
trial O
was O
to O
evaluate O
the O
efficacy O
of O
quality O
circles O
( O
QCs O
) O
working O
either O
with O
general O
data O
- O
based O
feedback O
or O
with O
an O
open O
benchmark O
within O
the O
field O
of O
asthma O
care O
and O
drug O
- O
drug O
interactions O
. O
Twelve O
QCs O
, O
involving O
96 O
general O
practitioners O
from O
85 O
practices O
, O
were O
randomised O
. O
Six O
QCs O
worked O
with O
traditional O
anonymous O
feedback O
and O
six O
with O
an O
open O
benchmark O
. O
Two O
QC O
meetings O
supported O
with O
feedback O
reports O
were O
held O
covering O
the O
topics O
" O
drug O
- O
drug O
interactions O
" O
and O
" O
asthma O
" O
; O
in O
both O
cases O
discussions O
were O
guided O
by O
a O
trained O
moderator O
. O
Outcome O
measures O
included O
health O
- O
related O
quality O
of O
life O
and O
patient O
satisfaction O
with O
treatment O
, O
asthma O
severity O
and O
number O
of O
potentially O
inappropriate O
drug O
combinations O
as O
well O
as O
the O
general O
practitioners O
' O
satisfaction O
in O
relation O
to O
the O
performance O
of O
the O
QC O
. O
A O
significant O
improvement O
in O
the O
treatment O
of O
asthma O
was O
observed O
in O
both O
trial O
arms O
. O
However O
, O
there O
was O
only O
a O
slight O
improvement O
regarding O
inappropriate O
drug O
combinations O
. O
There O
were O
no O
relevant O
differences O
between O
the O
group O
with O
open O
benchmark O
( O
B O
- O
QC O
) O
and O
traditional O
quality O
circles O
( O
T O
- O
QC O
) O
. O
The O
physicians O
' O
satisfaction O
with O
the O
QC O
performance O
was O
significantly O
higher O
in O
the O
T O
- O
QCs O
. O
General O
practitioners O
seem O
to O
take O
a O
critical O
perspective O
about O
open O
benchmarking O
in O
quality O
circles O
. O
Caution O
should O
be O
used O
when O
implementing O
benchmarking O
in O
a O
quality O
circle O
as O
it O
did O
not O
improve O
healthcare O
when O
compared O
to O
the O
traditional O
procedure O
with O
anonymised O
comparisons O
. O

[ O
Interaction O
between O
clopidogrel B-DRUG
and O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
] O
. O
The O
drug O
interaction O
between O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
and O
clopidogrel B-DRUG
has O
been O
the O
subject O
of O
much O
study O
in O
recent O
years O
. O
Contradictory O
results O
regarding O
the O
effect O
of O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
on O
platelet O
reactivity O
and O
on O
clinical O
outcome O
in O
clopidogrel B-DRUG
- O
treated O
patients O
have O
been O
reported O
in O
literature O
. O
Concomitant O
use O
of O
omeprazole B-DRUG
and O
clopidogrel B-DRUG
was O
found O
to O
decrease O
the O
exposure O
( O
AUC O
) O
to O
clopidogrel O
' O
s O
active O
metabolite O
by O
50 O
% O
and O
to O
sharply O
increase O
platelet O
reactivity O
, O
as O
a O
result O
of O
inhibition O
by O
omeprazole B-DRUG
of O
CYP2C19 O
, O
a O
cytochrome O
P450 O
( O
CYP O
) O
enzyme O
. O
Pantoprazole B-DRUG
has O
a O
much O
weaker O
effect O
on O
clopidogrel B-DRUG
' O
s O
pharmacokinetics O
and O
on O
platelet O
reactivity O
during O
concomitant O
use O
. O
The O
influence O
of O
the O
other O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
when O
used O
simultaneously O
with O
clopidogrel B-DRUG
has O
not O
yet O
been O
investigated O
in O
adequately O
randomized O
studies O
. O
Regulatory O
agencies O
state O
that O
the O
combination O
of O
clopidogrel B-DRUG
and O
the O
CYP2C19 O
inhibitors O
omeprazole B-DRUG
and O
esomeprazole B-DRUG
should O
be O
avoided O
. O
To O
date O
, O
there O
is O
no O
conclusive O
evidence O
of O
a O
clinically O
- O
relevant O
interaction O
between O
any O
of O
the O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
and O
clopidogrel B-DRUG
. O

ABC O
transporters O
influence O
sensitivity O
of O
Brugia O
malayi O
to O
moxidectin B-DRUG_N
and O
have O
potential O
roles O
in O
drug O
resistance O
. O
Some O
ABC O
transporters O
play O
a O
significant O
role O
in O
human O
health O
and O
illness O
because O
they O
confer O
multidrug O
resistance O
( O
MDR O
) O
through O
their O
overexpression O
. O
Compounds O
that O
inhibit O
the O
drug O
efflux O
mechanism O
can O
improve O
efficacy O
or O
reverse O
resistance O
. O
Of O
the O
eight O
described O
ABC O
transporter O
subfamilies O
, O
those O
proteins O
conferring O
MDR O
in O
humans O
are O
in O
subfamilies O
A O
, O
B O
, O
C O
, O
and O
G O
. O
In O
nematodes O
, O
transporters O
in O
subfamilies O
B O
and O
C O
are O
suggested O
to O
confer O
resistance O
to O
ivermectin B-DRUG
. O
The O
Brugia O
malayi O
ABC O
transporter O
superfamily O
was O
examined O
to O
assess O
their O
potential O
to O
influence O
sensitivity O
to O
moxidectin B-DRUG_N
. O
There O
was O
an O
increase O
in O
expression O
of O
ABC O
transporters O
in O
subfamilies O
A O
, O
B O
, O
C O
, O
and O
G O
following O
treatment O
. O
Co O
- O
administration O
of O
moxidectin B-DRUG_N
with O
inhibitors O
of O
ABC O
transporter O
function O
did O
not O
enhance O
sensitivity O
to O
moxidectin B-DRUG_N
in O
males O
; O
however O
, O
sensitivity O
was O
significantly O
enhanced O
in O
females O
and O
microfilariae O
. O
The O
work O
suggests O
that O
ABC O
transporters O
influence O
sensitivity O
to O
moxidectin B-DRUG_N
and O
have O
a O
potential O
role O
in O
drug O
resistance O
. O

In O
vitro O
activity O
of O
minocycline B-DRUG
combined O
with O
fosfomycin B-DRUG
against O
clinical O
isolates O
of O
methicillin B-DRUG
- O
resistant O
Staphylococcus O
aureus O
. O
This O
study O
aimed O
to O
evaluate O
the O
in O
vitro O
activity O
of O
minocycline B-DRUG
combined O
with O
fosfomycin B-DRUG
against O
isolates O
of O
methicillin B-DRUG
- O
resistant O
Staphylococcus O
aureus O
( O
MRSA O
) O
. O
A O
total O
of O
87 O
clinical O
isolates O
of O
MRSA O
collected O
from O
three O
Chinese O
hospitals O
were O
included O
in O
the O
study O
. O
The O
checkerboard O
method O
with O
determination O
of O
the O
fractional O
IC O
index O
( O
FICI O
) O
was O
used O
to O
determine O
whether O
antibiotic B-GROUP
combinations O
act O
synergistically O
against O
these O
isolates O
. O
The O
susceptibility O
results O
for O
minocycline B-DRUG
and O
fosfomycin B-DRUG
were O
interpreted O
according O
to O
the O
most O
relevant O
criteria O
. O
The O
results O
demonstrated O
the O
following O
interactions O
: O
76 O
isolates O
( O
87 O
. O
4 O
% O
) O
showed O
synergistic O
interactions O
( O
FICI O
0 O
. O
5 O
) O
and O
11 O
isolates O
( O
12 O
. O
6 O
% O
) O
showed O
indifferent O
interactions O
( O
0 O
. O
5 O
& O
lt O
; O
FICI O
& O
lt O
; O
4 O
) O
. O
No O
antagonistic O
interactions O
( O
FICI O
4 O
) O
were O
observed O
. O
The O
combination O
of O
minocycline B-DRUG
and O
fosfomycin B-DRUG
can O
be O
synergistic O
against O
MRSA O
. O
Further O
studies O
are O
required O
to O
determine O
the O
potential O
clinical O
role O
of O
this O
combination O
regimen O
as O
a O
therapeutic O
alternative O
for O
certain O
types O
of O
MRSA O
infections O
. O

The O
role O
of O
interneurons O
in O
shaping O
Purkinje O
cell O
responses O
in O
the O
cerebellar O
cortex O
. O
The O
well O
established O
anatomy O
of O
the O
cerebellar O
cortex O
has O
led O
to O
suggestions O
that O
cerebellar O
molecular O
layer O
interneurons O
laterally O
inhibit O
Purkinje O
cells O
. O
In O
support O
of O
the O
anatomical O
predictions O
, O
on O
- O
beam O
excitation O
and O
off O
- O
beam O
inhibition O
of O
Purkinje O
cells O
have O
been O
shown O
to O
occur O
when O
the O
surface O
of O
the O
cerebellum O
is O
electrically O
excited O
. O
Patchy O
excitation O
of O
Purkinje O
cells O
with O
flanking O
inhibition O
of O
sagittally O
oriented O
Purkinje O
cells O
have O
also O
been O
demonstrated O
following O
peripheral O
stimulation O
in O
vivo O
. O
To O
extend O
these O
observations O
, O
we O
mapped O
the O
functional O
connectivity O
between O
granule O
cells O
, O
molecular O
layer O
interneurons O
, O
and O
Purkinje O
cells O
in O
rats O
. O
Patches O
of O
granule O
cells O
were O
asynchronously O
activated O
by O
photostimulation O
to O
mimic O
their O
excitation O
by O
a O
mossy O
fiber O
as O
it O
occurs O
in O
vivo O
. O
We O
found O
with O
remarkable O
consistency O
that O
, O
in O
the O
sagittal O
orientation O
, O
granule O
cells O
elicit O
a O
stereotypic O
set O
of O
responses O
. O
Granule O
cells O
immediately O
underneath O
a O
Purkinje O
cell O
provide O
pure O
excitation O
. O
Granule O
cells O
positioned O
340 O
- O
400 O
m O
laterally O
provided O
pure O
inhibition O
, O
consistent O
with O
the O
lateral O
inhibition O
proposed O
earlier O
. O
The O
net O
effect O
of O
exciting O
granule O
cells O
in O
between O
these O
two O
extremes O
was O
to O
provide O
a O
systematic O
change O
in O
the O
response O
of O
Purkinje O
cells O
, O
from O
net O
excitation O
to O
net O
inhibition O
moving O
laterally O
from O
the O
Purkinje O
cell O
. O
In O
contrast O
to O
the O
sagittal O
orientation O
, O
in O
the O
coronal O
orientation O
the O
organization O
of O
Purkinje O
cell O
responses O
with O
granule O
cell O
activation O
was O
remarkably O
different O
. O
Independent O
of O
the O
location O
of O
granule O
cells O
, O
within O
the O
480 O
m O
lateral O
distance O
examined O
, O
molecular O
layer O
interneurons O
reduced O
the O
strength O
of O
granule O
cell O
inputs O
to O
Purkinje O
cells O
to O
a O
comparable O
extent O
. O

The O
influence O
of O
chemical O
activation O
on O
tooth O
bleaching O
using O
10 O
% O
carbamide B-DRUG_N
peroxide I-DRUG_N
. O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
influence O
of O
manganese B-DRUG_N
gluconate I-DRUG_N
, O
a O
chemical O
activator O
of O
bleaching O
agents O
, O
at O
a O
concentration O
of O
0 O
. O
01 O
% O
on O
the O
efficiency O
of O
a O
10 O
% O
carbamide B-DRUG_N
peroxide I-DRUG_N
- O
based O
bleaching O
agent O
. O
Forty O
bovine O
incisors O
were O
immersed O
in O
a O
25 O
% O
instant O
coffee O
solution O
for O
seven O
days O
and O
randomly O
divided O
into O
two O
groups O
. O
Group O
1 O
was O
the O
control O
group O
and O
consisted O
of O
10 O
% O
carbamide B-DRUG_N
peroxide I-DRUG_N
- O
based O
bleaching O
gel O
only O
. O
Group O
2 O
consisted O
of O
10 O
% O
carbamide B-DRUG_N
peroxide I-DRUG_N
- O
based O
bleaching O
gel O
and O
0 O
. O
01 O
% O
manganese B-DRUG_N
gluconate I-DRUG_N
. O
Three O
readings O
of O
color O
were O
taken O
using O
the O
Vita O
Easyshade O
spectrophotometer O
: O
the O
initial O
reading O
, O
a O
reading O
at O
seven O
days O
, O
and O
a O
reading O
at O
14 O
days O
. O
Total O
color O
variation O
was O
calculated O
by O
E O
* O
Lab O
. O
Data O
were O
submitted O
to O
the O
statistical O
t O
- O
test O
( O
5 O
% O
) O
, O
which O
showed O
that O
after O
seven O
days O
group O
2 O
had O
a O
significant O
increase O
in O
the O
degree O
of O
tooth O
bleaching O
compared O
with O
group O
1 O
. O
The O
mean O
values O
( O
SD O
) O
were O
16 O
. O
33 O
( O
3 O
. O
95 O
) O
for O
group O
1 O
and O
19 O
. O
29 O
( O
4 O
. O
97 O
) O
for O
group O
2 O
. O
However O
, O
the O
results O
for O
group O
1 O
and O
group O
2 O
were O
similar O
after O
14 O
days O
. O
Adding O
0 O
. O
01 O
% O
manganese B-DRUG_N
gluconate I-DRUG_N
to O
10 O
% O
carbamide B-DRUG_N
peroxide I-DRUG_N
bleaching O
gel O
increased O
the O
degree O
of O
tooth O
bleaching O
after O
a O
seven O
- O
day O
treatment O
and O
did O
not O
influence O
the O
resulting O
shade O
after O
14 O
days O
. O

Drug O
interaction O
of O
levothyroxine B-DRUG
with O
infant O
colic O
drops O
. O
Infacol B-BRAND
( O
Forest O
Laboratories O
UK O
, O
Kent O
, O
UK O
) O
is O
a O
widely O
available O
over O
- O
the O
- O
counter O
preparation O
used O
to O
relieve O
colic O
symptoms O
in O
neonates O
and O
infants O
. O
The O
active O
ingredient O
is O
simeticone B-DRUG
. O
No O
drug O
interactions O
with O
simeticone B-DRUG
are O
documented O
in O
the O
current O
summary O
of O
product O
characteristics O
. O
The O
authors O
report O
the O
case O
of O
an O
infant O
with O
confirmed O
congenital O
hypothyroidism O
on O
levothyroxine B-DRUG
who O
experienced O
a O
possible O
drug O
interaction O
with O
simeticone B-DRUG
. O
Despite O
adequate O
levothyroxine B-DRUG
dosage O
, O
thyroid O
stimulating O
hormone O
( O
TSH O
) O
was O
high O
, O
suggesting O
undertreatment O
. O
Questioning O
revealed O
the O
child O
was O
taking O
Infacol B-BRAND
drops O
before O
feeds O
while O
on O
levothyroxine B-DRUG
. O
The O
colic O
drops O
were O
immediately O
discontinued O
and O
TSH O
promptly O
normalised O
with O
a O
reduction O
in O
thyroxine O
requirement O
to O
an O
age O
appropriate O
dosage O
. O
Drug O
interaction O
of O
thyroxine B-DRUG
with O
simeticone B-DRUG
has O
not O
been O
reported O
previously O
and O
is O
not O
listed O
in O
the O
British O
National O
Formulary O
for O
Children O
. O
Clinicians O
and O
parents O
need O
to O
be O
aware O
of O
this O
interaction O
to O
avoid O
unnecessary O
undertreatment O
and O
prevent O
potential O
long O
- O
term O
neurological O
sequelae O
. O

Novel O
insights O
into O
the O
synergistic O
interaction O
of O
Bortezomib B-DRUG
and O
TRAIL O
: O
tBid O
provides O
the O
link O
. O
The O
proteasome O
inhibitor O
Bortezomib B-DRUG
has O
been O
identified O
as O
a O
potent O
enhancer O
of O
TRAIL O
- O
induced O
apoptosis O
in O
several O
human O
cancers O
. O
However O
, O
the O
identification O
of O
the O
underlying O
molecular O
mechanisms O
of O
this O
synergistic O
cell O
death O
induction O
has O
been O
ongoing O
over O
the O
last O
years O
. O
A O
recent O
study O
identifies O
a O
new O
mechanism O
of O
action O
for O
the O
synergism O
of O
TRAIL O
and O
Bortezomib B-DRUG
. O

Nitric B-DRUG
oxide I-DRUG
is O
an O
activity O
- O
dependent O
regulator O
of O
target O
neuron O
intrinsic O
excitability O
. O
Activity O
- O
dependent O
changes O
in O
synaptic O
strength O
are O
well O
established O
as O
mediating O
long O
- O
term O
plasticity O
underlying O
learning O
and O
memory O
, O
but O
modulation O
of O
target O
neuron O
excitability O
could O
complement O
changes O
in O
synaptic O
strength O
and O
regulate O
network O
activity O
. O
It O
is O
thought O
that O
homeostatic O
mechanisms O
match O
intrinsic O
excitability O
to O
the O
incoming O
synaptic O
drive O
, O
but O
evidence O
for O
involvement O
of O
voltage O
- O
gated O
conductances O
is O
sparse O
. O
Here O
, O
we O
show O
that O
glutamatergic O
synaptic O
activity O
modulates O
target O
neuron O
excitability O
and O
switches O
the O
basis O
of O
action O
potential O
repolarization O
from O
Kv3 O
to O
Kv2 O
potassium O
channel O
dominance O
, O
thereby O
adjusting O
neuronal O
signaling O
between O
low O
and O
high O
activity O
states O
, O
respectively O
. O
This O
nitric O
oxide O
- O
mediated O
signaling O
dramatically O
increases O
Kv2 O
currents O
in O
both O
the O
auditory O
brain O
stem O
and O
hippocampus O
( O
& O
gt O
; O
3 O
- O
fold O
) O
transforming O
synaptic O
integration O
and O
information O
transmission O
but O
with O
only O
modest O
changes O
in O
action O
potential O
waveform O
. O
We O
conclude O
that O
nitric O
oxide O
is O
a O
homeostatic O
regulator O
, O
tuning O
neuronal O
excitability O
to O
the O
recent O
history O
of O
excitatory O
synaptic O
inputs O
over O
intervals O
of O
minutes O
to O
hours O
. O

Spontaneous O
spiking O
and O
synaptic O
depression O
underlie O
noradrenergic O
control O
of O
feed O
- O
forward O
inhibition O
. O
Inhibitory O
interneurons O
across O
diverse O
brain O
regions O
commonly O
exhibit O
spontaneous O
spiking O
activity O
, O
even O
in O
the O
absence O
of O
external O
stimuli O
. O
It O
is O
not O
well O
understood O
how O
stimulus O
- O
evoked O
inhibition O
can O
be O
distinguished O
from O
background O
inhibition O
arising O
from O
spontaneous O
firing O
. O
We O
found O
that O
noradrenaline O
simultaneously O
reduced O
spontaneous O
inhibitory O
inputs O
and O
enhanced O
evoked O
inhibitory O
currents O
recorded O
from O
principal O
neurons O
of O
the O
mouse O
dorsal O
cochlear O
nucleus O
( O
DCN O
) O
. O
Together O
, O
these O
effects O
produced O
a O
large O
increase O
in O
signal O
- O
to O
- O
noise O
ratio O
for O
stimulus O
- O
evoked O
inhibition O
. O
Surprisingly O
, O
the O
opposing O
effects O
on O
background O
and O
evoked O
currents O
could O
both O
be O
attributed O
to O
noradrenergic O
silencing O
of O
spontaneous O
spiking O
in O
glycinergic O
interneurons O
. O
During O
spontaneous O
firing O
, O
glycine O
release O
was O
decreased O
due O
to O
strong O
short O
- O
term O
depression O
. O
Elimination O
of O
background O
spiking O
relieved O
inhibitory O
synapses O
from O
depression O
and O
thereby O
enhanced O
stimulus O
- O
evoked O
inhibition O
. O
Our O
findings O
illustrate O
a O
simple O
yet O
powerful O
neuromodulatory O
mechanism O
to O
shift O
the O
balance O
between O
background O
and O
stimulus O
- O
evoked O
signals O
. O

Approach O
to O
the O
evaluation O
of O
a O
patient O
with O
an O
increased O
serum O
osmolal O
gap O
and O
high O
- O
anion O
- O
gap O
metabolic O
acidosis O
. O
An O
increase O
in O
serum O
osmolality O
and O
serum O
osmolal O
gap O
with O
or O
without O
high O
- O
anion O
- O
gap O
metabolic O
acidosis O
is O
an O
important O
clue O
to O
exposure O
to O
one O
of O
the O
toxic O
alcohols O
, O
which O
include O
methanol B-DRUG_N
, O
ethylene B-DRUG_N
glycol I-DRUG_N
, O
diethylene B-DRUG_N
glycol I-DRUG_N
, O
propylene B-DRUG_N
glycol I-DRUG_N
, O
or O
isopropanol B-DRUG
. O
However O
, O
the O
increase O
in O
serum O
osmolal O
gap O
and O
metabolic O
acidosis O
can O
occur O
either O
together O
or O
alone O
depending O
on O
several O
factors O
, O
including O
baseline O
serum O
osmolal O
gap O
, O
molecular O
weight O
of O
the O
alcohol O
, O
and O
stage O
of O
metabolism O
of O
the O
alcohol O
. O
In O
addition O
, O
other O
disorders O
, O
including O
diabetic O
or O
alcoholic O
ketoacidosis O
, O
acute O
kidney O
injury O
, O
chronic O
kidney O
disease O
, O
and O
lactic O
acidosis O
, O
can O
cause O
high O
- O
anion O
- O
gap O
metabolic O
acidosis O
associated O
with O
an O
increased O
serum O
osmolal O
gap O
and O
therefore O
should O
be O
explored O
in O
the O
differential O
diagnosis O
. O
It O
is O
essential O
for O
clinicians O
to O
understand O
the O
value O
and O
limitations O
of O
osmolal O
gap O
to O
assist O
in O
reaching O
the O
correct O
diagnosis O
and O
initiating O
appropriate O
treatment O
. O
In O
this O
teaching O
case O
, O
we O
present O
a O
systematic O
approach O
to O
diagnosing O
high O
serum O
osmolality O
and O
increased O
serum O
osmolal O
gap O
with O
or O
without O
high O
- O
anion O
- O
gap O
metabolic O
acidosis O
. O

Calcium B-DRUG
does O
not O
inhibit O
the O
absorption O
of O
5 O
milligrams O
of O
nonheme B-DRUG
or I-DRUG
heme I-DRUG
iron I-DRUG
at O
doses O
less O
than O
800 O
milligrams O
in O
nonpregnant O
women O
. O
Calcium B-DRUG
is O
the O
only O
known O
component O
in O
the O
diet O
that O
may O
affect O
absorption O
of O
both O
nonheme B-DRUG
and I-DRUG
heme I-DRUG
iron I-DRUG
. O
However O
, O
the O
evidence O
for O
a O
calcium B-DRUG
effect O
on O
iron B-DRUG
absorption O
mainly O
comes O
from O
studies O
that O
did O
not O
isolate O
the O
effect O
of O
calcium B-DRUG
from O
that O
of O
other O
dietary O
components O
, O
because O
it O
was O
detected O
in O
single O
- O
meal O
studies O
. O
Our O
objective O
was O
to O
establish O
potential O
effects O
of O
calcium B-DRUG
on O
absorption O
of O
nonheme B-DRUG
and I-DRUG
heme I-DRUG
iron I-DRUG
and O
the O
dose O
response O
for O
this O
effect O
in O
the O
absence O
of O
a O
meal O
. O
Fifty O
- O
four O
healthy O
, O
nonpregnant O
women O
were O
selected O
to O
participate O
in O
4 O
iron B-DRUG
absorption O
studies O
using O
iron O
radioactive O
tracers O
. O
We O
evaluated O
the O
effects O
of O
calcium B-DRUG
doses O
between O
200 O
and O
1500 O
mg O
on O
absorption O
of O
5 O
mg O
nonheme B-DRUG
iron I-DRUG
( O
as O
ferrous B-DRUG
sulfate I-DRUG
) O
. O
We O
also O
evaluated O
the O
effects O
of O
calcium B-DRUG
doses O
between O
200 O
and O
800 O
mg O
on O
absorption O
of O
5 O
mg O
heme B-DRUG
iron I-DRUG
[ O
as O
concentrated O
RBC O
( O
CRBC O
) O
] O
. O
Calcium B-DRUG
was O
administered O
as O
calcium B-DRUG
chloride I-DRUG
in O
all O
studies O
and O
minerals B-GROUP
were O
ingested O
on O
an O
empty O
stomach O
. O
Calcium B-DRUG
doses O
1000 O
mg O
diminished O
nonheme B-DRUG
iron I-DRUG
absorption O
by O
an O
average O
of O
49 O
. O
6 O
% O
. O
A O
calcium B-DRUG
dose O
of O
800 O
mg O
diminished O
absorption O
of O
5 O
mg O
heme B-DRUG
iron I-DRUG
by O
37 O
. O
7 O
% O
. O
In O
conclusion O
, O
we O
demonstrated O
an O
isolated O
effect O
of O
calcium B-DRUG
( O
as O
chloride O
) O
on O
absorption O
of O
5 O
mg O
of O
iron O
provided O
as O
nonheme B-DRUG
( I-DRUG
as I-DRUG
sulfate I-DRUG
) I-DRUG
and I-DRUG
heme I-DRUG
( I-DRUG
as I-DRUG
CRBC I-DRUG
) I-DRUG
iron I-DRUG
. O
This O
effect O
was O
observed O
at O
doses O
higher O
than O
previously O
reported O
from O
single O
- O
meal O
studies O
, O
starting O
at O
~ O
800 O
mg O
of O
calcium B-DRUG
. O

Synergistic O
interaction O
between O
sunitinib B-DRUG
and O
docetaxel B-DRUG
is O
sequence O
dependent O
in O
human O
non O
- O
small O
lung O
cancer O
with O
EGFR O
TKIs O
- O
resistant O
mutation O
. O
Previous O
studies O
have O
demonstrated O
that O
sunitinib B-DRUG
has O
the O
anti O
- O
tumor O
activity O
in O
human O
non O
- O
small O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O
This O
study O
was O
aimed O
to O
investigate O
the O
efficacy O
of O
single O
use O
of O
sunitinib B-DRUG
and O
that O
of O
concurrent O
or O
sequential O
administration O
of O
sunitinib B-DRUG
and O
docetaxel B-DRUG
in O
NSCLC O
cell O
lines O
that O
are O
resistant O
to O
EGFR O
TKIs O
. O
NSCLC O
cell O
lines O
with O
EGFR O
T790M O
mutation O
and O
K O
- O
ras O
mutation O
were O
exposed O
to O
either O
sunitinib B-DRUG
or O
docetaxel B-DRUG
or O
both O
based O
on O
various O
sequential O
administrations O
. O
After O
exposure O
, O
the O
cell O
viability O
was O
measured O
by O
MTT O
assay O
, O
cell O
cycle O
distribution O
was O
analyzed O
by O
flow O
cytometry O
, O
and O
alterations O
in O
signaling O
pathway O
were O
determined O
by O
immunoblotting O
. O
Sunitinib B-DRUG
exhibited O
dose O
- O
dependent O
growth O
inhibition O
in O
NSCLC O
cell O
lines O
and O
arrested O
cell O
cycle O
at O
G1 O
phase O
, O
whereas O
docetaxel B-DRUG
arrested O
at O
S O
phase O
. O
Although O
single O
or O
concurrent O
use O
of O
sunitinib B-DRUG
and O
docetaxel B-DRUG
has O
some O
anti O
- O
proliferative O
effects O
, O
the O
sequential O
administrations O
of O
both O
drugs O
remarkably O
enhanced O
anti O
- O
tumor O
activity O
. O
When O
cells O
were O
exposed O
to O
docetaxel B-DRUG
followed O
by O
sunitinib B-DRUG
, O
synergism O
was O
observed O
. O
The O
molecular O
basis O
of O
this O
synergism O
is O
that O
the O
signaling O
pathways O
that O
were O
initially O
activated O
by O
docetaxel B-DRUG
exposure O
were O
efficiently O
suppressed O
by O
the O
subsequent O
exposure O
to O
sunitinib B-DRUG
. O
In O
contrast O
, O
the O
reverse O
of O
this O
sequential O
administration O
resulted O
in O
antagonism O
, O
which O
may O
be O
due O
to O
differential O
effects O
on O
cell O
cycle O
arrest O
. O
Sunitinib B-DRUG
as O
a O
single O
agent O
exhibits O
anti O
- O
proliferative O
effects O
in O
vitro O
in O
NSCLC O
cell O
lines O
with O
EGFR O
T790M O
and O
K O
- O
ras O
mutations O
but O
the O
sequential O
administration O
of O
docetaxel B-DRUG
followed O
by O
sunitinib B-DRUG
is O
superior O
to O
sunitinib B-DRUG
followed O
by O
docetaxel B-DRUG
and O
concurrent O
administration O
. O

Pharmacological O
drugs O
inducing O
ototoxicity O
, O
vestibular O
symptoms O
and O
tinnitus O
: O
a O
reasoned O
and O
updated O
guide O
. O
The O
present O
work O
on O
drug O
- O
induced O
ototoxicity O
, O
tinnitus O
and O
vertigo O
represents O
the O
update O
and O
revision O
of O
a O
previous O
guide O
to O
adverse O
drug O
reactions O
for O
italian O
physicians O
( O
2005 O
) O
. O
The O
panorama O
of O
drug O
- O
induced O
side O
effects O
causing O
ototoxicity O
or O
symptoms O
such O
as O
tinnitus O
or O
dizziness O
and O
vertigo O
has O
enlarged O
in O
recent O
years O
, O
thanks O
to O
a O
better O
knowledge O
and O
a O
more O
specific O
attention O
of O
pharmaceutical O
firms O
and O
drug O
- O
control O
institutions O
. O
In O
daily O
clinical O
practice O
, O
there O
is O
a O
need O
for O
the O
family O
physician O
and O
the O
ENT O
specialist O
or O
audiologist O
( O
also O
in O
consideration O
of O
the O
possible O
medico O
- O
legal O
implications O
) O
to O
focus O
the O
attention O
on O
the O
possible O
risk O
of O
otological O
side O
effects O
. O
This O
would O
allow O
a O
clinical O
risk O
- O
benefit O
evaluation O
, O
weighing O
the O
possible O
clinical O
advantage O
in O
their O
field O
of O
competence O
against O
possible O
otological O
side O
- O
effects O
. O
The O
list O
of O
active O
ingredients O
and O
drugs O
is O
subdivided O
in O
categories O
based O
on O
their O
audiological O
and O
otoneurological O
side O
- O
effects O
, O
that O
have O
been O
signaled O
by O
the O
drug O
companies O
and O
/ O
or O
ministerial O
notes O
. O
Drugs O
have O
also O
been O
subcategorized O
with O
regards O
to O
the O
field O
in O
which O
they O
are O
applied O
, O
the O
therapeutic O
indications O
and O
the O
clinical O
behaviour O
. O
They O
have O
also O
been O
organized O
in O
alphabetical O
order O
, O
for O
an O
easier O
consultation O
. O
The O
guide O
above O
, O
even O
if O
initially O
conceived O
for O
being O
used O
in O
Italy O
, O
also O
presents O
a O
more O
general O
and O
international O
interest O
, O
expecially O
as O
for O
as O
the O
concepts O
of O
pharmacology O
and O
the O
features O
of O
the O
active O
ingredients O
are O
concerned O
. O
The O
guide O
is O
, O
therefore O
, O
useful O
as O
for O
as O
we O
are O
concerned O
to O
any O
physician O
, O
regardless O
of O
the O
country O
he O
/ O
she O
operates O
in O
. O

Distinct O
synergistic O
action O
of O
piperacillin B-DRUG
and O
methylglyoxal B-DRUG_N
against O
Pseudomonas O
aeruginosa O
. O
The O
dicarbonyl O
compound O
methylglyoxal B-DRUG_N
is O
a O
natural O
constituent O
of O
Manuka O
honey O
produced O
from O
Manuka O
flowers O
in O
New O
Zealand O
. O
It O
is O
known O
to O
possess O
both O
anticancer O
and O
antibacterial O
activity O
. O
Such O
observations O
prompted O
to O
investigate O
the O
ability O
of O
methylglyoxal B-DRUG_N
as O
a O
potent O
drug O
against O
multidrug O
resistant O
Pseudomonas O
aeruginosa O
. O
A O
total O
of O
12 O
test O
P O
. O
aeruginosa O
strains O
isolated O
from O
various O
hospitals O
were O
tested O
for O
their O
resistances O
against O
many O
antibiotics B-GROUP
, O
most O
of O
which O
are O
applied O
in O
the O
treatment O
of O
P O
. O
aeruginosa O
infections O
. O
Results O
revealed O
that O
the O
strains O
were O
resistant O
to O
many O
drugs O
at O
high O
levels O
, O
only O
piperacillin B-DRUG
, O
carbenicillin B-DRUG
, O
amikacin B-DRUG
and O
ciprofloxacin B-DRUG
showed O
resistances O
at O
comparatively O
lower O
levels O
. O
Following O
multiple O
experimentations O
it O
was O
observed O
that O
methylglyoxal B-DRUG_N
was O
also O
antimicrobic O
against O
all O
the O
strains O
at O
comparable O
levels O
. O
Distinct O
and O
statistically O
significant O
synergism O
was O
observed O
between O
methylglyoxal B-DRUG_N
and O
piperacillin B-DRUG
by O
disc O
diffusion O
tests O
when O
compared O
with O
their O
individual O
effects O
. O
The O
fractional O
inhibitory O
concentration O
index O
of O
this O
combination O
evaluated O
by O
checkerboard O
analysis O
, O
was O
0 O
. O
5 O
, O
which O
confirmed O
synergism O
between O
the O
pair O
. O
Synergism O
was O
also O
noted O
when O
methylglyoxal B-DRUG_N
was O
combined O
with O
carbenicillin B-DRUG
and O
amikacin B-DRUG
. O

Protective O
effect O
of O
acetyl B-DRUG
- I-DRUG
l I-DRUG
- I-DRUG
carnitine I-DRUG
and O
alpha B-DRUG_N
lipoic I-DRUG_N
acid I-DRUG_N
against O
the O
acute O
toxicity O
of O
diepoxybutane O
to O
human O
lymphocytes O
. O
The O
biotransformation O
and O
oxidative O
stress O
may O
contribute O
to O
1 O
, O
2 O
: O
3 O
, O
4 O
- O
diepoxybutane O
( O
DEB O
) O
- O
induced O
toxicity O
to O
human O
lymphocytes O
of O
Fanconi O
Anemia O
( O
FA O
) O
patients O
. O
Thus O
, O
the O
identification O
of O
putative O
inhibitors O
of O
bioactivation O
, O
as O
well O
as O
the O
determination O
of O
the O
protective O
role O
of O
oxidant O
defenses O
, O
on O
DEB O
- O
induced O
toxicity O
, O
can O
help O
to O
understand O
what O
is O
failing O
in O
FA O
cells O
. O
In O
the O
present O
work O
we O
studied O
the O
contribution O
of O
several O
biochemical O
pathways O
for O
DEB O
- O
induced O
acute O
toxicity O
in O
human O
lymphocyte O
suspensions O
, O
by O
using O
inhibitors O
of O
epoxide O
hydrolases O
, O
inhibitors O
of O
protective O
enzymes O
as O
glutathione O
S O
- O
transferase O
and O
catalase O
, O
the O
depletion O
of O
glutathione O
( O
GSH O
) O
, O
and O
the O
inhibition O
of O
protein O
synthesis O
; O
and O
a O
variety O
of O
putative O
protective O
compounds O
, O
including O
antioxidants O
, O
and O
mitochondrial O
protective O
agents O
. O
The O
present O
study O
reports O
two O
novel O
findings O
: O
( O
i O
) O
it O
was O
clearly O
evidenced O
, O
for O
the O
first O
time O
, O
that O
the O
acute O
exposure O
of O
freshly O
isolated O
human O
lymphocytes O
to O
DEB O
results O
in O
severe O
GSH O
depletion O
and O
loss O
of O
ATP O
, O
followed O
by O
cell O
death O
; O
( O
ii O
) O
acetyl B-DRUG
- I-DRUG
l I-DRUG
- I-DRUG
carnitine I-DRUG
elicits O
a O
significant O
protective O
effect O
on O
DEB O
induced O
toxicity O
, O
which O
was O
potentiated O
by O
alpha B-DRUG
- I-DRUG
lipoic I-DRUG
acid I-DRUG
. O
Collectively O
, O
these O
findings O
contribute O
to O
increase O
our O
knowledge O
of O
DEB O
- O
induce O
toxicity O
and O
will O
be O
very O
useful O
when O
applied O
in O
studies O
with O
lymphocytes O
from O
FA O
patients O
, O
in O
order O
to O
find O
out O
a O
protective O
agent O
against O
spontaneous O
and O
DEB O
- O
induced O
chromosome O
instability O
. O

[ O
Ticagrelor B-DRUG
: O
a O
novel O
antiplatelet B-GROUP
agent I-GROUP
for O
patients O
with O
acute O
coronary O
syndrome O
] O
. O
Ticagrelor B-DRUG
is O
an O
oral O
, O
reversible O
blocker O
of O
the O
P2Y12 O
adenosine O
receptor O
. O
In O
clinical O
trials O
the O
antiplatelet B-GROUP
agent I-GROUP
reduced O
significantly O
vascular O
mortality O
and O
death O
from O
any O
cause O
when O
compared O
to O
clopidogrel B-DRUG
in O
patients O
with O
acute O
coronary O
syndrome O
. O

[ O
Infections O
with O
human O
immunodeficiency O
viruses O
. O
Part O
II O
: O
Antiretroviral B-GROUP
drugs I-GROUP
, O
therapeutic O
options O
, O
and O
diagnostics O
] O
. O
Infections O
with O
the O
human O
immunodeficiency O
virus O
1 O
( O
HIV O
- O
1 O
) O
lead O
to O
the O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
, O
resulting O
in O
the O
establishment O
of O
a O
wide O
range O
of O
severe O
opportunistic O
infections O
. O
Since O
the O
introduction O
of O
the O
highly B-GROUP
active I-GROUP
antiretroviral I-GROUP
therapy O
( O
HAART O
) O
into O
the O
treatment O
of O
HIV O
infections O
, O
in O
many O
cases O
a O
delayed O
appearance O
of O
AIDS O
- O
defining O
diseases O
is O
achievable O
. O
Life O
expectancy O
of O
antiretrovirally O
treated O
HIV O
- O
infected O
people O
applying O
HAART O
could O
be O
considerably O
extended O
and O
now O
resembles O
that O
of O
several O
other O
chronic O
diseases O
. O
For O
the O
initial O
treatment O
of O
HIV O
- O
1 O
infection O
, O
an O
adjunction O
with O
three O
antiretroviral B-GROUP
agents I-GROUP
is O
generally O
used O
. O
In O
most O
cases O
, O
the O
application O
of O
two O
nucleoside B-GROUP
or I-GROUP
nucleotide I-GROUP
reverse I-GROUP
transcriptase I-GROUP
inhibitors I-GROUP
( O
NRTI B-GROUP
) O
together O
with O
a O
non B-GROUP
- I-GROUP
nucleoside I-GROUP
reverse I-GROUP
transcriptase I-GROUP
inhibitor I-GROUP
( O
NNRTI B-GROUP
) O
, O
a O
protease B-GROUP
inhibitor I-GROUP
( O
PI B-GROUP
) O
or O
an O
integrase B-GROUP
inhibitor I-GROUP
( O
II B-GROUP
) O
is O
recommended O
. O
Before O
and O
during O
antiretroviral B-GROUP
treatment O
, O
antiretroviral B-GROUP
drug O
resistances O
, O
individual O
tolerance O
profiles O
and O
the O
needs O
of O
the O
individual O
patient O
, O
as O
well O
as O
several O
interactions O
with O
other O
drugs O
have O
to O
be O
considered O
. O
Diagnostics O
of O
HIV O
infection O
is O
based O
upon O
the O
proof O
of O
specific O
antibodies O
. O

[ O
Influence O
of O
hemantane B-DRUG_N
and O
doxycycline B-DRUG
on O
MPTP O
- O
evoked O
behavior O
violations O
in O
C57BL O
/ O
6 O
mice O
] O
. O
The O
effects O
of O
anti B-GROUP
- I-GROUP
parkinsonian I-GROUP
drug I-GROUP
hemantane B-DRUG_N
[ O
( B-DRUG_N
2 I-DRUG_N
- I-DRUG_N
adamantyl I-DRUG_N
) I-DRUG_N
hexamethylenimine I-DRUG_N
] O
( O
10 O
mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
and O
/ O
or O
antibiotic B-GROUP
drug I-GROUP
doxycycline B-DRUG
( O
100 O
mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
, O
as O
well O
as O
that O
of O
neurotoxin O
1 B-DRUG_N
- I-DRUG_N
methyl I-DRUG_N
- I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
phenyl I-DRUG_N
- I-DRUG_N
1 I-DRUG_N
, I-DRUG_N
2 I-DRUG_N
, I-DRUG_N
3 I-DRUG_N
, I-DRUG_N
4 I-DRUG_N
- I-DRUG_N
tetrahydropyridine I-DRUG_N
( O
MPTP B-DRUG_N
) O
( O
4 O
x O
20 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
were O
studied O
in O
elevated O
plus O
maze O
test O
on O
C57BL O
/ O
6 O
mice O
. O
On O
second O
day O
after O
injection O
, O
MPTP B-DRUG_N
decreased O
the O
locomot O
or O
activity O
in O
comparison O
to O
saline O
. O
Acute O
administration O
of O
hemantane B-DRUG_N
or O
doxycycline B-DRUG
failed O
to O
influence O
locomotion O
in O
mice O
, O
while O
their O
combination O
normalized O
motor O
activity O
. O
The O
results O
obtained O
confirm O
the O
role O
of O
inflammatory O
processes O
in O
parkinsonism O
and O
suggest O
expediency O
of O
combined O
pharmacotherapy O
of O
neurodegenerative O
diseases O
. O

The O
role O
of O
p27 O
( O
Kip1 O
) O
in O
dasatinib B-DRUG
- O
enhanced O
paclitaxel B-DRUG
cytotoxicity O
in O
human O
ovarian O
cancer O
cells O
. O
Less O
than O
50 O
% O
of O
ovarian O
cancers O
respond O
to O
paclitaxel B-DRUG
. O
Effective O
strategies O
are O
needed O
to O
enhance O
paclitaxel B-DRUG
sensitivity O
. O
A O
library O
of O
silencing O
RNAs O
( O
siRNAs O
) O
was O
used O
to O
identify O
kinases O
that O
regulate O
paclitaxel B-DRUG
sensitivity O
in O
human O
ovarian O
cancer O
SKOv3 O
cells O
. O
The O
effect O
of O
dasatinib B-DRUG
, O
an O
inhibitor O
of O
Src O
and O
Abl O
kinases O
, O
on O
paclitaxel B-DRUG
sensitivity O
was O
measured O
in O
ovarian O
cancer O
cells O
and O
HEY O
xenografts O
. O
The O
roles O
of O
p27 O
( O
Kip1 O
) O
, O
Bcl O
- O
2 O
, O
and O
Cdk1 O
in O
apoptosis O
induced O
by O
dasatinib B-DRUG
and O
paclitaxel B-DRUG
were O
assessed O
using O
a O
terminal O
deoxynucleotidyl O
transferase O
- O
mediated O
dUTP O
nick O
- O
end O
labeling O
( O
TUNEL O
) O
assay O
, O
siRNA O
knockdown O
of O
gene O
expression O
, O
transfection O
with O
Bcl O
- O
2 O
and O
Cdk1 O
expression O
vectors O
, O
and O
flow O
cytometry O
. O
All O
statistical O
tests O
were O
two O
- O
sided O
. O
Src O
family O
and O
Abl O
kinases O
were O
identified O
as O
modulators O
of O
paclitaxel B-DRUG
sensitivity O
in O
SKOv3 O
cells O
. O
The O
siRNA O
knockdown O
of O
Src O
, O
Fyn O
, O
or O
Abl1 O
enhanced O
paclitaxel B-DRUG
- O
mediated O
growth O
inhibition O
in O
ovarian O
cancer O
cells O
compared O
with O
a O
control O
siRNA O
. O
HEY O
cells O
treated O
with O
dasatinib B-DRUG
plus O
paclitaxel B-DRUG
formed O
fewer O
colonies O
than O
did O
cells O
treated O
with O
either O
agent O
alone O
. O
Treatment O
of O
HEY O
xenograft O
- O
bearing O
mice O
with O
dasatinib B-DRUG
plus O
paclitaxel B-DRUG
inhibited O
tumor O
growth O
more O
than O
treatment O
with O
either O
agent O
alone O
( O
average O
tumor O
volume O
per O
mouse O
, O
dasatinib B-DRUG
+ O
paclitaxel B-DRUG
vs O
paclitaxel B-DRUG
: O
0 O
. O
28 O
vs O
. O
0 O
. O
81 O
cm3 O
, O
difference O
= O
0 O
. O
53 O
cm3 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0 O
. O
44 O
to O
0 O
. O
62 O
cm3 O
, O
P O
= O
. O
014 O
) O
; O
dasatinib B-DRUG
+ O
paclitaxel B-DRUG
vs O
. O
dasatinib B-DRUG
: O
0 O
. O
28 O
vs O
. O
0 O
. O
55 O
cm3 O
, O
difference O
= O
0 O
. O
27 O
cm3 O
, O
95 O
% O
CI O
= O
0 O
. O
21 O
to O

0 O
. O
33 O
cm3 O
, O
P O
= O
. O
035 O
) O
. O
Combined O
treatment O
induced O
more O
TUNEL O
- O
positive O
apoptotic O
cells O
than O
did O
either O
agent O
alone O
. O
The O
siRNA O
knockdown O
of O
p27 O
( O
Kip1 O
) O
decreased O
dasatinib B-DRUG
- O
and O
paclitaxel B-DRUG
- O
induced O
apoptosis O
compared O
with O
a O
negative O
control O
siRNA O
( O
sub O
- O
G1 O
fraction O
, O
control O
siRNA O
vs O
. O
p27 O
( O
Kip1 O
) O
siRNA O
: O
42 O
. O
5 O
% O
vs O
. O
20 O
. O
1 O
% O
, O
difference O
= O
22 O
. O
4 O
% O
, O
95 O
% O
CI O
= O
20 O
. O
1 O
% O
to O
24 O
. O
7 O
% O
, O
P O
= O
. O
017 O
) O
. O
Studies O
with O
forced O
expression O
and O
siRNA O
knockdown O
of O
Bcl O
- O
2 O
and O
Cdk1 O
suggest O
that O
dasatinib B-DRUG
- O
mediated O
induction O
of O
p27 O
( O
Kip1 O
) O
enhanced O
paclitaxel B-DRUG
- O
induced O
apoptosis O
by O
negatively O
regulating O
Bcl O
- O
2 O
and O
Cdk1 O
expression O
. O
Inhibition O
of O
Src O
family O
and O
Abl O
kinases O
with O
either O
siRNAs O
or O
dasatinib B-DRUG
enhances O
paclitaxel B-DRUG
sensitivity O
of O
ovarian O
cancer O
cells O
through O
p27 O
( O
Kip1 O
) O
- O
mediated O
suppression O
of O
Bcl O
- O
2 O
and O
Cdk1 O
expression O
. O

Identification O
of O
a O
dopamine O
receptor O
- O
mediated O
opiate B-GROUP
reward O
memory O
switch O
in O
the O
basolateral O
amygdala O
- O
nucleus O
accumbens O
circuit O
. O
The O
basolateral O
amygdala O
( O
BLA O
) O
, O
ventral O
tegmental O
area O
( O
VTA O
) O
, O
and O
nucleus O
accumbens O
( O
NAc O
) O
play O
central O
roles O
in O
the O
processing O
of O
opiate B-GROUP
- O
related O
associative O
reward O
learning O
and O
memory O
. O
The O
BLA O
receives O
innervation O
from O
dopaminergic O
fibers O
originating O
in O
the O
VTA O
, O
and O
both O
dopamine O
( O
DA O
) O
D1 O
and O
D2 O
receptors O
are O
expressed O
in O
this O
region O
. O
Using O
a O
combination O
of O
in O
vivo O
single O
- O
unit O
extracellular O
recording O
in O
the O
NAc O
combined O
with O
behavioral O
pharmacology O
studies O
, O
we O
have O
identified O
a O
double O
dissociation O
in O
the O
functional O
roles O
of O
DA O
D1 O
versus O
D2 O
receptor O
transmission O
in O
the O
BLA O
, O
which O
depends O
on O
opiate B-GROUP
exposure O
state O
; O
thus O
, O
in O
previously O
opiate B-GROUP
- O
naive O
rats O
, O
blockade O
of O
intra O
- O
BLA O
D1 O
, O
but O
not O
D2 O
, O
receptor O
transmission O
blocked O
the O
acquisition O
of O
associative O
opiate O
reward O
memory O
, O
measured O
in O
an O
unbiased O
conditioned O
place O
preference O
procedure O
. O
In O
direct O
contrast O
, O
in O
rats O
made O
opiate B-GROUP
dependent O
and O
conditioned O
in O
a O
state O
of O
withdrawal O
, O
intra O
- O
BLA O
D2 O
, O
but O
not O
D1 O
, O
receptor O
blockade O
blocked O
opiate B-GROUP
reward O
encoding O
. O
This O
functional O
switch O
was O
dependent O
on O
cAMP O
signaling O
as O
comodulation O
of O
intra O
- O
BLA O
cAMP O
levels O
reversed O
or O
replicated O
the O
functional O
effects O
of O
intra O
- O
BLA O
D1 O
or O
D2 O
transmission O
during O
opiate B-GROUP
reward O
processing O
. O
Single O
- O
unit O
in O
vivo O
extracellular O
recordings O
performed O
in O
neurons O
of O
the O
NAc O
confirmed O
an O
opiate B-GROUP
- O
state O
- O
dependent O
role O
for O
BLA O
D1 O
/ O
D2 O
transmission O
in O
NAc O
neuronal O
response O
patterns O
to O
morphine B-DRUG
. O
Our O
results O
characterize O
and O
identify O
a O
novel O
opiate B-GROUP
addiction O
switching O
mechanism O
directly O
in O
the O
BLA O
that O
can O
control O
the O
processing O
of O
opiate B-GROUP
reward O
information O
as O
a O
direct O
function O
of O
opiate B-GROUP
exposure O
state O
via O
D1 O
or O
D2 O
receptor O
signaling O
substrates O
. O

Potential O
underuse O
, O
overuse O
, O
and O
inappropriate O
use O
of O
antidepressants B-GROUP
in O
older O
veteran O
nursing O
home O
residents O
. O
To O
examine O
prevalence O
and O
resident O
- O
and O
site O
- O
level O
factors O
associated O
with O
potential O
underuse O
, O
overuse O
, O
and O
inappropriate O
use O
of O
antidepressants B-GROUP
in O
older O
Veterans O
Affairs O
( O
VA O
) O
Community O
Living O
Center O
( O
CLC O
) O
residents O
. O
Longitudinal O
study O
. O
One O
hundred O
thirty O
- O
three O
VA O
CLCs O
. O
Three O
thousand O
six O
hundred O
ninety O
- O
two O
veterans O
aged O
65 O
and O
older O
admitted O
between O
January O
1 O
, O
2004 O
, O
and O
June O
3 O
, O
2005 O
, O
with O
long O
stays O
( O
90 O
days O
) O
. O
Prevalence O
of O
potential O
underuse O
, O
inappropriate O
use O
, O
and O
overuse O
of O
antidepressants B-GROUP
in O
residents O
with O
and O
without O
depression O
( O
as O
documented O
according O
to O
International O
Classification O
of O
Diseases O
, O
Ninth O
Revision O
, O
Clinical O
Modification O
, O
codes O
or O
Depression O
Rating O
Scale O
) O
. O
Selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
were O
the O
most O
commonly O
prescribed O
antidepressant B-GROUP
. O
Of O
the O
877 O
residents O
with O
depression O
, O
25 O
. O
4 O
% O
did O
not O
receive O
an O
antidepressant B-GROUP
, O
suggesting O
potential O
underuse O
. O
Of O
residents O
with O
depression O
who O
received O
antidepressants B-GROUP
, O
57 O
. O
5 O
% O
had O
potential O
inappropriate O
use O
due O
primarily O
to O
problems O
seen O
with O
drug O
- O
drug O
and O
drug O
- O
disease O
interactions O
. O
Of O
the O
2 O
, O
815 O
residents O
who O
did O
not O
have O
depression O
, O
1 O
, O
190 O
( O
42 O
. O
3 O
% O
) O
were O
prescribed O
one O
or O
more O
antidepressants B-GROUP
; O
only O
48 O
( O
4 O
. O
0 O
% O
) O
of O
these O
had O
a O
Food O
and O
Drug O
Administration O
- O
approved O
labeled O
indication O
, O
suggesting O
potential O
overuse O
. O
Overall O
, O
only O
17 O
. O
6 O
% O
of O
antidepressant B-GROUP
use O
was O
appropriate O
( O
324 O
/ O
1 O
, O
844 O
) O
. O
The O
only O
consistent O
resident O
factor O
associated O
with O
potential O
underuse O
and O
overuse O
use O
was O
taking O
an O
antipsychotic B-GROUP
without O
evidence O
of O
schizophrenia O
( O
underuse O
: O
adjusted O
relative O
risk O
ratio O
( O
ARRR O
) O
= O
0 O
. O
56 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
= O
0 O
. O
33 O
- O
0 O
. O
94 O
; O
overuse O
: O
adjusted O
odds O
ratio O
= O
1 O
. O
52 O
, O
95 O
% O
CI O
= O
1 O
. O
21 O
- O
1 O
. O
91 O
) O
. O
Having O
moderate O
to O
severe O
pain O
( O
ARRR O
= O
1 O
. O
54 O
, O
95 O
% O
CI O
= O
1 O
. O
08 O
- O
2 O
. O
20 O
) O
and O
the O
prescribing O
of O
an O
anxiolytic B-GROUP
or O
hypnotic B-GROUP
( O
ARRR O
= O
1 O
. O
33 O
, O
95 O
% O
CI O
= O
1 O
. O
02 O
- O
1 O
. O
74 O
) O
increased O
the O
risk O
of O
potential O
inappropriate O
antidepressant B-GROUP
use O
. O
Potential O
problems O
with O
the O
use O
of O
antidepressants B-GROUP

were O
frequently O
observed O
in O
older O
U O
. O
S O
. O
veteran O
CLC O
residents O
. O
Future O
studies O
are O
needed O
to O
examine O
the O
true O
risks O
and O
benefits O
of O
antidepressant B-GROUP
use O
in O
CLC O
and O
non O
- O
VA O
nursing O
homes O
. O

Phase O
I O
trial O
of O
lenalidomide B-DRUG
and O
CCI B-DRUG
- I-DRUG
779 I-DRUG
in O
patients O
with O
relapsed O
multiple O
myeloma O
: O
evidence O
for O
lenalidomide B-DRUG
- O
CCI B-DRUG
- I-DRUG
779 I-DRUG
interaction O
via O
P O
- O
glycoprotein O
. O
Multiple O
myeloma O
( O
MM O
) O
is O
an O
incurable O
plasma O
- O
cell O
neoplasm O
for O
which O
most O
treatments O
involve O
a O
therapeutic O
agent O
combined O
with O
dexamethasone B-DRUG
. O
The O
preclinical O
combination O
of O
lenalidomide B-DRUG
with O
the O
mTOR O
inhibitor O
CCI B-DRUG
- I-DRUG
779 I-DRUG
has O
displayed O
synergy O
in O
vitro O
and O
represents O
a O
novel O
combination O
in O
MM O
. O

Treatment O
of O
nicotine B-DRUG
dependence O
with O
Chantix B-BRAND
( O
varenicline B-DRUG
) O
. O
Varenicline B-DRUG
is O
the O
generic O
name O
for O
Chantix B-BRAND
, O
the O
newest O
drug O
available O
for O
the O
treatment O
of O
tobacco O
dependence O
. O
In O
a O
randomized O
controlled O
clinical O
trial O
, O
the O
abstinence O
rate O
at O
1 O
year O
for O
patients O
using O
varencline B-DRUG
was O
superior O
to O
that O
of O
patients O
in O
the O
group O
using O
bupropion B-DRUG
SR I-DRUG
( O
Zyban B-BRAND
) O
and O
in O
the O
placebo O
group O
( O
11 O
) O
. O
Varenicline B-DRUG
reduces O
nicotine B-DRUG
withdrawal O
symptoms O
, O
cigarette O
craving O
and O
nicotine B-DRUG
satisfaction O
. O
Post O
- O
market O
reports O
prompted O
a O
warning O
of O
serious O
adverse O
neuropsychiatric O
events O
in O
patients O
taking O
varenicline B-DRUG
. O
As O
is O
the O
case O
with O
any O
surgical O
procedure O
and O
/ O
or O
prescription O
medication O
, O
full O
disclosure O
of O
the O
risks O
and O
benefits O
should O
be O
discussed O
with O
the O
patient O
. O
The O
significant O
health O
benefits O
of O
quitting O
smoking O
should O
be O
weighed O
against O
the O
individual O
' O
s O
risk O
of O
adverse O
events O
associated O
with O
the O
use O
of O
varenicline B-DRUG
for O
smoking O
cessation O
. O

[ O
Study O
on O
synergic O
and O
decreasing O
toxic O
effects O
of O
mineral O
water O
and O
Chinese O
herbal O
compound O
preparation O
on O
cisplatin B-DRUG
] O
. O
The O
synergic O
and O
decreasing O
toxic O
effects O
of O
mineral O
water O
and O
Chinese O
herbal O
compound O
preparation O
( O
MWCHCP O
) O
on O
cisplatin B-DRUG
were O
investigated O
in O
sarcoma O
180 O
( O
S180 O
) O
mice O
. O
The O
S180 O
mice O
were O
treated O
for O
5 O
days O
with O
intraperitoneal O
injection O
of O
cisplatin B-DRUG
( O
7 O
. O
33 O
mg O
x O
kg O
( O
- O
1 O
) O
) O
and O
oral O
administration O
of O
MWCHCP O
( O
1 O
925 O
, O
3 O
850 O
, O
7 O
700 O
mg O
x O
kg O
( O
- O
1 O
) O
) O
. O
Then O
the O
mice O
were O
killed O
and O
the O
tumor O
growth O
inhibition O
rate O
, O
organ O
index O
, O
diarrhea O
index O
were O
determined O
. O
Observe O
pathological O
sections O
of O
stomach O
to O
study O
the O
protective O
effect O
of O
MWCHCP O
. O
Reverse O
transcription O
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
was O
applied O
to O
investigate O
the O
tumour O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
expression O
level O
of O
the O
intestine O
. O
Combining O
with O
cisplatin B-DRUG
and O
MWCHCP O
caused O
a O
tendency O
of O
increasing O
the O
tumor O
growth O
inhibition O
rate O
and O
significant O
attenution O
of O
cisplatin B-DRUG
- O
induced O
diarrhea O
, O
visceral O
organ O
injury O
, O
gastric O
mucosal O
injury O
and O
decreased O
TNF O
- O
alpha O
mRNA O
level O
of O
intestine O
. O
The O
present O
findings O
suggest O
that O
MWCHCP O
increases O
the O
inhibition O
rate O
of O
tumor O
growth O
of O
cisplatin B-DRUG
and O
has O
a O
beneficial O
influence O
on O
gastrointestinal O
lesion O
induced O
by O
cisplatin B-DRUG
. O

CPP B-DRUG_N
- I-DRUG_N
ACP I-DRUG_N
complex I-DRUG_N
as O
a O
new O
adjunctive O
agent O
for O
remineralisation O
: O
a O
review O
. O
In O
addition O
to O
regular O
professional O
oral O
hygiene O
visits O
and O
the O
application O
of O
appropriate O
preventive O
medications O
, O
successful O
preventive O
strategies O
involve O
oral O
health O
promotion O
, O
patient O
education O
and O
patient O
compliance O
. O
The O
Casein B-DRUG_N
phosphopeptide I-DRUG_N
- I-DRUG_N
amorphous I-DRUG_N
calcium I-DRUG_N
phosphate I-DRUG_N
( I-DRUG_N
CPP I-DRUG_N
- I-DRUG_N
ACP I-DRUG_N
) I-DRUG_N
complex I-DRUG_N
has O
been O
shown O
to O
remineralise O
tooth O
surfaces O
in O
situ O
when O
delivered O
in O
oral O
care O
products O
. O
This O
complex O
has O
a O
unique O
ability O
to O
deliver O
bio O
- O
available O
calcium B-DRUG
and O
phosphate B-DRUG
when O
they O
are O
needed O
most O
. O
The O
effectiveness O
of O
casein O
derivatives O
, O
specifically O
CCP B-DRUG_N
- I-DRUG_N
ACP I-DRUG_N
, O
in O
caries O
prevention O
and O
lesion O
reversal O
has O
been O
supported O
by O
many O
controlled O
clinical O
studies O
. O
This O
review O
summarises O
the O
research O
on O
Casein B-DRUG_N
phosphopeptide I-DRUG_N
- I-DRUG_N
amorphous I-DRUG_N
calcium I-DRUG_N
phosphate I-DRUG_N
complex I-DRUG_N
and O
provides O
information O
related O
to O
its O
benefit O
in O
dentistry O
. O
Further O
research O
is O
required O
to O
provide O
a O
scientifically O
supported O
recommendation O
for O
other O
clinical O
applications O
. O

IGF1R O
- O
targeted O
therapy O
and O
its O
enhancement O
of O
doxorubicin B-DRUG
chemosensitivity O
in O
human O
osteosarcoma O
cell O
lines O
. O
Type O
- O
I O
insulin O
- O
like O
growth O
factor O
receptor O
( O
IGF1R O
) O
and O
its O
signaling O
play O
an O
important O
role O
in O
osteosarcomagenesis O
, O
tumor O
progression O
, O
and O
chemoresistance O
. O
The O
purpose O
of O
this O
study O
was O
to O
investigate O
both O
the O
effect O
and O
mechanisms O
of O
IGF1R O
inhibition O
by O
tyrphostin B-DRUG_N
AG1024 I-DRUG_N
in O
the O
presence O
or O
absence O
of O
doxorubicin B-DRUG
in O
a O
panel O
of O
six O
osteosarcoma O
cell O
lines O
and O
a O
self O
- O
established O
doxorubicin B-DRUG
- O
resistant O
cell O
line O
. O
We O
are O
the O
first O
to O
indicate O
that O
targeting O
IGF1R O
together O
with O
doxorubicin B-DRUG
achieved O
additive O
anti O
- O
osteosarcoma O
growth O
effect O
, O
accompanied O
with O
increased O
apoptosis O
, O
cytotoxicity O
, O
and O
dual O
cell O
cycle O
arrests O
. O
In O
conclusion O
, O
IGF1R O
inhibition O
can O
enhance O
doxorubicin B-DRUG
chemotherapy O
in O
some O
osteosarcoma O
cell O
lines O
. O

Enhancement O
of O
humoral O
immune O
responses O
to O
inactivated O
Newcastle O
disease O
and O
avian B-GROUP
influenza I-GROUP
vaccines I-GROUP
by O
oral O
administration O
of O
ginseng B-DRUG_N
stem I-DRUG_N
- I-DRUG_N
and I-DRUG_N
- I-DRUG_N
leaf I-DRUG_N
saponins I-DRUG_N
in O
chickens O
. O
Newcastle O
disease O
( O
ND O
) O
and O
avian O
influenza O
( O
AI O
) O
are O
common O
in O
the O
poultry O
industry O
. O
The O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
oral O
administration O
of O
ginseng B-DRUG_N
stem I-DRUG_N
- I-DRUG_N
and I-DRUG_N
- I-DRUG_N
leaf I-DRUG_N
saponins I-DRUG_N
( O
GSLS B-DRUG_N
) O
on O
the O
humoral O
immune O
responses O
of O
chickens O
to O
inactivated B-DRUG
ND I-DRUG
and I-DRUG
AI I-DRUG
vaccines I-DRUG
. O
In O
experiment O
1 O
, O
oral O
administration O
of O
GSLS B-DRUG_N
at O
a O
dose O
of O
5 O
mg O
/ O
kg O
of O
BW O
for O
7 O
d O
on O
the O
immune O
response O
in O
chickens O
intramuscularly O
injected O
with O
inactivated B-DRUG
ND I-DRUG
vaccine I-DRUG
was O
evaluated O
. O
Results O
showed O
that O
GSLS B-DRUG_N
significantly O
increased O
the O
antibody O
level O
against O
ND O
in O
the O
serum O
of O
chickens O
. O
In O
experiment O
2 O
, O
the O
same O
regimen O
of O
GSLS B-DRUG_N
was O
administered O
to O
chickens O
inoculated O
with O
inactivated B-DRUG
AI I-DRUG
vaccines I-DRUG
, O
and O
an O
enhanced O
serum O
antibody O
response O
to O
AI O
vaccination O
was O
also O
observed O
. O
Considering O
the O
safety O
of O
GSLS B-DRUG_N
, O
because O
no O
adverse O
effect O
was O
found O
throughout O
the O
experiments O
, O
GSLS B-DRUG_N
may O
be O
a O
promising O
oral O
adjuvant O
to O
improve O
immunization O
in O
poultry O
. O

[ O
Variability O
of O
cannabinoid B-DRUG_N
findings O
in O
blood O
] O
. O
Cannabis O
products O
have O
been O
administered O
for O
many O
centuries O
; O
today O
, O
cannabis O
is O
the O
most O
widely O
used O
illegal O
drug O
all O
over O
the O
world O
. O
Nevertheless O
, O
the O
interpretation O
of O
cannabis O
findings O
in O
blood O
with O
regard O
to O
consumption O
behaviour O
and O
/ O
or O
estimating O
the O
elapsed O
time O
since O
the O
last O
cannabis O
use O
is O
still O
a O
very O
challenging O
task O
. O
A O
wide O
variation O
of O
pharmacokinetic O
parameters O
has O
been O
observed O
even O
in O
experimental O
studies O
. O
Different O
chemical O
structures O
of O
precursors O
, O
smoking O
dynamics O
, O
pyrolysis O
of O
phytocannabinoids B-DRUG_N
and O
frequency O
of O
drug O
use O
affect O
the O
amount O
of O
THC B-DRUG_N
absorbed O
. O
Polymorphic O
enzymes O
are O
involved O
in O
phase O
- O
I O
- O
metabolism O
of O
THC B-DRUG_N
. O
Pharmacological O
effects O
of O
other O
cannabinoids B-DRUG_N
or O
medication O
on O
the O
pharmacokinetics O
of O
THC B-DRUG_N
have O
not O
yet O
been O
studied O
in O
detail O
. O
Hydrolysis O
of O
cannabis O
conjugates O
may O
occur O
during O
storage O
of O
blood O
samples O
and O
processing O
of O
specimens O
for O
analysis O
; O
knowledge O
on O
the O
stability O
of O
cannabinoids B-DRUG_N
in O
forensic O
specimens O
is O
still O
poor O
. O
Whether O
determination O
of O
cannabinoid B-DRUG_N
conjugates O
may O
be O
useful O
is O
a O
matter O
of O
further O
consideration O
. O
At O
present O
, O
the O
broad O
variation O
of O
pharmacokinetic O
parameters O
and O
the O
limiting O
factors O
discussed O
in O
the O
present O
paper O
should O
be O
taken O
into O
account O
when O
using O
data O
from O
experimental O
studies O
for O
interpretation O
of O
analytical O
results O
in O
forensic O
case O
work O
. O

Interaction O
of O
dacarbazine B-DRUG
and O
imexon B-DRUG_N
, O
in O
vitro O
and O
in O
vivo O
, O
in O
human O
A375 O
melanoma O
cells O
. O
We O
evaluated O
mechanisms O
of O
interaction O
between O
the O
alkyating O
agent O
dacarbazine B-DRUG
( O
DTIC B-DRUG
) O
and O
the O
pro O
- O
oxidant O
, O
imexon B-DRUG
, O
in O
the O
human O
A375 O
melanoma O
cell O
line O
. O
The O
effect O
of O
DTIC B-DRUG
and O
imexon B-DRUG
, O
alone O
and O
in O
combination O
, O
was O
evaluated O
for O
growth O
inhibition O
( O
MTT O
) O
, O
radiolabeled O
drug O
uptake O
, O
cellular O
thiol O
content O
( O
HPLC O
) O
, O
and O
DNA O
strand O
breaks O
( O
Comet O
assay O
) O
. O
Pharmacokinetic O
and O
antitumor O
effects O
were O
evaluated O
in O
mice O
. O
Growth O
inhibition O
in O
vitro O
was O
additive O
with O
the O
two O
drugs O
. O
There O
was O
no O
effect O
on O
drug O
uptake O
or O
on O
the O
number O
of O
DNA O
strand O
breaks O
. O
There O
was O
a O
> O
75 O
% O
reduction O
in O
cellular O
glutathione O
and O
cysteine O
with O
imexon B-DRUG
but O
not O
DTIC B-DRUG
. O
Co O
- O
administration O
of O
the O
two O
drugs O
in O
mice O
caused O
an O
increase O
in O
the O
area O
under O
the O
curve O
of O
both O
drugs O
, O
but O
the O
combination O
was O
not O
effective O
in O
reducing O
human O
A375 O
melanoma O
tumors O
in O
vivo O
. O
Imexon B-DRUG
and O
dacarbazine B-DRUG
show O
additive O
effects O
in O
vitro O
but O
not O
in O
vivo O
in O
human O
A375 O
melanoma O
cells O
. O

Lapatinib B-DRUG
enhances O
herceptin B-BRAND
- O
mediated O
antibody O
- O
dependent O
cellular O
cytotoxicity O
by O
up O
- O
regulation O
of O
cell O
surface O
HER2 O
expression O
. O
Although O
it O
was O
previously O
reported O
that O
lapatinib B-DRUG
combined O
with O
Herceptin B-BRAND
improved O
the O
progression O
- O
free O
survival O
rate O
compared O
with O
lapatinib B-DRUG
alone O
for O
patients O
with O
Herceptin B-BRAND
- O
refractory O
HER2 O
- O
positive O
metastatic O
breast O
cancer O
, O
the O
mechanism O
is O
purported O
to O
be O
an O
antiproliferative O
effect O
relating O
to O
the O
synergism O
of O
these O
two O
agents O
. O
We O
evaluated O
how O
lapatinib B-DRUG
interacts O
with O
Herceptin B-BRAND
in O
HER2 O
- O
positive O
breast O
cancer O
, O
with O
a O
particular O
focus O
on O
Herceptin B-BRAND
- O
mediated O
antibody O
- O
dependent O
cellular O
cytotoxicity O
( O
ADCC O
) O
. O
In O
an O
in O
vitro O
assay O
, O
lapatinib B-DRUG
induced O
HER2 O
expression O
at O
the O
cell O
surface O
of O
HER2 O
- O
positive O
breast O
cancer O
cell O
lines O
, O
leading O
to O
the O
enhancement O
of O
Herceptin B-BRAND
- O
mediated O
ADCC O
. O
Furthermore O
, O
we O
present O
a O
case O
report O
in O
which O
a O
second O
Herceptin B-BRAND
treatment O
following O
lapatinib B-DRUG
resulted O
in O
the O
marked O
shrinkage O
of O
multiple O
metastatic O
tumors O
in O
HER2 O
- O
positive O
breast O
cancer O
. O
Lapatinib B-DRUG
may O
have O
the O
potential O
to O
convert O
Herceptin B-BRAND
- O
refractory O
to O
Herceptin B-BRAND
- O
sensitive O
tumors O
in O
HER2 O
- O
positive O
breast O
cancer O
by O
up O
- O
regulation O
of O
the O
cell O
surface O
expression O
of O
HER2 O
. O

Antitumor O
effects O
of O
CRM197 B-DRUG_N
, O
a O
specific O
inhibitor O
of O
HB O
- O
EGF O
, O
in O
T O
- O
cell O
acute O
lymphoblastic O
leukemia O
. O
The O
therapeutic O
outcome O
for O
T O
- O
cell O
acute O
lymphoblastic O
leukemia O
( O
T O
- O
ALL O
) O
remains O
poor O
; O
thus O
, O
novel O
, O
targeted O
therapies O
are O
urgently O
needed O
. O
Recently O
, O
we O
showed O
that O
heparin O
- O
binding O
epidermal O
growth O
factor O
- O
like O
growth O
factor O
( O
HB O
- O
EGF O
) O
, O
a O
member O
of O
the O
EGF O
family O
, O
is O
a O
promising O
target O
for O
the O
treatment O
of O
various O
types O
of O
cancer O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
whether O
HB O
- O
EGF O
is O
a O
therapeutic O
target O
for O
T O
- O
ALL O
, O
and O
to O
further O
elucidate O
the O
antitumor O
effects O
of O
a O
specific O
inhibitor O
of O
HB O
- O
EGF O
, O
cross B-DRUG_N
- I-DRUG_N
reacting I-DRUG_N
material I-DRUG_N
197 I-DRUG_N
( O
CRM197 B-DRUG_N
) O
. O
We O
elucidated O
the O
expression O
of O
HB O
- O
EGF O
in O
T O
- O
ALL O
cell O
lines O
, O
and O
evaluated O
the O
effect O
of O
CRM197 B-DRUG_N
on O
these O
cells O
alone O
or O
in O
combination O
with O
anticancer B-GROUP
agent I-GROUP
. O
The O
expression O
of O
EGFR O
and O
EGFR O
ligands O
was O
determined O
by O
flow O
cytometry O
, O
RT O
- O
PCR O
and O
real O
- O
time O
quantitative O
PCR O
. O
Induction O
of O
apoptosis O
was O
assessed O
by O
TUNEL O
assay O
. O
HB O
- O
EGF O
was O
strongly O
expressed O
by O
T O
- O
ALL O
cell O
lines O
, O
and O
the O
expression O
of O
both O
HB O
- O
EGF O
and O
EGFR O
was O
enhanced O
by O
doxorubicin B-DRUG
. O
CRM197 B-DRUG_N
induced O
apoptosis O
, O
and O
furthermore O
, O
the O
combination O
of O
CRM197 B-DRUG_N
plus O
doxorubicin B-DRUG
enhanced O
cytotoxicity O
in O
a O
T O
- O
ALL O
cell O
line O
. O
These O
results O
suggest O
that O
HB O
- O
EGF O
is O
a O
promising O
therapeutic O
target O
for O
T O
- O
ALL O
. O

A O
circadian O
clock O
in O
hippocampus O
is O
regulated O
by O
interaction O
between O
oligophrenin O
- O
1 O
and O
Rev O
- O
erb O
. O

Oligophrenin O
- O
1 O
regulates O
dendritic O
spine O
morphology O
in O
the O
brain O
. O
Mutations O
in O
the O
oligophrenin O
- O
1 O
gene O
( O
OPHN1 O
) O
cause O
intellectual O
disability O
. O
We O
discovered O
a O
previously O
unknown O
partner O
of O
oligophrenin O
- O
1 O
, O
Rev O
- O
erb O
, O
a O
nuclear O
receptor O
that O
represses O
the O
transcription O
of O
circadian O
oscillators O
. O
We O
found O
that O
oligophrenin O
- O
1 O
interacts O
with O
Rev O
- O
erb O
in O
the O
mouse O
brain O
, O
causing O
it O
to O
locate O
to O
dendrites O
, O
reducing O
its O
repressor O
activity O
and O
protecting O
it O
from O
degradation O
. O
Our O
results O
indicate O
the O
presence O
of O
a O
circadian O
oscillator O
in O
the O
hippocampus O
, O
involving O
the O
clock O
gene O
Bmal1 O
( O
also O
known O
as O
Arntl O
) O
, O
that O
is O
modulated O
by O
Rev O
- O
erb O
and O
requires O
oligophrenin O
- O
1 O
for O
normal O
oscillation O
. O
We O
also O
found O
that O
synaptic O
activity O
induced O
Rev O
- O
erb O
localization O
to O
dendrites O
and O
spines O
, O
a O
process O
that O
is O
mediated O
by O
AMPA O
receptor O
activation O
and O
requires O
oligophrenin O
- O
1 O
. O
Our O
data O
reveal O
new O
interactions O
between O
synaptic O
activity O
and O
circadian O
oscillators O
, O
and O
delineate O
a O
new O
means O
of O
communication O
between O
nucleus O
and O
synapse O
that O
may O
provide O
insight O
into O
normal O
plasticity O
and O
the O
etiology O
of O
intellectual O
disability O
. O

Ephedrine B-DRUG
enhances O
the O
antinociceptive O
effect O
of O
dexmedetomidine B-DRUG
in O
mice O
. O
Dexmedetomidine B-DRUG
, O
a O
highly O
selective O
alpha O
- O
2 O
- O
adrenoceptor O
agonist O
, O
was O
recently O
introduced O
into O
clinical O
practice O
for O
its O
sedative O
and O
analgesic O
properties O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
whether O
the O
psychostimulant O
drug O
ephedrine B-DRUG
has O
any O
effect O
on O
dexmedetomidine B-DRUG
- O
induced O
antinociception O
and O
locomotor O
inhibitor O
activity O
in O
mice O
in O
acute O
application O
. O
In O
both O
sexes O
of O
swiss O
albino O
mice O
; O
antinociception O
was O
assessed O
with O
hot O
- O
plate O
test O
and O
the O
locomotor O
, O
exploratory O
activities O
were O
assessed O
with O
holed O
open O
field O
test O
. O
The O
animals O
were O
received O
; O
saline O
+ O
saline O
, O
ephedrine B-DRUG
( O
10 O
mg O
/ O
kg O
) O
+ O
saline O
, O
saline O
+ O
dexmedetomidine B-DRUG
( O
15 O
g O
/ O
kg O
) O
and O
ephedrine B-DRUG
( O
10 O
mg O
/ O
kg O
) O
+ O
dexmedetomidine B-DRUG
( O
15 O
g O
/ O
kg O
) O
, O
intraperitoneally O
, O
30 O
min O
before O
hot O
plate O
or O
holed O
open O
field O
tests O
. O
In O
the O
hot O
plate O
test O
in O
mice O
, O
co O
- O
administration O
of O
15 O
g O
/ O
kg O
dexmedetomidine B-DRUG
with O
10 O
mg O
/ O
kg O
ephedrine B-DRUG
intraperitoneally O
not O
only O
enhanced O
, O
but O
also O
prolonged O
the O
duration O
of O
antinociception O
induced O
by O
dexmedetomidine B-DRUG
. O
At O
the O
same O
time O
, O
the O
locomotor O
inhibitory O
effect O
of O
dexmedetomidine B-DRUG
was O
counteracted O
by O
ephedrine B-DRUG
. O
We O
concluded O
that O
the O
combined O
administration O
of O
dexmedetomidine B-DRUG
with O
ephedrine B-DRUG
may O
have O
beneficial O
effects O
in O
the O
treatment O
of O
pain O
without O
causing O
sedation O
, O
which O
limits O
the O
use O
of O
dexmedetomidine B-DRUG
as O
an O
analgesic B-GROUP
in O
humans O
. O

[ O
Efficacy O
of O
fixed O
combination O
amlodipine B-DRUG
/ O
valsartan B-DRUG
in O
hospitalized O
patients O
with O
hypertensive O
disease O
] O
Efficacy O
and O
tolerability O
of O
fixed O
amlodipine B-DRUG
/ O
valsartan B-DRUG
combination O
was O
studied O
in O
86 O
patients O
with O
hypertensive O
disease O
hospitalized O
in O
departments O
of O
general O
internal O
medicine O
or O
cardiology O
. O
All O
patients O
had O
indications O
for O
antihypertensive O
therapy O
and O
were O
randomized O
either O
to O
fixed O
combination O
amlodipine B-DRUG
/ O
valsartan B-DRUG
( O
n O
= O
43 O
) O
or O
to O
therapy O
which O
corresponded O
to O
the O
hospital O
formulary O
( O
n O
= O
43 O
) O
. O
Correction O
of O
antihypertensive B-GROUP
therapy O
was O
performed O
by O
treating O
physician O
at O
daily O
rounds O
. O
Self O
- O
control O
of O
blood O
pressure O
( O
BP O
) O
was O
performed O
by O
patients O
with O
the O
use O
of O
UA767PC O
apparatus O
. O
Results O
of O
BP O
self O
- O
control O
were O
compared O
with O
clinical O
measurements O
in O
order O
to O
detect O
concealed O
inefficacy O
of O
treatment O
. O
Results O
. O
Rate O
of O
achievement O
of O
target O
BP O
with O
fixed O
combination O
amlodipine B-DRUG
/ O
valsartan B-DRUG
( O
93 O
% O
) O
was O
comparable O
with O
that O
on O
traditional O
therapy O
( O
90 O
% O
) O
. O
But O
the O
use O
of O
fixed O
combination O
amlodipine B-DRUG
/ O
valsartan B-DRUG
compared O
with O
traditional O
therapy O
was O
associated O
with O
lower O
clinical O
and O
self O
measured O
BP O
, O
quicker O
achievement O
of O
target O
BP O
( O
5 O
. O
8 O
+ O
/ O
- O
2 O
. O
3 O
and O
9 O
. O
2 O
+ O
/ O
- O
1 O
. O
8 O
days O
, O
respectively O
, O
0 O
. O
05 O
) O
, O
lesser O
number O
of O
antihypertensive B-GROUP
drugs I-GROUP
( O
2 O
. O
5 O
+ O
/ O
- O
0 O
. O
6 O
and O
3 O
. O
0 O
+ O
/ O
- O
0 O
. O
9 O
days O
, O
respectively O
) O
, O
lower O
rate O
of O
concealed O
inefficacy O
of O
treatment O
( O
12 O
and O
31 O
% O
, O
respectively O
, O
0 O
. O
05 O
) O
. O
Conclusions O
. O
We O
have O
demonstrated O
appropriateness O
of O
inhospital O
administration O
of O
fixed O
amlodipine B-DRUG
/ O
valsartan B-DRUG
combination O
as O
an O
approach O
allowing O
to O
achieve O
target O
BP O
in O
shorter O
time O
, O
with O
the O
use O
of O
fewer O
antihypertensive B-GROUP
drugs I-GROUP
, O
and O
diminishing O
concealed O
inefficacy O
of O
treatment O
. O

[ O
Cyclooxygenase B-GROUP
inhibitors I-GROUP
and O
antiplatelet O
effect O
of O
acetylsalicylic B-DRUG
acid I-DRUG
. O
selective O
approach O
to O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
in O
cardiological O
practice O
] O
. O
Nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
( O
NSAIDs B-GROUP
) O
represent O
class O
of O
medicines O
which O
is O
wide O
concerning O
chemical O
structure O
and O
mechanism O
of O
action O
. O
In O
the O
light O
of O
contradictory O
data O
on O
efficacy O
and O
safety O
of O
NSAID B-GROUP
in O
cardiovascular O
patients O
selection O
of O
most O
appropriate O
NSAID B-GROUP
( O
basing O
on O
profile O
of O
efficacy O
and O
safety O
) O
in O
patients O
receiving O
continuous O
therapy O
with O
low O
dose O
aspirin B-BRAND
appears O
to O
be O
a O
problem O
. O
In O
this O
paper O
we O
discuss O
peculiarities O
of O
drug O
interaction O
between O
cyclooxygenase B-GROUP
inhibitors I-GROUP
and O
acetylsalicylic B-DRUG
acid I-DRUG
, O
and O
principles O
of O
selection O
of O
adequate O
NSAI B-GROUP
. O

Tradition O
and O
toxicity O
: O
evidential O
cultures O
in O
the O
kava O
safety O
debate O
. O
This O
paper O
examines O
the O
debate O
about O
the O
safety O
of O
kava O
( O
Piper O
methysticum O
Forst O
. O
f O
, O
Piperaceae O
) O
, O
a O
plant O
native O
to O
Oceania O
, O
where O
it O
has O
a O
long O
history O
of O
traditional O
use O
. O
Kava O
became O
popular O
as O
an O
anti O
- O
anxiety O
treatment O
in O
Western O
countries O
in O
the O
late O
1990s O
, O
but O
it O
was O
subsequently O
banned O
in O
many O
places O
due O
to O
adverse O
reports O
of O
liver O
toxicity O
. O
This O
paper O
focuses O
on O
the O
responses O
to O
the O
bans O
by O
scientists O
involved O
in O
kava O
research O
, O
contrasting O
their O
evidential O
culture O
with O
that O
employed O
by O
clinicians O
and O
regulatory O
officials O
. O
Cultural O
constructions O
and O
social O
negotiations O
of O
risk O
are O
shown O
to O
be O
context O
- O
specific O
, O
and O
are O
shaped O
by O
professional O
, O
disciplinary O
, O
and O
organizational O
factors O
, O
among O
others O
. O
Though O
the O
science O
of O
hepatotoxicity O
is O
uncertain O
enough O
to O
allow O
for O
multiple O
interpretations O
of O
the O
same O
data O
, O
the O
biomedical O
/ O
clinical O
narrative O
about O
kava O
remains O
dominant O
. O
This O
case O
study O
explores O
the O
influence O
of O
these O
cultural O
, O
social O
, O
and O
political O
factors O
on O
the O
production O
of O
scientific O
knowledge O
and O
the O
assessment O
of O
benefit O
/ O
risk O
posed O
by O
comestibles O
. O

An O
autopsy O
case O
of O
multiple O
psychotropic B-GROUP
drug I-GROUP
poisoning O
. O
A O
fatal O
poisoning O
case O
involving O
etizolam B-DRUG
, O
phenobarbital B-DRUG
, O
promethazine B-DRUG
and O
chlorpromazine B-DRUG
is O
presented O
. O
Quantitative O
toxicological O
analysis O
showed O
that O
the O
concentrations O
of O
etizolam B-DRUG
, O
phenobarbital B-DRUG
, O
promethazine B-DRUG
and O
chlorpromazine B-DRUG
in O
the O
femoral O
blood O
were O
86 O
ng O
/ O
ml O
, O
5082 O
microg O
/ O
ml O
, O
0 O
. O
107 O
microg O
/ O
ml O
and O
0 O
. O
144 O
microg O
/ O
ml O
, O
respectively O
, O
and O
large O
amounts O
of O
drugs O
were O
also O
detected O
in O
the O
stomach O
contents O
. O
We O
conclude O
that O
the O
cause O
of O
death O
was O
due O
to O
the O
interaction O
of O
multiple O
psychotropic B-GROUP
drugs I-GROUP
. O

It O
makes O
scents O
. O
Aromatherapy O
, O
and O
the O
claims O
made O
for O
it O
, O
is O
the O
subject O
of O
the O
second O
article O
in O
our O
six O
- O
part O
series O
on O
alternative O
and O
complementary O
therapies O
. O

Pulmonary O
tuberculosis O
: O
clinical O
features O
and O
patient O
management O
. O
Pulmonary O
tuberculosis O
( O
TB O
) O
is O
a O
common O
infectious O
disease O
and O
a O
major O
cause O
of O
illness O
and O
death O
throughout O
the O
world O
, O
particularly O
in O
developing O
countries O
. O
This O
article O
explores O
the O
difference O
between O
latent O
TB O
infection O
and O
active O
TB O
disease O
, O
and O
discusses O
the O
pharmacological O
management O
of O
TB O
and O
issues O
around O
adherence O
to O
medication O
. O
Although O
TB O
is O
usually O
managed O
by O
specialist O
teams O
it O
is O
essential O
that O
all O
practitioners O
have O
an O
understanding O
of O
the O
signs O
and O
symptoms O
of O
the O
disease O
to O
ensure O
early O
referral O
and O
accurate O
diagnosis O
. O

In O
- O
vitro O
antimicrobial O
activity O
and O
synergistic O
/ O
antagonistic O
effect O
of O
interactions O
between O
antibiotics B-GROUP
and O
some O
spice O
essential O
oils O
. O
Spices O
and O
herbs O
have O
been O
used O
for O
many O
years O
by O
different O
cultures O
. O
The O
aim O
of O
the O
present O
study O
is O
( O
1 O
) O
to O
investigate O
in O
- O
vitro O
antimicrobial O
effects O
of O
different O
spices O
and O
herbs O
( O
5 O
species O
: O
Rosmarinus O
officinalis O
( O
Rosemary O
) O
, O
Coriandrum O
sativum O
( O
coriander O
) O
, O
Micromeria O
fruticosa O
( O
L O
. O
) O
Druce O
subsp O
. O
Brachycalyx O
P O
. O
H O
. O
Davis O
( O
White O
micromeria O
) O
, O
Cumium O
cyminum O
( O
cumin O
) O
, O
Mentha O
piperita O
( O
Peppermint O
) O
against O
different O
bacteria O
and O
fungi O
species O
, O
and O
( O
2 O
) O
to O
discuss O
the O
in O
- O
vitro O
possible O
effects O
between O
the O
plants O
and O
antibiotics B-GROUP
. O
The O
microorganisms O
used O
were O
Micrococcus O
luteus O
LA O
2971 O
, O
Bacillus O
megaterium O
NRS O
, O
Bacillus O
brevis O
FMC O
3 O
, O
Enterococcus O
faecalis O
ATCC O
15753 O
, O
Pseudomonas O
pyocyaneus O
DC O
127 O
, O
Mycobacterium O
smegmatis O
CCM O
2067 O
, O
Escherichia O
coil O
DM O
, O
Aeromonas O
hydrophila O
ATCC O
7966 O
, O
Yersinia O
enterocolitica O
AU O
19 O
, O
Staphylococcus O
aureus O
Cowan O
1 O
, O
Streptococcus O
faecalis O
DC O
74 O
bacteria O
, O
and O
Saccharomyces O
cerevisiae O
WET O
136 O
, O
Kluvyeromyces O
fragilis O
DC O
98 O
fungi O
in O
this O
study O
. O
The O
results O
indicated O
that O
essential O
oils O
of O
Rosmarinus O
officinalis O
, O
Coriandrum O
sativum O
L O
. O
, O
Micromeria O
fruticosa O
( O
L O
. O
) O
Druce O
subsp O
. O
brachycalyx O
P O
. O
H O
. O
Davis O
, O
Cumium O
cyminum O
L O
. O
, O
Mentha O
piperita O
L O
. O
were O
shown O
antimicrobial O
activity O
in O
the O
range O
of O
7 O
- O
60 O
mm O
2 O
microl O
( O
- O
1 O
) O
inhibition O
zone O
to O
the O
microorganisms O
tested O
, O
using O
disc O
diffusion O
method O
. O
Standard O
antibiotic B-GROUP
such O
as O
Gentamicin B-DRUG
( O
10 O
microg O
) O
, O
Cephalothin B-DRUG
( O
30 O
microg O
) O
, O
Ceftriaxone B-DRUG
( O
10 O
microg O
) O
, O
Nystatin B-DRUG
( O
10 O
U O
) O
discs O
were O
used O
for O
comparison O
with O
the O
antimicrobial O
activities O
of O
essential O

oils O
of O
these O
plants O
. O
In O
addition O
, O
antibacterial O
activity O
of O
essential O
oils O
of O
these O
plants O
was O
researched O
by O
effects O
when O
it O
was O
used O
together O
with O
these O
standard O
antibiotics B-GROUP
in O
vitro O
. O
However O
, O
antibacterial O
activity O
changed O
also O
by O
in O
vitro O
interactions O
between O
these O
standard O
antibiotics B-GROUP
and O
essential O
oils O
of O
these O
plants O
. O
Synergic O
, O
additive O
or O
antagonist O
effects O
were O
observed O
in O
antibacterial O
activity O
. O

Ticagrelor B-DRUG
( O
Brilinta B-BRAND
) O
- O
- O
better O
than O
clopidogrel B-DRUG
( O
Plavix B-BRAND
) O
The O
FDA O
has O
approved O
ticagrelor B-DRUG
( O
Brilinta B-BRAND
- O
AstraZeneca O
) O
, O
an O
oral O
antiplatelet B-GROUP
drug I-GROUP
, O
for O
use O
with O
low O
- O
dose O
aspirin B-BRAND
to O
reduce O
the O
rate O
of O
thrombotic O
cardiovascular O
events O
in O
patients O
with O
acute O
coronary O
syndrome O
( O
ACS O
) O
. O
It O
will O
compete O
with O
clopidogrel B-DRUG
( O
Plavix B-BRAND
) O
and O
prasugrel B-DRUG
( O
Effient B-BRAND
) O
for O
such O
use O
. O
Clopidogrel B-DRUG
is O
expected O
to O
become O
available O
generically O
in O
the O
US O
within O
the O
next O
few O
months O
. O

Positive O
shifts O
of O
the O
GABAA O
receptor O
reversal O
potential O
due O
to O
altered O
chloride O
homeostasis O
is O
widespread O
after O
status O
epilepticus O
. O
- O
Aminobutyric O
acid O
( O
GABA O
) O
ergic O
transmission O
plays O
an O
important O
role O
in O
the O
initiation O
of O
epileptic O
activity O
and O
the O
generation O
of O
ictal O
discharges O
. O
The O
functional O
alterations O
in O
the O
epileptiform O
hippocampus O
critically O
depend O
on O
GABAergic O
mechanisms O
and O
cation O
- O
chloride O
cotransporters O
. O
To O
understand O
the O
cellular O
basis O
of O
specific O
functional O
alterations O
in O
the O
epileptic O
hippocampus O
, O
we O
studied O
physiologic O
characteristics O
and O
pharmacologically O
isolated O
evoked O
GABA O
( O
A O
) O
receptor O
- O
mediated O
inhibitory O
postsynaptic O
currents O
( O
IPSCs O
) O
recorded O
from O
principal O
neurons O
in O
hippocampal O
slices O
from O
status O
epilepticus O
( O
SE O
) O
and O
control O
rats O
using O
whole O
- O
cell O
and O
gramicidin O
perforated O
patch O
- O
clamp O
recordings O
. O
Whereas O
the O
resting O
membrane O
potential O
and O
input O
resistance O
were O
not O
significantly O
different O
between O
control O
and O
epileptic O
tissue O
, O
the O
reversal O
potential O
( O
E O
( O
GABA O
) O
) O
of O
IPSCs O
was O
significantly O
shifted O
to O
more O
positive O
values O
in O
SE O
rats O
with O
regard O
to O
the O
resting O
membrane O
potential O
. O
Pharmacologic O
experiments O
and O
quantitative O
reverse O
transcriptase O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
showed O
that O
the O
observed O
changes O
in O
the O
epileptic O
tissue O
were O
due O
to O
a O
decreased O
ratio O
of O
the O
main O
Cl O
( O
- O
) O
extrusion O
transporter O
( O
K O
( O
+ O
) O
- O
Cl O
( O
- O
) O
cotransporter O
, O
KCC2 O
) O
to O
the O
main O
Cl O
( O
- O
) O
uptake O
transporter O
( O
Na O
( O
+ O
) O
- O
K O
( O
+ O
) O
- O
2Cl O
( O
- O
) O
cotransporter O
, O
NKCC1 O
) O
. O
Our O
results O
suggest O
that O
alterations O
of O
cation O
- O
chloride O
cotransporter O
functions O
, O
comprising O
a O
higher O
NKCC1 O
action O
, O
contribute O
to O
hyperexcitability O
within O
the O
hippocampus O
following O
SE O
. O

Evaluation O
of O
hepatic O
clearance O
and O
drug O
- O
drug O
interactions O
of O
luteolin B-DRUG_N
and O
apigenin B-DRUG_N
by O
using O
primary O
cultured O
rat O
hepatocytes O
. O
The O
hepatic O
clearance O
and O
drug O
- O
drug O
interactions O
of O
luteolin B-DRUG_N
and O
apigenin B-DRUG_N
were O
studied O
by O
using O
primary O
cultured O
rat O
hepatocytes O
. O
Luteolin B-DRUG_N
and O
apigenin B-DRUG_N
experienced O
extensive O
first O
- O
pass O
metabolism O
. O
The O
elimination O
percent O
of O
luteolin B-DRUG_N
and O
apigenin B-DRUG_N
was O
found O
to O
be O
91 O
. O
9 O
% O
and O
86 O
. O
7 O
% O
after O
120 O
min O
of O
incubation O
. O
The O
predicted O
% O
liver O
blood O
flow O
was O
82 O
. O
3 O
% O
and O
85 O
. O
4 O
% O
for O
luteolin B-DRUG_N
and O
apigenin B-DRUG_N
, O
respectively O
. O
Total O
glucuronidated O
/ O
sulfated O
conjugates O
of O
luteolin O
/ O
apigenin O
were O
determined O
by O
an O
enzyme O
hydrolysis O
method O
. O
Compared O
with O
the O
elimination O
of O
pure O
luteolin B-DRUG_N
and O
apigenin B-DRUG_N
, O
the O
elimination O
of O
luteolin B-DRUG_N
and O
apigenin B-DRUG_N
was O
much O
lower O
in O
hydrolyzed O
Flos O
Chrysanthemi O
extract O
( O
FCE O
) O
containing O
comparable O
amounts O
of O
luteolin B-DRUG_N
and O
apigenin B-DRUG_N
. O
The O
effect O
of O
a O
series O
of O
flavonoids B-DRUG_N
, O
including O
flavonols B-DRUG_N
, O
flavones B-DRUG_N
, O
isoflavone B-DRUG_N
, O
flavanone B-DRUG_N
, O
flavanonols B-DRUG_N
and O
catechins B-DRUG_N
, O
on O
the O
elimination O
of O
luteolin B-DRUG_N
and O
apigenin B-DRUG_N
was O
studied O
. O
At O
least O
four O
key O
determinants O
in O
the O
chemical O
structures O
of O
flavonoids B-DRUG_N
are O
necessary O
for O
exerting O
the O
inhibitory O
effects O
on O
the O
conjugation O
: O
1 O
) O
catechol O
structure O
( O
3 O
' O
, O
4 O
' O
- O
dihydroxylation O
) O
in O
the O
B O
- O
ring O
; O
2 O
) O
B O
- O
ring O
is O
attached O
to O
the O
C O
- O
2 O
position O
on O
the O
C O
- O
ring O
; O
3 O
) O
the O
C2 O
- O
3 O
double O
bond O
in O
conjunction O
with O
the O
C4 O
carbonyl O
group O
on O
the O
C O
- O
ring O
; O
4 O
) O
no O
glycoside O
present O
. O
Investigation O
of O
clearance O
and O
interaction O
among O
flavonoids B-DRUG_N
could O
help O
us O
better O
understand O
their O
bioavailability O
and O
offer O
insight O
into O
the O
approaches O
to O
be O
taken O
to O
minimize O
competitive O
effects O
, O
and O
to O
design O
appropriate O
bioavailability O
studies O
in O
humans O
. O

Evaluation O
of O
antidepressant O
like O
activity O
of O
curcumin B-DRUG_N
and O
its O
combination O
with O
fluoxetine B-DRUG
and O
imipramine B-DRUG
: O
an O
acute O
and O
chronic O
study O
. O
Curcumin B-DRUG_N
is O
the O
active O
ingredient O
of O
commonly O
used O
spice O
Curuma O
longa O
Linn O
. O
In O
the O
present O
study O
, O
the O
antidepressant O
like O
activity O
of O
curcumin B-DRUG_N
and O
its O
combination O
with O
fluoxetine B-DRUG
and O
imipramine B-DRUG
was O
studied O
in O
acute O
model O
( O
three O
doses O
24 O
, O
5 O
and O
1 O
h O
before O
test O
) O
of O
forced O
swimming O
test O
( O
FST O
) O
in O
glass O
jar O
and O
tail O
suspension O
test O
( O
TST O
) O
in O
mice O
and O
in O
chronic O
model O
( O
14 O
day O
study O
) O
of O
FST O
with O
water O
wheel O
in O
rats O
. O
All O
the O
tests O
were O
carried O
out O
in O
the O
following O
seven O
groups O
( O
n O
= O
6 O
in O
each O
group O
) O
, O
drugs O
being O
given O
orally O
( O
doses O
for O
mice O
) O
: O
Group O
1 O
( O
vehicle O
) O
, O
group O
2 O
( O
curcumin B-DRUG_N
50 O
mg O
/ O
kg O
) O
, O
group O
3 O
( O
curcumin B-DRUG_N
100 O
mg O
/ O
kg O
) O
, O
group O
4 O
( O
fluoxetine B-DRUG
20 O
mg O
/ O
kg O
) O
, O
group O
5 O
( O
imipramine B-DRUG
15 O
mg O
/ O
kg O
) O
, O
group O
6 O
( O
curcumin B-DRUG_N
100 O
mg O
/ O
kg O
plus O
fluoxetine B-DRUG
20 O
mg O
/ O
kg O
) O
and O
group O
7 O
( O
curcumin B-DRUG_N
100 O
mg O
/ O
kg O
plus O
imipramine B-DRUG
15 O
mg O
/ O
kg O
) O
. O
Equivalent O
doses O
for O
rats O
were O
used O
. O
Both O
the O
acute O
model O
of O
FST O
and O
TST O
, O
and O
the O
chronic O
model O
of O
FST O
with O
water O
wheel O
showed O
significant O
antidepressant O
like O
activity O
of O
curcumin B-DRUG_N
in O
100 O
mg O
/ O
kg O
dose O
as O
compared O
to O
vehicle O
control O
( O
p O
< O
0 O
. O
05 O
) O
. O
The O
effect O
of O
curcumin B-DRUG_N
( O
100 O
mg O
/ O
kg O
) O
was O
similar O
to O
that O
of O
fluoxetine B-DRUG
and O
imipramine B-DRUG
( O
p O
> O
0 O
. O
05 O
) O
but O
its O
addition O
to O
fluoxetine B-DRUG
and O
imipramine B-DRUG
did O
not O
improve O
their O
antidepressant O
activity O
( O
p O
> O
0 O
. O
05 O
) O
. O
Curcumin B-DRUG_N
increased O
both O
the O
swimming O
and O
climbing O
behavior O
in O
FST O
, O
thus O
its O
antidepressant O
like O
activity O
could O
be O
due O
to O
an O
increase O
in O
serotonin O
, O
norepinephrine O
and O
dopamine O
levels O
in O
the O
brain O
. O
Curcumin B-DRUG_N
can O
be O
a O
useful O
antidepressant B-GROUP
especially O
in O
cases O
which O
respond O
to O
drugs O
having O
mixed O
effects O
on O
serotonin O
and O
catecholamines O
levels O
in O
the O
brain O
. O

[ O
Polypharmacy O
and O
drug O
interactions O
] O
. O
The O
growing O
consumption O
of O
drugs O
and O
other O
numerous O
factors O
relates O
to O
the O
increasing O
incidence O
of O
polypharmacy O
. O
The O
proportion O
of O
patients O
currently O
treated O
with O
5 O
or O
more O
medicines O
at O
the O
elderly O
population O
in O
particular O
is O
30 O
- O
60 O
% O
of O
patients O
. O
Repeatedly O
has O
been O
proven O
the O
dependence O
between O
the O
number O
of O
concomitant O
drugs O
and O
occurrence O
of O
adverse O
effects O
, O
patients O
requiring O
hospitalization O
, O
or O
incidence O
of O
moderate O
and O
serious O
drug O
interactions O
. O
Some O
works O
show O
that O
it O
is O
possible O
to O
satisfactorily O
address O
the O
issues O
of O
polypharmacy O
, O
but O
it O
requires O
great O
courage O
and O
an O
interdisciplinary O
approach O
involving O
modern O
information O
technology O
. O

[ O
Vitamin B-GROUP
D I-GROUP
and O
drugs O
] O
. O
; O
Interactions O
between O
drugs O
and O
vitamin B-GROUP
D I-GROUP
have O
received O
only O
little O
or O
no O
attention O
in O
the O
medical O
and O
pharmaceutical O
world O
in O
the O
past O
. O
Since O
more O
and O
more O
drugs O
are O
used O
for O
the O
treatment O
of O
patients O
, O
this O
topic O
is O
increasingly O
relevant O
. O
As O
such O
interactions O
impact O
the O
health O
of O
the O
patient O
and O
the O
action O
and O
side O
effects O
of O
the O
drug O
, O
physicians O
and O
pharmacists O
should O
pay O
more O
attention O
to O
such O
interactions O
in O
the O
future O
. O
A O
number O
of O
drugs O
can O
interfere O
with O
the O
vitamin B-GROUP
D I-GROUP
and O
bone O
metabolism O
. O
The O
drug O
- O
induced O
activation O
of O
the O
pregnane O
X O
receptor O
( O
PXR O
) O
is O
likely O
to O
enhance O
CYP24 O
expression O
and O
the O
catabolism O
of O
25 O
( O
OH O
) O
D O
, O
leading O
to O
vitamin O
D O
deficiency O
. O
PXR O
- O
ligands O
include O
a O
wide O
variety O
of O
pharmaceutical O
agents O
, O
such O
as O
antiepileptic B-GROUP
drugs I-GROUP
, O
taxol B-BRAND
, O
rifampicin B-DRUG
, O
and O
human B-GROUP
immunodeficiency I-GROUP
virus I-GROUP
protease I-GROUP
inhibitors I-GROUP
such O
as O
ritonavir B-DRUG
and O
saquinavir B-DRUG
. O
Beside O
this O
, O
the O
medication O
oriented O
supplementation O
of O
vitamin B-GROUP
D I-GROUP
can O
also O
ameliorate O
the O
pharmacologic O
action O
of O
many O
drugs O
, O
such O
as O
bisphosphonates B-GROUP
, O
statins B-GROUP
and O
cytostatic B-GROUP
drugs I-GROUP
. O

[ O
Drug O
interactions O
on O
P O
- O
glycoprotein O
transport O
level O
and O
its O
application O
] O
. O
Potential O
drug O
interactions O
on O
P O
- O
glycoprotein O
transport O
level O
were O
discussed O
in O
this O
article O
. O
As O
an O
efflux O
transporter O
protein O
widely O
distributed O
in O
various O
tissues O
, O
P O
- O
glycoprotein O
plays O
an O
important O
role O
in O
many O
drugs O
interactions O
, O
via O
affecting O
the O
metabolic O
process O
to O
alter O
the O
concentration O
of O
drug O
in O
plasma O
and O
tissue O
. O
Interactions O
between O
herb O
and O
western O
drug O
may O
occur O
by O
inducing O
or O
inhibiting O
P O
- O
glycoprotein O
, O
resulting O
in O
either O
efficacy O
enhancement O
or O
adverse O
effects O
. O
So O
it O
is O
important O
for O
clinical O
drug O
use O
by O
rational O
utilization O
of O
the O
interaction O
between O
herb O
and O
western O
drug O
which O
medicated O
by O
P O
- O
glycoprotein O
. O

[ O
Summary O
of O
revised O
contents O
of O
medical O
standards O
of O
preparation O
recorded O
in O
Chinese O
Pharmacopeia O
( O
I O
division O
, O
2010 O
edition O
) O
] O
. O
China O
pharmacopoeia O
is O
a O
civil O
code O
which O
is O
to O
ensure O
pharmaceutical O
quality O
and O
protect O
people O
' O
s O
drug O
safety O
and O
effectiveness O
. O
Drug O
standards O
are O
consist O
of O
two O
parts O
, O
the O
pharmaceutical O
standards O
and O
medical O
standards O
. O
Medical O
standards O
include O
four O
contents O
, O
such O
as O
prescription O
, O
function O
and O
indications O
, O
usage O
and O
dosage O
and O
attentions O
. O
This O
paper O
summarized O
the O
revised O
contents O
of O
medical O
standards O
and O
suggested O
some O
propositions O
. O

Determination O
of O
propiverine B-DRUG
hydrochloride I-DRUG
in O
human O
plasma O
by O
high O
performance O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
: O
application O
to O
the O
pharmacokinetic O
study O
of O
a O
sustained O
release O
formulation O
. O
A O
rapid O
, O
sensitive O
and O
reliable O
high O
performance O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
( O
HPLC O
- O
MS O
/ O
MS O
) O
method O
was O
developed O
and O
validated O
for O
the O
determination O
of O
propiverine B-DRUG
hydrochloride I-DRUG
( O
CAS O
54556 O
- O
98 O
- O
8 O
) O
in O
human O
plasma O
using O
cetirizine B-DRUG
di I-DRUG
- I-DRUG
hydrochloride I-DRUG
as O
internal O
standard O
( O
IS O
, O
CAS O
8388 O
- O
51 O
- O
0 O
) O
. O
Following O
liquid O
- O
liquid O
extraction O
with O
ethyl B-DRUG_N
acetate I-DRUG_N
, O
the O
separation O
was O
performed O
on O
a O
reverse O
phase O
C18 O
column O
with O
a O
mobile O
phase O
consisted O
of O
methanol B-DRUG_N
- I-DRUG_N
ammonium I-DRUG_N
acetate I-DRUG_N
( O
pH O
4 O
. O
0 O
; O
10 O
mM O
) O
( O
70 O
: O
30 O
, O
v O
/ O
v O
) O
. O
The O
detection O
was O
performed O
by O
a O
triple O
- O
quadrupole O
mass O
spectrometer O
in O
the O
positive O
ion O
and O
multiple O
reaction O
monitoring O
( O
MRM O
) O
mode O
, O
m O
/ O
z O
368 O
. O
3 O
- O
- O
> O
116 O
. O
1 O
for O
propiverine B-DRUG
and O
m O
/ O
z O
389 O
. O
2 O
- O
- O
> O
201 O
. O
0 O
for O
the O
IS O
. O
The O
calibration O
curve O
fitted O
well O
over O
the O
concentration O
range O
of O
0 O
. O
2 O
- O
200 O
ng O
/ O
mL O
( O
all O
the O
concentration O
data O
in O
this O
study O
are O
related O
to O
salt O
( O
propiverine B-DRUG
hydrochloride I-DRUG
) O
) O
. O
The O
limit O
of O
detection O
( O
LOD O
) O
and O
lower O
limit O
of O
quantification O
( O
LLOQ O
) O
in O
human O
plasma O
were O
0 O
. O
05 O
and O
0 O
. O
2 O
ng O
/ O
mL O
, O
respectively O
. O
The O
method O
was O
proved O
to O
be O
rapid O
, O
sensitive O
, O
specific O
, O
accurate O
and O
reproducible O
and O
has O
been O
successfully O
applied O
to O
a O
pharmacokinetic O
study O
of O
propiverine B-DRUG
hydrochloride I-DRUG
sustained O
release O
capsules O
( O
the O
30 O
mg O
dose O
in O
this O

Influence O
of O
piperine B-DRUG_N
on O
ibuprofen B-DRUG
induced O
antinociception O
and O
its O
pharmacokinetics O
. O
Piperine B-DRUG_N
( O
CAS O
94 O
- O
62 O
- O
2 O
) O
, O
an O
alkaloid O
obtained O
from O
Piper O
nigrum O
and O
P O
. O
longum O
, O
is O
a O
known O
inhibitor O
of O
various O
enzymes O
( O
CYP O
isozymes O
) O
responsible O
for O
biotransformation O
of O
drugs O
. O
By O
inhibiting O
the O
metabolism O
of O
drugs O
, O
piperine B-DRUG_N
improves O
the O
bioavailability O
of O
drugs O
. O
In O
the O
present O
study O
piperine B-DRUG_N
( O
10 O
mg O
/ O
kg O
) O
significantly O
increased O
the O
dose O
- O
dependent O
antinociceptive O
activity O
of O
ibuprofen B-DRUG
evaluated O
by O
both O
acetic B-DRUG
acid I-DRUG
writhing O
and O
formalin O
test O
, O
when O
it O
was O
administered O
with O
ibuprofen B-DRUG
. O
Ibuprofen B-DRUG
plasma O
concentration O
was O
also O
increased O
when O
it O
was O
administered O
with O
piperine B-DRUG_N
. O
The O
synergistic O
antinociception O
activity O
of O
ibuprofen B-DRUG
when O
administered O
with O
piperine B-DRUG_N
can O
be O
attributed O
to O
increased O
plasma O
concentration O
of O
ibuprofen B-DRUG
. O
From O
this O
study O
it O
can O
be O
concluded O
that O
piperine B-DRUG_N
can O
be O
used O
as O
a O
bioenhancer O
along O
with O
ibuprofen B-DRUG
. O

